Feeds:
Posts
Comments

Archive for the ‘HTN’ Category

Reporter: Aviva Lev-Ari, PhD, RN

See on Scoop.it – Cardiovascular Disease: PHARMACO-THERAPY

FDA Adds Antinausea, Cardiac Drugs to Watch List
Medscape
The beta blocker metoprolol succinate (Toprol-XL, AstraZeneca) also landed on the list, posted on the FDA Web site last month, because of reports that suggested therapeutic ineffectiveness.

FDA Adds Cardiac Drugs to Watch List

Jun 25, 2013

Drug & Reference Information

The other drug on the latest watch list, metoprolol succinate, is used to treat angina, heart failure, and hypertension

The US Food and Drug Administration (FDA) has put a class of antiemetic drugs, including ondansetron (Zofran, GlaxoSmithKline, and Zuplenz, Par Pharmaceutical), on its latest quarterly list of products to monitor because of potential signals of an increased risk for serotonin syndrome.

The beta blocker metoprolol succinate (Toprol-XL, AstraZeneca) also landed on the list, posted on the FDA Web site last month, because of reports that suggested therapeutic ineffectiveness.

The agency received reports of possible adverse events for these products in the FDA Adverse Event Reporting System (FAERS) database during the first 3 months of 2013. The FDA cautions that an appearance on the watch list does not mean that the agency has concluded that the drug poses the health risk reported through FAERS. What it does mean is that the FDA will investigate whether there is a causal connection. If there is one, the agency would consider a regulatory action such as collecting more data to better characterize the risk, revising the drug’s label, or requiring a risk evaluation and mitigation strategy.

Likewise, by adding a drug to the list, the FDA is not implying that clinicians should cease prescribing it or that patients should stop taking it, the agency says.

The antiemetics on the watch list belong to a subtype of serotonin blockers that bind to the 5-HT3 receptor. Clinicians prescribe them to prevent nausea and vomiting in patients undergoing chemotherapy for cancer. Serotonin syndrome, which was reported to FAERS in conjunction with these antiemetics, is caused by excessive levels of the neurotransmitter. It can be fatal. Symptoms include confusion, agitation, dilated pupils, headache, rapid heart rate, and changes in blood pressure and temperature.

The other drug on the latest watch list, metoprolol succinate, is used to treat angina, heart failure, and hypertension.

Potential Signals of Serious Risks/New Safety Information Identified by FAERS, January 2013 to March 2013

Product name: active ingredient (trade) or product class Potential signal of a serious risk/new safety information Additional information (as of May 1, 2013)
Metoprolol succinate (Toprol-XL, AstraZeneca) extended-release products Lack of therapeutic effect, possibly related to product quality issues FDA is continuing to evaluate this issue to determine the need for any regulatory action.
Serotonin-3 (5-HT3) receptor antagonist products: ondansetron(Zofran, GlaxoSmithKline, andZuplenz, Par Pharmaceutical), palonosetron (Aloxi, Helsinn Healthcare), granisetron (Kytril, Hoffmann-La Roche) Serotonin syndrome FDA is continuing to evaluate this issue to determine the need for any regulatory action.

 SOURCE

http://www.medscape.com/viewarticle/806890

More information on FAERS and its quarterly watch list is available on the FDA Web site.

Potential Signals of Serious Risks/New Safety Information Identified by FAERS, January 2013 to March 2013

http://www.medscape.com/viewarticle/806890

Carvedilol superior to Metoprolol in MADIT-CRT analysis

APRIL 2, 2013 

Rochester, NY – Treatment with carvedilol is associated with a significant 30% reduction in the risk of hospitalization for heart failure (HF) or death when compared with patients treated metoprolol, according to a new analysis of the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) [1].

The benefit of carvedilol over metoprolol was more pronounced in the subgroup of patients with a cardiac resynchronization therapy defibrillator (CRT-D), where carvedilol was associated with a significant 39% reduction in the risk of hospitalization for HF or death, and in those with left bundle branch block (LBBB). In the LBBB patients with a CRT-D, treatment with carvedilol was associated with a 49% reduction in risk compared with metoprolol.

“Furthermore, we found a pronounced dosage-dependent relationship between outcome and dose in carvedilol, which was not found in metoprolol-treated patients,” write Dr Martin Ruwald (University of Rochester Medical Center, New York) and colleagues in the April 1, 2013 issue of the Journal of the American College of Cardiology.

Benefit follows results observed in COMET
The MADIT-CRT study was presented and published in 2009 and included patients with mild HF or left ventricular dysfunction without symptoms. Participants in the trial had NYHA class 1 and 2 disease, systolic dysfunction, and ventricular dyssynchrony (wide QRS complexes). As reported by heartwire, the study showed that the addition of resynchronization pacing in primary-prevention patients with an implantable cardioverter defibrillator (ICD) reduced the risk of HF events by approximately one-third over 2.5 years.

Both metoprolol and carvedilol have a class IA indication in the management of patients with HF, with choice of the drug left to the discretion of the physician. In the Carvedilol or Metoprolol European Trial (COMET), there was an absolute 5.7% survival benefit with carvedilol over metoprolol. Other studies and analyses have suggested that there are differences between the two beta-blockers, say Ruwald and colleagues.

In this analysis of MADIT-CRT, which included 1515 patients with left ventricular ejection fraction (LVEF)<30%, QRS duration >130 ms, and NYHA functional class 1 or 2, the primary end point of hospitalization for HF or death from any cause occurred in 132 patients (30%) taking metoprolol and 243 patients (23%) taking carvedilol. During the 3.4-year follow-up, 48 patients (11%) taking metoprolol and 104 patients (10%) taking carvedilol died.

In multivariate analysis, the reduction in the primary end point with carvedilol translated into a 30% reduction in risk compared with metoprolol, a benefit that was driven primarily by a reduction in HF hospitalizations. There was only a trend toward a reduction in the risk of ventricular tachycardia/ventricular fibrillation (VT/VF). The reduction in the risk of hospitalization for HF/death from any cause was more pronounced in patients receiving CRT-Ds.

Reduction in HF hospitalization/death (carvedilol vs metoprolol)

Study population and subgroups Hazard ratio (95% CI)
MADIT-CRT 0.70 (0.57-0.87)
CRT-D 0.61 (0.46-0.82)
ICD 0.81 (0.59-1.11)
CRT-D and LBBB 0.51 (0.35-0.76)
CRT and non-LBBB 0.79 (0.51-1.23)
ICD and LBBB 0.96 (0.66-1.39)
ICD and non-LBBB 0.55 (0.30-1.00)
LBBB 0.73 (0.56-0.95)
Non-LBBB 0.64 (0.45-0.91)

The researchers note that mean carvedilol and metoprolol doses in MADIT-CRT were 18 mg and 64 mg, respectively. These dosages are comparable to real-life dosages administered to patients in the clinical setting, although somewhat lower than in previous randomized controlled trials, according to the researchers.

“We speculate that low baseline resting heart rates in our study indicate that the patients generally were well titrated at baseline and that the rate may have contributed to a relatively low dose in both metoprolol and carvedilol compared with the beta-blocker dosage in clinical trials,” state Ruwald et al.

http://www.theheart.org/article/1524745.do

J Am Coll Cardiol. 2013 Apr 9;61(14):1518-26. doi: 10.1016/j.jacc.2013.01.020.

Effect of metoprolol versus carvedilol on outcomes in MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy).

Ruwald MH, Ruwald AC, Jons C, Alexis J, McNitt S, Zareba W, Moss AJ.

Source

Heart Research Follow-up Program, Cardiology Division, University of Rochester Medical Center, Rochester, NY 14642, USA. mruwald@hotmail.com

Abstract

OBJECTIVES:

This study sought to compare the effects of metoprolol and carvedilol in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy) study.

BACKGROUND:

The impact of beta-blockers in heart failure (HF) patients with devices is uninvestigated.

METHODS:

All patients receiving either metoprolol or carvedilol in the MADIT-CRT study were identified and compared. Time-dependent Cox proportional hazard regression analyses were performed to assess differences in hospitalization for HF or death and ventricular arrhythmias.

RESULTS:

Hospitalization for HF or death occurred in 30% of the patients on metoprolol and in 23% on carvedilol. Treatment with carvedilol was associated with a significantly decreased risk of hospitalization for HF or death when compared with metoprolol (hazard ratio [HR]: 0.70, [95% confidence interval (CI): 0.57 to 0.87], p = 0.001). This reduction in risk was further attenuated in the subgroup of cardiac resynchronization therapy with implantable cardioverter-defibrillator (CRT-D) patients (HR: 0.61 [95% CI: 0.46 to 0.82], p = 0.001) and CRT-D patients with left bundle branch block (LBBB) (HR: 0.51 [95% CI: 0.35 to 0.76], p < 0.001). Ventricular arrhythmias occurred in 26% and in 22%, respectively, of the patients receiving metoprolol or carvedilol (HR: 0.80 [95% CI: 0.63 to 1.00], p = 0.050). General use of beta-blockers and adherence in this study was high, and a clear dose-dependent relationship was found in carvedilol, but not in metoprolol.

CONCLUSIONS:

In HF patients in New York Heart Association functional class I and II and with wide QRS complexes, carvedilol was associated with a 30% reduction in hospitalizations for HF or death when compared with metoprolol. A novel beneficial and synergistic effect of carvedilol was seen in patients with CRT-D and LBBB. Furthermore, we found a pronounced dose-dependent relationship in carvedilol, but not in metoprolol.

http://www.ncbi.nlm.nih.gov/pubmed/23500269?dopt=Abstract

Extended-Release Metoprolol ( Toprol-XL) Must Be Combined With Alpha-Blocker in Pheochromocytoma

On February 12, the FDA approved safety labeling revisions for metoprolol succinate (Toprol-XL extended-release tablets; AstraZeneca LP) to provide recommendations regarding its use in the setting of pheochromocytoma.

Patients diagnosed with pheochromocytoma should only receive extended-release metoprolol in combination with an alpha-blocker and only after alpha-blocker therapy has been initiated. Administration of beta-blockers alone in this setting has been linked to a paradoxic increase in blood pressure because of the attenuation of beta-mediated vasodilation in skeletal muscle.

Metoprolol is a beta 1-selective (cardioselective) adrenoceptor-blocking agent indicated for the treatment of hypertension; angina pectoris; and stable, symptomatic heart failure of ischemic, hypertensive, or cardiomyopathic origin.

http://www.medscape.com/viewarticle/591151

Study Suggests Benefit For Beta Blockers During Noncardiac Surgery
The use of perioperative beta-blockade for noncardiac surgery has been declining as a result of the controversial POISE study, which turned up evidence for harm associated with extended-release metoprolol in this setting. Now a large new observational study published in JAMA offers a contrary perspective by suggesting that perioperative beta-blockade may be beneficial in low- to intermediate-risk patients. But without better evidence the debate about this topic is unlikely to be resolved. Martin London and colleagues performed a retrospective analysis of 136,745 patients who underwent noncardiac surgery at VA hospitals, 40…
Source: CardioBrief – April 23, 2013 Category: Cardiology Authors: Larry Husten Tags: Interventional Cardiology & Surgery Prevention, Epidemiology & Outcomes beta blockers JAMA Observational study Source Type: blogs

http://www.medworm.com/rss/search.php?t=Toprol&f=drugs&blogs=1

NDA 19-962/S-038 Page 3 Rx only

TOPROL-XL® 

(metoprolol succinate) 

EXTENDED-RELEASE TABLETS TABLETS: 25 MG, 50 MG, 100 MG, AND 200 MG

DESCRIPTION 

TOPROL-XL, metoprolol succinate, is a beta1-selective (cardioselective) adrenoceptor blocking agent, for oral administration, available as extended release tablets. TOPROL-XL has been formulated to provide a controlled and predictable release of metoprolol for once-daily administration. The tablets comprise a multiple unit system containing metoprolol succinate in a multitude of controlled release pellets. Each pellet acts as a separate drug delivery unit and is designed to deliver metoprolol continuously over the dosage interval. The tablets contain 23.75, 47.5, 95 and 190 mg of metoprolol succinate equivalent to 25, 50, 100 and 200 mg of metoprolol tartrate, USP, respectively. Its chemical name is (±)1-(isopropylamino)-3-[p-(2-methoxyethyl) phenoxy]-2-propanol succinate (2:1) (salt). Its structural formula is:

Metoprolol succinate is a white crystalline powder with a molecular weight of 652.8. It is freely soluble in water; soluble in methanol; sparingly soluble in ethanol; slightly soluble in dichloromethane and 2-propanol; practically insoluble in ethyl-acetate, acetone, diethylether and heptane. Inactive ingredients: silicon dioxide, cellulose compounds, sodium stearyl fumarate, polyethylene glycol, titanium dioxide, paraffin.

CLINICAL PHARMACOLOGY General 

Metoprolol is a beta1-selective (cardioselective) adrenergic receptor blocking agent. This preferential effect is not absolute, however, and at higher plasma concentrations, metoprolol also inhibits beta2adrenoreceptors, chiefly located in the bronchial and vascular musculature. Metoprolol has no intrinsic sympathomimetic activity, and membrane-stabilizing activity is detectable only at plasma concentrations much greater than required for beta-blockade. Animal and human experiments indicate that metoprolol slows the sinus rate and decreases AV nodal conduction.

Clinical pharmacology studies have confirmed the beta-blocking activity of metoprolol in man, as shown by (1) reduction in heart rate and cardiac output at rest and upon exercise, (2) reduction of systolic blood pressure upon exercise, (3) inhibition of isoproterenol-induced tachycardia, and (4) reduction of reflex orthostatic tachycardia. NDA 19-962/S-038 Page 4

The relative beta1-selectivity of metoprolol has been confirmed by the following: (1) In normal subjects, metoprolol is unable to reverse the beta2-mediated vasodilating effects of epinephrine. This contrasts with the effect of nonselective beta-blockers, which completely reverse the vasodilating effects of epinephrine. (2) In asthmatic patients, metoprolol reduces FEV1 and FVC significantly less than a nonselective beta-blocker, propranolol, at equivalent beta1-receptor blocking doses.

In five controlled studies in normal healthy subjects, the same daily doses of TOPROL-XL and immediate release metoprolol were compared in terms of the extent and duration of beta1-blockade produced. Both formulations were given in a dose range equivalent to 100-400 mg of immediate release metoprolol per day. In these studies, TOPROL-XL was administered once a day and immediate release metoprolol was administered once to four times a day. A sixth controlled study compared the beta1-blocking effects of a 50 mg daily dose of the two formulations. In each study, beta1-blockade was expressed as the percent change from baseline in exercise heart rate following standardized submaximal exercise tolerance tests at steady state. TOPROL-XL administered once a day, and immediate release metoprolol administered once to four times a day, provided comparable total beta1blockade over 24 hours (area under the beta1-blockade versus time curve) in the dose range 100–400 mg. At a dosage of 50 mg once daily, TOPROL-XL produced significantly higher total beta1-blockade over 24 hours than immediate release metoprolol. For TOPROL-XL, the percent reduction in exercise heart rate was relatively stable throughout the entire dosage interval and the level of beta1-blockade increased with increasing doses from 50 to 300 mg daily. The effects at peak/trough (ie, at 24-hours post-dosing) were: 14/9, 16/10, 24/14, 27/22 and 27/20% reduction in exercise heart rate for doses of 50, 100, 200, 300 and 400 mg TOPROL-XL once a day, respectively. In contrast to TOPROL-XL, immediate release metoprolol given at a dose of 50–100 mg once a day produced a significantly larger peak effect on exercise tachycardia, but the effect was not evident at 24 hours. To match the peak to trough ratio obtained with TOPROL-XL over the dosing range of 200 to 400 mg, a t.i.d. to q.i.d. divided dosing regimen was required for immediate release metoprolol. A controlled cross-over study in heart failure patients compared the plasma concentrations and beta1-blocking effects of 50 mg immediate release metoprolol administered t.i.d., 100 mg and 200 mg TOPROL-XL once daily. A 50 mg dose of immediate release metoprolol t.i.d. produced a peak plasma level of metoprolol similar to the peak level observed with 200 mg of TOPROL-XL. A 200 mg dose of TOPROL-XL produced a larger effect on suppression of exercise-induced and Holter-monitored heart rate over 24 hours compared to 50 mg t.i.d. of immediate release metoprolol.

The relationship between plasma metoprolol levels and reduction in exercise heart rate is independent of the pharmaceutical formulation. Using an Emax model, the maximum effect is a 30% reduction in exercise heart rate, which is attributed to beta1-blockade. Beta1-blocking effects in the range of 30– 80% of the maximal effect (approximately 8–23% reduction in exercise heart rate) correspond to metoprolol plasma concentrations from 30-540 nmol/L. The relative beta1-selectivity of metoprolol diminishes and blockade of beta2-adrenoceptors increases at plasma concentrations above 300 nmol/L.

Although beta-adrenergic receptor blockade is useful in the treatment of angina, hypertension, and heart failure there are situations in which sympathetic stimulation is vital. In patients with severely damaged hearts, adequate ventricular function may depend on sympathetic drive. In the presence of AV block, beta-blockade may prevent the necessary facilitating effect of sympathetic activity on conduction. Beta2-adrenergic blockade results in passive bronchial constriction by interfering with endogenous adrenergic bronchodilator activity in patients subject to bronchospasm and may also interfere with exogenous bronchodilators in such patients. NDA 19-962/S-038 Page 5

In other studies, treatment with TOPROL-XL produced an improvement in left ventricular ejection fraction. TOPROL-XL was also shown to delay the increase in left ventricular end-systolic and end-diastolic volumes after 6 months of treatment.

Pharmacokinetics 

Adults In man, absorption of metoprolol is rapid and complete. Plasma levels following oral administration of conventional metoprolol tablets, however, approximate 50% of levels following intravenous administration, indicating about 50% first-pass metabolism. Metoprolol crosses the blood-brain barrier and has been reported in the CSF in a concentration 78% of the simultaneous plasma concentration.

Plasma levels achieved are highly variable after oral administration. Only a small fraction of the drug (about 12%) is bound to human serum albumin. Metoprolol is a racemic mixture of R- and S- enantiomers, and is primarily metabolized by CYP2D6. When administered orally, it exhibits stereoselective metabolism that is dependent on oxidation phenotype. Elimination is mainly by biotransformation in the liver, and the plasma half-life ranges from approximately 3 to 7 hours. Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity. Following intravenous administration of metoprolol, the urinary recovery of unchanged drug is approximately 10%. The systemic availability and half-life of metoprolol in patients with renal failure do not differ to a clinically significant degree from those in normal subjects. Consequently, no reduction in dosage is usually needed in patients with chronic renal failure.

Metoprolol is metabolized predominantly by CYP2D6, an enzyme that is absent in about 8% of Caucasians (poor metabolizers) and about 2% of most other populations. CYP2D6 can be inhibited by a number of drugs. Concomitant use of inhibiting drugs in poor metabolizers will increase blood levels of metoprolol several-fold, decreasing metoprolol’s cardioselectivity. (See PRECAUTIONS, Drug Interactions.)

In comparison to conventional metoprolol, the plasma metoprolol levels following administration of TOPROL-XL are characterized by lower peaks, longer time to peak and significantly lower peak to trough variation. The peak plasma levels following once-daily administration of TOPROL-XL average one-fourth to one-half the peak plasma levels obtained following a corresponding dose of conventional metoprolol, administered once daily or in divided doses. At steady state the average bioavailability of metoprolol following administration of TOPROL-XL, across the dosage range of 50 to 400 mg once daily, was 77% relative to the corresponding single or divided doses of conventional metoprolol. Nevertheless, over the 24-hour dosing interval, ß1-blockade is comparable and dose-related (see CLINICAL PHARMACOLOGY). The bioavailability of metoprolol shows a dose-related, although not directly proportional, increase with dose and is not significantly affected by food following TOPROL-XL administration.

Pediatrics The pharmacokinetic profile of TOPROL-XL was studied in 120 pediatric hypertensive patients (6-17 years of age) receiving doses ranging from 12.5 to 200 mg once daily. The pharmacokinetics of metoprolol were similar to those described previously in adults. Age, gender, race, and ideal body weight had no significant effects on metoprolol pharmacokinetics. Metoprolol apparent oral clearance (CL/F) increased linearly with body weight. Metoprolol pharmacokinetics have not been investigated in patients < 6 years of age. NDA 19-962/S-038 Page 6

Hypertension 

The mechanism of the antihypertensive effects of beta-blocking agents has not been elucidated. However, several possible mechanisms have been proposed: (1) competitive antagonism of catecholamines at peripheral (especially cardiac) adrenergic neuron sites, leading to decreased cardiac output; (2) a central effect leading to reduced sympathetic outflow to the periphery; and

(3) suppression of renin activity.

Clinical Trials

In a double-blind study, 1092 patients with mild-to-moderate hypertension were randomized to once daily TOPROL-XL (25, 100, or 400 mg), PLENDIL® (felodipine extended release tablets), the combination, or placebo. After 9 weeks, TOPROL-XL alone decreased sitting blood pressure by 6-8/47 mmHg (placebo-corrected change from baseline) at 24 hours post-dose. The combination of TOPROL-XL with PLENDIL has greater effects on blood pressure.

In controlled clinical studies, an immediate release dosage form of metoprolol was an effective antihypertensive agent when used alone or as concomitant therapy with thiazide-type diuretics at dosages of 100-450 mg daily. TOPROL-XL, in dosages of 100 to 400 mg once daily, produces similar ß1-blockade as conventional metoprolol tablets administered two to four times daily. In addition, TOPROL-XL administered at a dose of 50 mg once daily lowered blood pressure 24-hours post-dosing in placebo-controlled studies. In controlled, comparative, clinical studies, immediate release metoprolol appeared comparable as an antihypertensive agent to propranolol, methyldopa, and thiazide-type diuretics, and affected both supine and standing blood pressure. Because of variable plasma levels attained with a given dose and lack of a consistent relationship of antihypertensive activity to drug plasma concentration, selection of proper dosage requires individual titration.

Angina Pectoris 

By blocking catecholamine-induced increases in heart rate, in velocity and extent of myocardial contraction, and in blood pressure, metoprolol reduces the oxygen requirements of the heart at any given level of effort, thus making it useful in the long-term management of angina pectoris.

Clinical Trials

In controlled clinical trials, an immediate release formulation of metoprolol has been shown to be an effective antianginal agent, reducing the number of angina attacks and increasing exercise tolerance. The dosage used in these studies ranged from 100 to 400 mg daily. TOPROL-XL, in dosages of 100 to 400 mg once daily, has been shown to possess beta-blockade similar to conventional metoprolol tablets administered two to four times daily.

Heart Failure 

The precise mechanism for the beneficial effects of beta-blockers in heart failure has not been elucidated. NDA 19-962/S-038 Page 7

Clinical Trials

MERIT-HF was a double-blind, placebo-controlled study of TOPROL-XL conducted in 14 countries including the US. It randomized 3991 patients (1990 to TOPROL-XL) with ejection fraction ≤ 0.40 and NYHA Class II-IV heart failure attributable to ischemia, hypertension, or cardiomyopathy. The protocol excluded patients with contraindications to beta-blocker use, those expected to undergo heart surgery, and those within 28 days of myocardial infarction or unstable angina. The primary endpoints of the trial were (1) all-cause mortality plus all-cause hospitalization (time to first event) and

(2) all-cause mortality. Patients were stabilized on optimal concomitant therapy for heart failure, including diuretics, ACE inhibitors, cardiac glycosides, and nitrates. At randomization, 41% of patients were NYHA Class II, 55% NYHA Class III; 65% of patients had heart failure attributed to ischemic heart disease; 44% had a history of hypertension; 25% had diabetes mellitus; 48% had a history of myocardial infarction. Among patients in the trial, 90% were on diuretics, 89% were on ACE inhibitors, 64% were on digitalis, 27% were on a lipid-lowering agent, 37% were on an oral anticoagulant, and the mean ejection fraction was 0.28. The mean duration of follow-up was one year. At the end of the study, the mean daily dose of TOPROL-XL was 159 mg.

The trial was terminated early for a statistically significant reduction in all-cause mortality (34%, nominal p= 0.00009). The risk of all-cause mortality plus all-cause hospitalization was reduced by 19% (p= 0.00012). The trial also showed improvements in heart failure-related mortality and heart failure-related hospitalizations, and NYHA functional class.

The table below shows the principal results for the overall study population. The figure below illustrates principal results for a wide variety of subgroup comparisons, including US vs. non-US populations (the latter of which was not pre-specified). The combined endpoints of all-cause mortality plus all-cause hospitalization and of mortality plus heart failure hospitalization showed consistent effects in the overall study population and the subgroups, including women and the US population. However, in the US subgroup (n=1071) and women (n=898), overall mortality and cardiovascular mortality appeared less affected. Analyses of female and US patients were carried out because they each represented about 25% of the overall population. Nonetheless, subgroup analyses can be difficult to interpret and it is not known whether these represent true differences or chance effects.

SOURCE

http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019962s038lbl.pdf

Clinical Endpoints in the MERIT-HF Study 

CLINICAL ENDPOINT NUMBER OF PATIENTS RELATIVE RISK (95% CI) RISK REDUCTION WITH TOPROLXL NOMINAL P-VALUE
PLACEBO N=2001 TOPROLXL N=1990
ALL-CAUSE MORTALITY PLUS ALL-CAUSE HOSPITALIZATION* 767 641 0.81 (0.730.90) 19% 0.00012

Read Full Post »

CVD Core

CVD Core

Reporter: Aviva Lev-Ari, PhD, RN

Article ID #62: CVD Core. Published on 6/26/2013

WordCloud Image Produced by Adam Tubman

When this post will be ready it needs be place

under below link 

http://pharmaceuticalintelligence.com/biomed-e-books/cardiovascular-diseases-causes-risks-and-management/introduction-to-the-three-volume-series-core-research-on-cardiovascular-diseases/

See in red my comments, below

Cardiovascular Diseases: Causes, Risks and Management

Justin D. Pearlman MD PhD MA FACC, Editor

Cardiovascular diseases comprise problems of the heart and blood vessels, including rhythm, blood supply, blood pressure, birth defects, or damage from cholesterol, tobacco, street drugs, radiation, viruses, bacteria, or fungi.

Thus the category includes heart failure (inadequate pump function), heart or vessel infection (endocarditis, vasculitis), birth defects (congenital heart disease)

Cardiovascular Diseases: Causes, Risks and Management

Justin D. Pearlman MD ME PhD MA FACC, Editor

 

Leaders in Pharmaceutical Business Intelligence

Aviva Lev-Ari, PhD, RN

Director and Founder

Editor-in-Chief

Other e-Books  in the  BioMedicine Series

Perspectives on Nitric Oxide in Disease Mechanisms

Human Immune System in Health and in Disease

Metabolic Genomics & Pharmaceutics

Infectious Disease & New Antibiotic Targets

Cancer Biology and Genomics for Disease Diagnosis

Nanotechnology in Drug Delivery

Genomics Orientations for Personalized Medicine 

This book is a comprehensive review of Innovations in Cardiovascular Medicine, including the latest discoveries in

  • Cardiac Medical Imaging,
  • Regenerative Medicine,
  • Pharmacotherapy,
  • Medical Devices for Cardiac Repair,
  • Genomics, and opportunities for Targeted Therapy.

It is written by experts in their respective subspecialties. The e-Book’s articles have been published on the Open Access Online Scientific Journal, since April 2012.  All new articles on this subject will continue to be incorporated with periodical updates.

http://www.pharmaceuticalIntelligence.com

The Journal is a scientific, medical and business, multi-expert authoring environment for information syndication in domains of Life Sciences, Medicine, Pharmaceutical and Healthcare Industries, BioMedicine, Medical Technologies & Devices. Scientific critical interpretations and original articles are written by PhDs, MDs, MD/PhDs, PharmDs, Technical MBAs as Experts, Authors, Writers (EAWs) on an Equity Sharing basis.

The Editor, Justin D. Pearlman MD ME PhD MA FACC, has many different perspectives developed during the years, including:

  • Chief of Cardiology,
  • non-invasive imaging,
  • molecular biology,
  • mathematics,
  • imaging research

contributed a number of firsts:

  • non-endemic Chagas diagnosis,
  • intensity projection angiography,
  • magnetization tagging,
  • myocardial injury mapping by magnetic resonance contrast retention,
  • myocardial viability by MRI,
  • atheroma lipid liquid crystal characterization,
  • outpatient inotropic infusion therapy,
  • angiogenesis imaging,
  • multimodal in vivo stem cell imaging,
  • real-time velocity beam MRI,
  • in vivo microscopic MRI,
  • dobutamine stress echocardiography for low gradient valve disease,
  • alternative stress tests,
  • diagnostic electrocardiography in magnetic environments,
  • statistical methods to solve error propagation of large array genomics,
  • discovery of monocyte role in native coronary collateral development,
  • image tracked stem cell treatment of  heart attacks,
  • singularity editing in differential topology.

 

Preface to the Three Volume Series

Cardiovascular disease has been a leading cause of death and disability and so it has also been a major focus for intense research, development, and progress. Knowledge of the causes, risks, and best practices for management continually change. That is why a dynamic electronic living textbook presents an exciting opportunity to help you keep current with the ephemeral leading edge. This book is an outgrowth of the commitment of Leaders in Pharmaceutical Business Intelligence to present the most exciting timely and pertinent advances of our day, in a continual medium to stay fresh and up to date. We hope diverse multispecialty perspectives will help you in your quest to understand, adapt and advance the leading edge of cardiovascular disease causes, risks and best practices management.

On the Diagnosis of Cardiovascular Disease: causes, manifestations, consequences and priorities

Doctors aim to spend their time on prevention, diagnosis, and disease management. More and more the time is diverted to expanding demands for documentation and bureaucratic navigation. This article focuses on the art of diagnosis, with examples based on cardiovascular diseases. Diagnosis cannot be achieved without a knowledge of the causes (etiology) of ailments, a necessary but not sufficient component of diagnosis. The causes broadly relate to nature and nurture, how our biological system develops and functions (nature), and its interactions with the outside world driven in part by behavior, diet, exposures, and activities (nurture). The nature of our individuality has been traced to the human genome, a map of code for protein products that build our structures and mediate our body part functions. Numerous blood tests have been devised to check the expression and activity level of such genomic products to identify disease and characterize its stage. The role of diet, behavior, exposures, activities or lack thereof is well established as a complicit factor in disease development and progression.

The art of diagnosis is designed to find out what is wrong. Literally, it is a flow of knowing, based on knowledge of causes of ailments, probabilities (prevalence), consequences, manifestations, priorities (which would be most urgent) and tests: CPCMPT. Review of those elements generates a list of concerns, often expressed as a “differential diagnosis” which is  a prioritized list of plausible explanations for the observations, patient’s report of symptoms and findings from patient examination. The second stage of diagnosis, called the “work-up,” selects and applies tests to stratify the list of possibilities further as well as to characterize the manifestations and stage of disease. Technically, analysis of biological samples, imaging studies and intervention trials each represent tests; however, they are often viewed as distinct tools with just the former labeled as tests (biological samples include blood tests, urine tests, sputum or saliva samples, and biopsies). The primary goal of the work-up is to establish one or more specific diagnoses as the cause of ailment. The secondary goal of the work-up is to characterize the manifestations and stage of disease to define expectations and clarify options for the disease management. The third goal is to develop a management a plan to slow or stop the ailment, decrease risks of complications, slow or stop progression of disease manifestations or otherwise minimize functional impairment.

The manifestations of disease are categorized as signs and symptoms.

  • Signs are observable evidence of consequences,
  • Symptoms are subjective complaints.

A major component of diagnostic skill is the ability to identify and characterize correctly signs and symptoms of all relevant disease conditions. A second major component of diagnostic skill is the ability to select appropriate tests and interpret their significance in context, in keeping with the patient’s presentation.

When someone sees a doctor about chest pain, coronary artery disease is a prominent consideration. The most common causes of chest pain are mechanical (muscle and bone, e.g., muscle spasms, muscle and bone inflammation), but those conditions are not generally life-threatening. The consequences of blocked arteries – arrhythmia, permanent weakness of the heart, blood clots, pulmonary emboli, stroke, cardiogenic shock, death – raise the stakes and push coronary disease high in priority even when the probabilities are low. The prioritization of the differential diagnosis list has multiple considerations: urgency (how quickly it can worsen), severity of consequences, and the probabilities of a macrovascualar event (prevalence, risk factors). A ten percent risk of coronary disease typically takes precedence over a 70% likelihood of muscle spasm in terms of diagnostic testing.

The road map for the construction of our individuality as humans has been fully mapped: the human genome. Genetic variation means we are not fully determined by the mix of genes inherited from our parents. In addition to the genetic material on our 48 chromosomes, and the genetic material in mitochondria inherited from the mother, there are spontaneous changes in the genetic code, and there are modifications that affect gene expression (which codes produce gene products, quantities, rates, and post-production modifications).

The causes of cardiovascular disease are defined by Murphy’s law: what can go wrong will. However, on the nature side, most malfunctions are too severe to reach the light of day, so there is a limited list of disease mechanisms associated with sufficient viability to reach medical attention. Those mechanisms can be summarized by a mnemonic: diseases can develop new metals in-flame, a-fact externs generated (disease mechanisms: congenital, developmental, neoplastic, metabolic, inflammatory, infectious, extrinsic (e.g. stab wound), and degenerative). A taxonomy of cardiovascular diseases can be constructed in various ways: (1) itemize the major cardiovascular functions and subclassify the dysfunctions, (2) itemize by principle anatomic involvement and subclassify by pathology, (3) classify by mechanism of disease, etiology. Compendiums of cardiovascular disease may be found in: (1) French’s Differential Diagnosis, (2) Robbins and Angel Pathology, (3) Guyton’s Textbook of Physiology, as well as cardiovascular disease textbooks such as Hurst, Braunwald, Mayo Clinic, Cleveland Clinic…

Diagnosis takes many forms. The paranoid inclusive approach, manifested as “medical student syndrome”, considers any semblance of a sign or symptom vaguely similar to a disease manifestation as a frightening prospect worthy of detailed pursuit. The minimalist pragmatic approach commonly attributed to general practitioners focuses on reassurance, and pursuit of persisting complaints that match a common ailment. That approach has been summarized by the advice: when you hear hoof beats think of horses, not zebras. Specialists, on the other hand, are taught to consider all possibilities, with due consideration to urgency and treatability, so that zebras are not punished.

The healthcare system promotes the idea of generalists serving as the front line, identifying who can be managed simply, with specialists serving as finishers for more complex cases or cases requiring special skills. A flaw in that model is the need for detailed knowledge of zebras and subtle findings that may represent an urgent issue at the front line for triage. If the generalist does not know that mild symptoms from mitral valve disease or aortic valve disease may require urgent detailed assessment, patients may be referred to a specialist too late to prevent consequences that requires an earlier intervention.

Parsimony in diagnosis refers to identifying the fewest number of diagnoses that explain all the findings. The concept has been attributed to Osler, and it builds on a guiding procedure voiced in the middle ages by Occum, known as Occum’s razor: when deciding between two explanations, favor the one that requires the fewest assumptions. Parsimony is a useful guide for diagnosis of a previously healthy patient who develops a number of findings that are temporally coherent. After age 65 (official geriatrics age), physicians are taught to abandon parsimony and expect more diagnoses than findings.

A study of difficult diagnoses lead to the concept of a pivotal finding as one that has a narrow differential list. The diagnostic process is prone to errors, including cognitive biases, which may benefit from computer assistance. Intuition and analytics can be applied to reduce cognitive bias. The author developed a just-in-time social networking system within a software package called Missive(c) that enables rapid access to such tools, combining efficiency in documentation with improved quality of analysis and reports (faster and better).

Among older Americans, more are hospitalized for heart failure than for any other medical condition (diastolic failure=stiff heart, systolic failure= inadequate pumping).

Genomics – the study of the genetic basis for disease – is rapidly expanding knowledge about etiology (cause of disease), and it helps identify opportunities for accurate diagnosis and treatment. The American Heart Association journal CIRCULATION has published 348 relevant articles related to cardiovascular genomics from 2010-2013.  For example, just on the subtopic of atherosclerosis (hardening of arteries), genomics offers major progress. The genetic factors that affect arterial stiffness are strongly related to a very common underlying health concern, hypertension (high blood pressure). The counterpart to genetics is environment (nature versus nurture), but genetics carries the trump cards because it determines the sensitivities to environment.

anatomy

physiology

laboratory tests

interventional trials

Boundaries of the Domain: Cardiovascular Diseases: Causes, Risks and Management – Volume 1,2,3

 

The scope of cardiovascular disease scholarly contributions will grow to include: anatomy, surgery, molecular biology, ethics, imaging (echo, nuclear, PET, MRI, OCT, CT), congenital, stress tests, ECG, electrophysiology/rhythm/channelopathies, pacing, resynchronizing, AICD, cardiomyopathies, syncope, valve disease, aorta, renal artery, thrombosis, venous diseases, vasculitis, endothelium, metabolic syndrome, dyslipidemia, risk factors, biomarkers, hypertension, embolism, pulmonary hypertension, cardiac tumors, women’s health, CAD, Angina,  Stem cells, complications of MI, thrombolysis, rehabilitation, reflexes, hormones, diastology, pharmaceuticals, myocarditis, hypertrophy, failure, shock, hemodynamics, interventions, contrast nephropathy, and contrast systemic fibrosis, as well as other relevant topics you may suggest.

An overview of the Core Research on Cardiovascular Diseases is based on the following NINE articles: 

Have only the article title as a live link of the following 9 [originally were on CVD Zero, title and links, now only links]

  1. http://pharmaceuticalintelligence.com/2013/05/15/diagnosis-of-cardiovascular-disease-treatment-and-prevention-current-predicted-cost-of-care-and-the-promise-of-individualized-medicine-using-clinical-decision-support-systems-2/ 
  2. http://pharmaceuticalintelligence.com/2013/05/04/cardiovascular-diseases-decision-support-systems-for-disease-management-decision-making/ 
  3. http://pharmaceuticalintelligence.com/2013/03/07/genomics-genetics-of-cardiovascular-disease-diagnoses-a-literature-survey-of-ahas-circulation-cardiovascular-genetics-32010-32013/
  4. http://pharmaceuticalintelligence.com/2013/05/17/synthetic-biology-on-advanced-genome-interpretation-for-gene-variants-and-pathways-what-is-the-genetic-base-of-atherosclerosis-and-loss-of-arterial-elasticity-with-aging/ 
  5. http://pharmaceuticalintelligence.com/2013/05/11/arterial-elasticity-in-quest-for-a-drug-stabilizer-isolated-systolic-hypertension-caused-by-arterial-stiffening-ineffectively-treated-by-vasodilatation-antihypertensives/ 
  6. http://pharmaceuticalintelligence.com/2013/05/24/imaging-biomarker-for-arterial-stiffness-pathways-in-pharmacotherapy-for-hypertension-and-hypercholesterolemia-management/ 
  7. http://pharmaceuticalintelligence.com/2013/04/28/genetics-of-conduction-disease-atrioventricular-av-conduction-disease-block-gene-mutations-transcription-excitability-and-energy-homeostasis/
  8. http://pharmaceuticalintelligence.com/2013/05/07/on-devices-and-on-algorithms-arrhythmia-after-cardiac-surgery-prediction-and-ecg-prediction-of-paroxysmal-atrial-fibrillation-onset/ 
  9. http://pharmaceuticalintelligence.com/2013/05/22/acute-and-chronic-myocardial-infarction-quantification-of-myocardial-viability-fdg-petmri-vs-mri-or-pet-alone

The main points are

[bring here ONLY the INTRODUCTION and the Summary of each, THEN The EDITOR will provide perspective on the Research and the current STate of Cardiology in the US in 2013/2014]

A. Now you provide ONLY links to 

Volume #

Contributors to Volume #

eTOCS in Volume #

REPEAT A. for each Volume

Volume One: Causes of Cardiovascular Diseases

Table of Contents

Hardening of the arteries is described as atherosclerosis, or porridge-like wall changes with scarring, which leads to heart attacks, high blood pressure, stroke, and organ injury mediated by ischemia (insufficient nutrient blood supply). The causes are both nature (genetic) and nurture (behavior, diet). Specifics of the causes guide diagnosis and management.

Chapter 1.2: Genomics

The completion of the human genome map was a major accomplishment, as gene products make signals, receptors and building blocks that establish health and disease. However, it is just a stepping stone, not explaining why, where, or how the gene products are regulated and  interact.

Chapter 1.3: Cardiovascular Imaging

Imaging applies a principle of physics (light transmission, sound transmission, xray transmission, magnetic resonance, radioactivity) to provide a map of interior structures and/or activities. Image processing (computing) derives further information than simple display of an observed tissue-sensitive parameter. In the case of computed tomography (CT), magnetic resonance (MRI), positron-emission tomography (PET), and single-photon emission tomography (SPECT),  computer reformatting of image data is essential.

Volume Two: Risk Assessment of Cardiovascular Diseases

Contributors

Table of Contents

Cardiovascular disease is the leading cause of death and disability, affecting more than four times as many people as all forms of cancer combined.

Chapter  2.2: Testing for cardiovascular risk

The volunteer population of Framingham Massachusetts provided decades of data clarifying determinants of risk for cardiovascular diseases. That data helped establish the usefulness of cholesterol screening, and lead to the search for additional tests to identify risk and guide management.

Chapter 2.3: Biomarkers

Biomarkers are chemistry levels (concentrations in the blood) that identify injury or risk for injury.

Volume Three: Management of Cardiovascular Diseases

Contributors

Chapter  3.1: Therapeutic Genomics

As the mysteries of the human genome products are unraveled, we get closer to identifying key components. One of them is Thymosin beta 4 (Tβ4) , which plays an essential role in cardiac and blood vessel development and regeneration. It may lead to breakthroughs in angiogenesis and vasculogenesis, or new vessel development, mimicking the behavior of the lucky few who develop new vessels, or collaterals, as a natural bypass system, without requiring a surgeon to provide a blood supply to avoid or limit heart attacks.

Chapter 3.2: Image guidance of Therapy

The US government is helping to sponsor new imaging methods, while they also inhibit it by adding new taxes.

Chapter 3.3: Drug therapy

Emerging new therapies are presented, along with the biological basis.

Chapter 3.4: Cardiovascular Interventions

Technological advances enable minimally invasive solutions to problems previously addressed by surgery or autopsy.

Introduction 

 

Contributors above, need a LINK to the appropriate contributors in each volume. Table of Contents of each volume above need a LINK to the eTOCS of each volume.  

Please UPDATE all links ABOVE to the appropriate locations in the respective volumes, after implementing the carry over, remove links below EXCEPT CVD1,2,3 and remove this comment of mine in RED, here

REFERENCES for CVD CORE

A.  Diagnosis of Cardiovascular Disease and Cost of Care

Bernstein, HL and A. Lev-Ari 5/15/2013 Diagnosis of Cardiovascular Disease, Treatment and Prevention: Current & Predicted Cost of Care and the Promise of Individualized Medicine Using Clinical Decision Support Systems

http://pharmaceuticalintelligence.com/2013/05/15/diagnosis-of-cardiovascular-disease-treatment-and-prevention-current-predicted-cost-of-care-and-the-promise-of-individualized-medicine-using-clinical-decision-support-systems-2/ 

B. Cardiovascular Diseases: Disease Management Decision Making – use of CDSS

Pearlman, JD and A. Lev-Ari 5/4/2013 Cardiovascular Diseases: Decision Support Systems for Disease Management Decision Making

http://pharmaceuticalintelligence.com/2013/05/04/cardiovascular-diseases-decision-support-systems-for-disease-management-decision-making/ 

C. Genomics & Genetics of Cardiovascular Disease Diagnoses

Lev-Ari, A. and L H Bernstein 3/7/2013 Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013

http://pharmaceuticalintelligence.com/2013/03/07/genomics-genetics-of-cardiovascular-disease-diagnoses-a-literature-survey-of-ahas-circulation-cardiovascular-genetics-32010-32013/

D.  Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

Lev-Ari, A. 5/17/2013 Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

http://pharmaceuticalintelligence.com/2013/05/17/synthetic-biology-on-advanced-genome-interpretation-for-gene-variants-and-pathways-what-is-the-genetic-base-of-atherosclerosis-and-loss-of-arterial-elasticity-with-aging/ 

E.  Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus

Pearlman, JD and A. Lev-Ari 5/11/2013 Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus

http://pharmaceuticalintelligence.com/2013/05/11/arterial-elasticity-in-quest-for-a-drug-stabilizer-isolated-systolic-hypertension-caused-by-arterial-stiffening-ineffectively-treated-by-vasodilatation-antihypertensives/ 

F.  Arterial Stiffness: Pharmacotherapy for Hypertension and Hypercholesterolemia Management

Pearlman, JD and A. Lev-Ari 5/24/2013 Imaging Biomarker for Arterial Stiffness: Pathways in Pharmacotherapy for Hypertension and Hypercholesterolemia Management

http://pharmaceuticalintelligence.com/2013/05/24/imaging-biomarker-for-arterial-stiffness-pathways-in-pharmacotherapy-for-hypertension-and-hypercholesterolemia-management/ 

G. Genetics of Conduction Disease

Lev-Ari, A. 4/28/2013 Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis

http://pharmaceuticalintelligence.com/2013/04/28/genetics-of-conduction-disease-atrioventricular-av-conduction-disease-block-gene-mutations-transcription-excitability-and-energy-homeostasis/

H.  Arrhythmia after Cardiac Surgery Prediction and ECG Prediction of Paroxysmal Atrial Fibrillation Onset

Pearlman, JD and A. Lev-Ari 5/7/2013 On Devices and On Algorithms: Arrhythmia after Cardiac Surgery Prediction and ECG Prediction of Paroxysmal Atrial Fibrillation Onset

http://pharmaceuticalintelligence.com/2013/05/07/on-devices-and-on-algorithms-arrhythmia-after-cardiac-surgery-prediction-and-ecg-prediction-of-paroxysmal-atrial-fibrillation-onset/ 

I.  Myocardial Infarction: Quantification of Myocardial Perfusion Viability

Pearlman, JD and A. Lev-Ari 5/22/2013 Acute and Chronic Myocardial Infarction: Quantification of Myocardial Perfusion Viability – FDG-PET/MRI vs. MRI or PET alone

http://pharmaceuticalintelligence.com/2013/05/22/acute-and-chronic-myocardial-infarction-quantification-of-myocardial-viability-fdg-petmri-vs-mri-or-pet-alone/

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

PRE-ECLAMPSIA

Preeclampsia is a disorder that occurs only during pregnancy and the postpartum period and affects both the mother and the unborn baby. Affecting at least 5-8% of all pregnancies, it is a rapidly progressive condition characterized by high blood pressure and the presence of protein in the urine. Swelling, sudden weight gain, headaches and changes in vision are important symptoms; however, some women with rapidly advancing disease report few symptoms.

Typically, preeclampsia occurs after 20 weeks gestation (in the late 2nd or 3rd trimesters or middle to late pregnancy) and up to six weeks postpartum, though in rare cases it can occur earlier than 20 weeks. Proper prenatal care is essential to diagnose and manage preeclampsia. Pregnancy Induced Hypertension (PIH) and toxemia are outdated terms for preeclampsia. HELLP syndrome and eclampsia (seizures) are other variants of preeclampsia.

Globally, preeclampsia and other hypertensive disorders of pregnancy are a leading cause of maternal and infant illness and death. By conservative estimates, these disorders are responsible for 76,000 maternal and 500,000 infant deaths each year.

http://www.preeclampsia.org/health-information/about-preeclampsia?gclid=CNeVjpG537cCFUYaOgodC0QASg

VIEW VIDEO – SIX Sections, Pauses in between

http://on.aol.com/video/preeclampsia-vs–pregnancy-induced-hypertension-484063856

  • Preeclampsia vs. Pregnency -Induced Hypertension
  • When Preeclampsia Occur
  • Preeclampsia – Effects on Fetus Health
  • Preeclampsia – Effects on the Baby

Genetic Aspects of Pre-eclampsia

The genetics of pre-eclampsia and other hypertensive disorders of pregnancy

Human Genetics Research Group, School of Molecular and Medical Sciences, University of Nottingham, A Floor West Block, Queen’s Medical Centre, Nottingham NG7 2UH, UK
*Corresponding author. Tel.: +44 (0) 115 8230758; Fax: +44 (0) 115 8230759. Email: Paula.Williams@nottingham.ac.uk
Epidemiological studies clearly confirm a genetic component to pre-eclampsia. Numerous candidate genes have been studied that fall into groups based on their proposed pathological mechanism, including

  • thrombophilia,
  • endothelial function,
  • vasoactive proteins,
  • oxidative stress and
  • lipid metabolism and
  • immunogenetics.
It is expected that no one gene will be identified as the sole risk factor for pre-eclampsia, as in the general population pre-eclampsia represents a complex genetic disorder. Interactions between numerous SNP either alone or with combination with predisposing environmental factors, are most likely underpin the genetic component of this disorder. We must be cautious in our approach to genetics and acknowledge that we are still in the infancy of this research. Following on from GWAS, further fine mapping studies to delineate SNP that are causal from those that are in linkage disequilibrium, followed by functional laboratory studies will be required. Only when we have a better understanding of how the environment interacts with genes will we be in a better position to target treatment for women, for example knowing that women with a certain genotype will benefit from losing weight, enabling us to yield clinical benefit.
At present no genetic test is available to predict pre-eclampsia. The lack of a predictive test can be overcome by careful monitoring and assessment of women, especially those in high-risk groups, including:

    Those at either end of the reproductive age spectrum•Obesity•Black ethnicity•Primiparity•Previous history of pre-eclampsia•Multiple pregnancy•Pre-existing medical conditions: renal disease, insulin-dependent diabetes, autoimmune disease, antiphospholipid syndrom

Genetic aspects of pre-eclampsia

Clustering of cases of pre-eclampsia within families has been recognised since the 19th century, suggesting a genetic component to the disorder.2 Deciphering the genetic involvement in pre-eclampsia is challenging, not least because the phenotype is expressed only in parous women. Furthermore, in complex disorders of pregnancy, it is necessary to consider two genotypes, that of the mother and that of the fetus, which includes genes inherited from both mother and father. Maternal and fetal genes may have independent or interactive effects on the risk of pre-eclampsia. Finally, the heterogeneous nature of the disorder, with a sliding scale of severity, has resulted in differences in the definition of pre-eclampsia used within studies (see above), often with overlap of non-proteinuric gestational hypertension.

Twin studies investigating the relative contribution of genetic versus environmental factors to pre-eclampsia risk, initially yielded disappointing results. They showed that discordance for pre-eclampsia between monozygotic twin sisters was common, suggesting that heritability caused by maternal genes was low.3 These early studies were small. More recent investigations, however, using the large Swedish Twin, Medical Birth and Multigeneration Registries have estimated the heritability of pre-eclampsia to be about 55%, with contributions from both maternal and fetal genes. A further study in monozygotic twins4 found concordance of pre-eclampsia to be as common as discordance. Evidence from the largest published twin study, which correlated the Swedish Twin Register with the Swedish Medical Register, revealed pre-eclampsia penetrance to be less than 50%, suggesting diversity within models of inheritance.5–7

Pre-eclampsia: a complex genetic disorder

For a small number of families, pre-eclampsia seems to follow Mendelian patterns of disease inheritance,8 consistent with a rare deleterious monogenic variant or mutation with high penetrance. For most of the population, however, pre-eclampsia seems to represent a complex genetic disorder, and occurs as the result of numerous common variants at different loci which, individually, have small effects but collectively contribute to an individual’s susceptibility to disease. Environmental exposures, including age and weight, also determine whether these low penetrant variants result in phenotypic manifestation of the disease. It is likely that no single cause or genetic variant will account for all cases of pre-eclampsia, although it is possible that different variants are associated with various subsets of disease (e.g. pre-eclampsia combined with intrauterine growth restriction). Complex genetic disorders affect a high proportion of the population, representing a large burden to public health. New approaches to susceptibility gene discovery have emerged to address this challenge. Unfortunately, early diagnosis would only permit closer focus on routine antenatal care, as at present no intervention other than delivery has been shown to alter the course of pre-eclampsia.

Determining susceptibility to pre-eclampsia

The need to assess both the maternal and the fetal genotype is clear. The role of the placenta in the primary pathogenesis of the disorder indisputably indicates a fetal contribution to susceptibility to the disorder.9 Reports of severe, very early-onset pre-eclampsia in cases of fetal chromosomal abnormalities such as diandric hydatifidiform moles of entirely paternal genetic origin10 are consistent with a role for paternally inherited fetal genes in the determination of clinical phenotype. This is supported by epidemiological studies reporting a higher rate of pre-eclampsia in pregnancies fathered by men who were themselves born of pre-eclamptic pregnancies.11 The occurrence of pre-eclampsia in daughters-in-law of index women9 further supports a genetic contribution from both parents. The genetic conflict hypothesis states that fetal (paternal) genes will be selected to increase the transfer of nutrients to the fetus, whereas maternal genes will be selected to limit transfer in excess of a specific maternal optimum.12 Fetal genes are predicted to raise maternal blood pressure in order to enhance the uteroplacental blood flow, whereas maternal genes act the opposite way. Endothelial dysfunction in mothers with pre-eclampsia could, therefore, be interpreted as a fetal attempt to compensate for an inadequate uteroplacental nutrient supply.

As the phenotype is apparently only expressed during pregnancy, identification of ‘susceptible’ men is impossible. Most genetic studies of pre-eclampsia have focused on maternal genotypes only. The Genetics of Pre-eclampsia consortium highlighted the need to include analysis of all contributing genotypes, and carried out transmission disequilibrium testing in maternal and fetal triads.13 Understanding the contribution of the fetal genotype will require large sample sizes, with the development of algorithms to determine the relative contribution from mother and fetus. Furthermore, the decreased incidence of pre-eclampsia in second and subsequent pregnancies hampers analysis of the contribution of the fetal genotype.

Candidate gene approach

The candidate gene approach has been widely used in pre-eclampsia, and largely focuses on the maternal genotype. In this method, a single gene is chosen as the candidate for investigation based on prior biological knowledge of the pathophysiology of pre-eclampsia. The choice is strengthened if the gene lies within a region identified by linkage studies. A case-control design is usually used, comparing the frequencies of allelic variants in women with pre-eclampsia and normotensive pregnancies. Such studies need careful definition of inclusion criteria for cases and controls, and subtle ethnic stratification of groups must be avoided. Such performance characteristics of the genotyping assays as the rate of mis-genotyping, and the quality assurance methods used, should be clearly stated, but this is rarely done. Over 70 biological candidate genes have been examined, representing pathways involved in various pathophysiological processes, including vasoactive proteins, thrombophilia and hypofibrinolysis, oxidative stress and lipid metabolism, endothelial injury and immunogenetics.14 In common with the experience in other genetically complex disorders, results from candidate gene studies have been inconsistent, and no universally accepted susceptibility gene has been identified. Although this may, in part, be attributed to variation within populations, a more important factor is the small size of most of the candidate studies, which have been underpowered to detect variants with small effects. As there are more than 20,000 genes and 10 million single nucleotide polymorphisms (SNP) available, multiple testing will inevitably result in numerous results that achieve P values of less than 0.05. The development of robust statistical techniques for the minimisation of both false positive and false negative results is an important area.15,16 Only in recent years, as susceptibility genes for other complex disorders have been reported, has the small effect size of individual genetic variants become apparent, the majority increasing the risk of disease by less than 50%. A further limitation of the candidate gene approach is its reliance on the generation of an a-priori hypothesis based on our current incomplete knowledge of the pathophysiology of the disorder. The candidate genes studied belong to different groups according to their functional properties and plausible role in the pathophysiology (Table 2).

Thrombophilia

A successful pregnancy requires the development of adequate placental circulation. It is hypothesised that thrombophilias may increase the risk of placental insufficiency because of placental micro-vascular thrombosis, macro-vascular thrombosis, or both, as well as effects on trophoblast growth and differentiation.17 Abnormalities of the clotting cascade are well documented in women with pre-eclampsia.18 The endothelial damage of pre-eclampsia is associated with an altered phenotype from anticoagulant to procoagulant and decreased endothelially mediated vasorelaxation. It is possible that this phenotype is present before pre-eclampsia in pregnancy, or it may develop as a consequence of damage initiated during placentation. Furthermore, a subset of women develop frank thrombocytopaenia, often in association with haemolysis, elevated liver enzymes and low platelet count (HELLP) syndrome. Association of the three most widely studied thrombophilic factors, factor V Leiden (F5), methylenetetrahydrofolate (MTHFR) and prothrombin (F2), with pre-eclampsia has been shown; however, several studies have also shown contradictory results.14 A recent meta-analysis indicated a two-fold increase in risk for pre-eclampsia associated with 1691G>A mutation in F5, but no associations were found for MTHFR or F2.19 To date, the number of studies showing no association with pre-eclampsia for these three genes is much higher than the number confirming association. Association with the inhibitor of fibrinolysis plasminogen activator factor-1 gene has also been reported; however, replication attempts have failed.20–22

Haemodynamics and endothelial function

The renin-angiotensin system (RAS) is important for regulating the cardiovascular and renal changes that occur in pregnancy. Several studies have implicated the RAS in the pathophysiology of pre-eclampsia.23 As such, genes in the RAS have been considered as plausible candidates for pre-eclampsia. Angiotensin-converting enzyme (ACE), angiotensin II type 1 and type 2 receptor (AGTR1, AGTR2), and angiotensinogen (AGT) have all been studied extensively in pre-eclampsia. Recent meta-analyses have identified the T allele of AGT M235T as increasing the risk of developing pre-eclampsia by 1.62 times and similar increases in disease risk have been found in AGT and the angiotensin-converting enzyme I/D polymorphism.24 A rare functional polymorphism in AGT, which results in replacement of leucine by phenylalanine at the site of renin cleavage, has been reported in association with severe pre-eclampsia.25

Endothelial nitric oxide synthase 3 (eNOS3), which is involved in vascular remodelling and vasodilation, has been shown to have reduced activity in pre-eclampsia26 Association studies in different ethnic populations, however, have yielded both positive and negative findings. A meta-analysis investigating the E298D polymorphism, which had initially been associated with pre-eclampsia in Colombian women, failed to find increased risk.24 Vascular endothelial growth factor (VEGF) is important for endothelial cell proliferation, migration, survival and regulation of vascular permeability. The number of studies that have investigated SNP in the genes involved in the VEGF system is small. Two polymorphisms in VEGF, 405G>C and 936C>T, were found to be associated with the severe form of pre-eclampsia in two small studies, but cannot at present be considered as major risk factors.27,28

Oxidative stress and lipid metabolism

Oxidative stress plays a central role in the pathogenesis of pre-eclampsia. Maternal perfusion of the placenta does not occur until towards the end of the first trimester,29 when a rapid increase in local oxygen tension takes place, and the probable occurrence of a period of hypoxia–reperfusion until stability is reached. This is accompanied by increased expression and activity of such antioxidants as glutathione peroxidase, catalase and the various forms of superoxide dismutase.30 If this antioxidant response were reduced, then the cascade of events leading to impaired placentation could be initiated. Evidence for reduced antioxidant activity in pre-eclampsia has recently been reviewed.31 Genes involved in the generation or inactivation of reactive oxygen species, if defective, could increase endothelial dysfunction via lipid peroxidation, which has been a candidate causative agent for the endothelial damage of pre-eclampsia for more than 20 years.32 Despite the strong correlation between oxidative stress and pre-eclampsia, only a small handful of genes have been investigated. Functional polymorphisms in the gene for microsomal epoxide hydrolase (EPHX) that catalyses the hydrolysis of certain oxides and may produce toxic intermediates that could be involved in pre-eclampsia, and glutathione S-transferase (GST), an antioxidant capable of inactivating reactive oxygen species, have shown associations. Conflicting results, however, have also been reported.33–36

Abnormal lipid profiles associated with the lipid peroxidation caused by oxidative stress are also characteristic of pre-eclampsia. Lipoprotein lipase (LPL) and apolipoprotein E (ApoE) are the two major regulators of lipid metabolism, abundantly expressed in placenta, and have therefore been proposed as possible candidate genes.37,38 A recent study using bioinformatic analysis identified altered glycosylation of circulating ApoE isoforms in pre-eclampsia.39 A deglycosylated basic ApoE isoform was increased in pre-eclampsia, and an acidic ApoE sialyated isoform was decreased. Functionally, this might increase the risk of developing placental atherotic changes. The most promising genetic variant in this context is a mis-sense mutation, Asn291Ser, in LPL which correlates with lowered LPL activity and increased dyslipidaemia in two separate studies. Again, others have failed to replicate these findings.38,40,41 The fetal genotype of these two genes has also been reported to contribute to the metabolism of the maternal lipoproteins.37

Immune system

The maternal immune response to pregnancy is crucial in determining pregnancy outcome and success. The increased incidence of pre-eclampsia in primiparous women, especially those at either end of the childbearing age range, indicates a strong association between immune factors and pre-eclampsia.42 However, the protective effect of multiparity is lost with change of partner. Advances in assisted reproductive technology are also posing new challenges to the maternal immune system. The use of donated sperm or eggs increases the risk of pre-eclampsia three-fold.43

Human leucocyte antigen

Trophoblast cells express an unusual repertoire of histocompatibility antigens, comprising human leucocyte C, E and G class antigens (HLA-C, HLA-E, HLA-E), of which only HLA-C displays marked polymorphism. The expression of HLA on the invading cytotrophoblast is important, as these interact with killer immunoglobulin, such as receptors (KIR) expressed on maternal uNKs and cytotoxic T-lymphocytes, down-regulating their cytolytic activity and stimulating the production of cytokines needed for successful placentation. Multiple highly homologous KIR genes map to chromosome 19q, probably arising from ancestral gene duplications, and the two main resulting gene clusters have been classified as haplotypes A and B. The A group codes mainly for KIR, which inhibit natural killer cells, whereas the B group has additional stimulatory genes.44 Pre-eclampsia is more frequent in women who are homozygous for the inhibitory A haplotypes (AA) than in women homozygous for the stimulatory B haplotypes (BB). The effect is strongest if the fetus is homozygous for the HLA-C2 haplotype.45 Alteration in KIR interaction on uNK cells with HLA-C on interstitial trophoblast alters the decidual immune response, resulting in impaired extravillous trophoblast invasion and deficient spiral artery remodelling, associated with pre-eclampsia.

An association of HLA-G, which displays limited polymorphism, with pre-eclampsia, has also been reported. A possible association between the presence of the HLA-G allele G*0106 in the placenta and an increased risk of pre-eclampsia has been identified in two small studies.46,47 these were underpowered, however, and further studies using larger cohorts of mothers and babies are needed to replicate these results. HLA-G variants foreign to the mother may lead to histo-incompatibility between mother and child. A maternal rejection response to the semi-allogeneic fetus may represent one of the pathways involved in the development of pre-eclampsia.

A number of pro-inflammatory cytokines have also been investigated for possible associations with pre-eclampsia. Excessive release of tumour necrosis factor alpha (TNFα) has been implicated owing to its contribution to endothelial activation, which in turn could contribute to maternal symptoms.48 Interestingly, in pregnant rats, TNF induces hypertension, a response not seen in non-pregnant rats.49 Furthermore, plasma levels of TNFα are significantly higher in women with pre-eclampsia than matched controls.50 TNFα is also involved in the production of reactive oxygen species and subsequently oxidant mediated endothelial damage. The most frequently studied variant in pre-eclampsia is the –308G>A transition in the promoter region, which is associated with increased levels of TNFα production and an increased risk for pre-eclampsia linked disorders, including type 2 diabetes, coronary artery disease and dyslipidaemia.51,52 However, a meta-analysis from 2008 combined 16 studies investigating this promoter SNP, but failed to detect a significant association to pre-eclampsia.53

Interleukin-10 (IL-10) has also been implicated in the pathogenesis of pre-eclampsia by enhancing the inflammatory response towards trophoblast cells resulting in reduced invasion and remodelling of the spiral arteries.54 Expression of IL-10 is reduced in pre-eclamptic placentae.55 Studies investigating associations of variants of the gene and pre-eclampsia, however, have yielded conflicting results.56–58 Associations have also been detected for two additional inflammatory genes, interleukin-1α (IL-1α) and the interleukin 1 receptor anatagonist (IL1Ra) in relatively small studies, but few studies have addressed the role of polymorphisms in these genes so far.59,60

Antioxidant enzymes

A large family of cytosolic glutathione-s-transferases (GST) exists, and the P class is highly expressed in the human placenta. Several relatively small case-control studies of polymorphisms in this family in relation to pre-eclampsia have failed to identify any significant effect of several GST polymorphisms studied individually. However, a cumulative effect of the number of polymorphisms in various biotransformation enzymes, including GST, which would result in decreased antioxidant capacity, has been reported.61 Intriguingly, the use of semi-quantitative polymerase chain reaction on a small data set identified using serial analysis of gene expression profiles, seems to identify a specific molecular signature for HELLP, which includes decreased expression of GST P1.62

Remarkably, few studies of possible functional polymorphisms in antioxidant enzyme systems have been reported. The 242C>T polymorphism in exon 4 of the gene for the p22phox subunit of NADPH/NADH oxidase (CYBA), which is part of the cascade of superoxide generation, has been reported as showing no evidence of an association with either pre-eclampsia or HELLP and pre-eclampsa.63 A small preliminary study of the Ala40Thr polymorphism of the superoxide dismutase 3 gene (SOD3), which has been associated with insulin resistance, reported a significant excess of the mutant allele in women with severe intrauterine growth restriction.64

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145161/?report=printable

High blood pressure in pregnancy: What’s your story?

By Mary M. Murry, R.N., C.N.M.

Blood pressure tends to fluctuate during pregnancy.

For example, it’s normal to experience a drop in blood pressure during the second trimester. In fact, your blood pressure might be lower than it’s ever been. During the third trimester, a gradual increase in blood pressure is common.

Sometimes, though, blood pressure changes more dramatically — or sustained high blood pressure becomes a concern.

By definition, there are various types of high blood pressure during pregnancy:

  • Chronic hypertension. If high blood pressure develops before pregnancy or during pregnancy but before 20 weeks, it’s known as chronic hypertension. High blood pressure that lasts more than 12 weeks after delivery is also considered chronic hypertension.
  • Gestational hypertension. If high blood pressure develops after 20 weeks of pregnancy, it’s known as gestational hypertension. Gestational hypertension usually goes away after delivery.
  • Preeclampsia. Sometimes chronic hypertension or gestational hypertension leads to preeclampsia. This is a serious condition characterized by high blood pressure and protein in the urine after 20 weeks of pregnancy.

All of these conditions can be dangerous for you and your baby. If your pregnancy has been normal until now, a diagnosis of high blood pressure can be especially jarring.

Depending on the circumstances, your health care provider might recommend close monitoring or, in some cases, an early delivery.

Count on your health care provider to help you understand what’s happening and what you can do to promote a healthy outcome. Above all, don’t hesitate to ask questions. Being fully informed can help you make the best decisions for you and your baby.

http://www.mayoclinic.com/health/high-blood-pressure-in-pregnancy/MY02263

Texas A&M Researcher Uncovers New Data for the Treatment of Preeclampsia


Posted Thursday , June 06,2013

preeclampsia

A Researcher From Texas A&M Has Uncovered New Data for the Treatment of Preeclampsia: Preclinical Research Shows PLX Cells May Be Effective in Treating Preeclampsia.

Preliminary research led by Brett Mitchell, PhD, an Associate Professor of Internal Medicine in the Cardiovascular Research Institute (CVRI) at Texas A&M University College of Medicine, is demonstrating that administrating placental stem cells may aid in reversing symptoms linked with preeclampsia within days after dosing with no apparent harmful effects to fetus or mother.

Preeclampsia may occur after the 20th week of pregnancy when the mother-to-be’s blood pressure has increased and there are signs of excessive protein in the urine. This condition affects somewhere between 6-8 percentage of pregnancies in the US, and can be serious, as there is a shift from protecting mother and fetus as immunologically privileged sites. This brings about vascular issues that involve the inability of blood vessels to dilate or relax.

Dr. Mitchel has been able to look at the immune cells that are responsible for the development of high blood pressure (hypertension) during pregnancy in hopes to develop new therapies that diminish the immune cells that are responsible for this action while maintaining normal immune cell function.

Mitchel and colleagues have taken mice that had preeclampsia and injected placenta-based cells (stem cells) known as PLX (Placentall eXpanded) into leg muscle.  PLX cells are used as a way of delivering drugs and in particular therapeutic proteins in response to inflammatory and ischemic events.  They tested eight groups of 2 separate animal models (preeclampsia models) and found that PLX cells were effective in treating preeclampsia.

They observed a reduction in

  • systolic pressure to normal levels within 3 days and a reduction of
  • urinary proteins within 4 days.

They also observed an

  • increase in endothelial function.  This was measured by acetylcholine-induced relaxation and was effective within 4 days. A
  • weight reduction of the spleen was also observed within 4 days.

Pregnant mice who didn’t have preeclampsia were subjected to the same protocol and it was found that muscle injection of PLX cells did not effect a normal pregnancy.  They also found that the number of pups or fetal demise in a litter were not different indicating that PLX cells caused no fetal harm.

Dr. Mitchel presented his findings at the Society for Gynecologic Investigation Summit in Jerusalem on May 30, 2013.  Mitchell suggests that the factors that were secreted from the PLX cells were able to decrease inflammation thereby restoring endothelial function.

Currently, there are no treatments available for preeclampsia, so this therapy looks promising.

http://bionews-tx.com/news/2013/06/06/texas-a-and-m-new-data-for-the-treatment-of-preeclampsia-preclinical-research-shows-plx-cells-may-be-effective-in-treating-preeclampsia/

REFERENCE

http://www.preeclampsia.org/health-information/about-preeclampsia?gclid=CNeVjpG537cCFUYaOgodC0QASg

  1. Pregnancy. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/hbp/issues/preg/preg.htm. Accessed March 9, 2011.
  2. Conde-Agudelo A, et al. Maternal infection and risk of preeclampsia: Systematic review and metaanalysis. American Journal of Obstetrics and Gynecology. 2008;198:7.
  3. Bodnar LM, et al. Maternal vitamin D deficiency increases the risk of preeclampsia. Journal of Clinical Endocrinology & Metabolism. 2007;92:3517.
  4. High blood pressure and preeclampsia. March of Dimes. http://www.marchofdimes.com/complications_preeclampsia.html. Accessed March 9, 2011.
  5. Norwitz ER, et al. Management of preeclampsia. http://www.uptodate.com/home/index.html. Accessed March 7, 2011.
  6. Leanos-Miranda A, et al. Urinary prolactin as a reliable marker for preeclampsia, its severity, and the occurrence of adverse pregnancy outcomes. Journal of Clinical Endocrinology & Metabolism. 2008;93:2492.
  7. August P, et al. Clinical features, diagnosis, and long-term prognosis of preeclampsia. http://www.uptodate.com/home/index.html. Accessed March 7, 2011.
  8. Sibai BM, et al. Hypertension. In: Gabbe SG, et al. Obstetrics: Normal and Problem Pregnancies. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2007. http://www.mdconsult.com/das/book/body/208746819-4/0/1528/0.html. Accessed March 9, 2011.
  9. Barton JR, et al. Prediction and prevention of recurrent preeclampsia. Obstetrics & Gynecology. 2008;112:359.
  10. Bellamy L, et al. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: Systematic review and meta-analysis. British Medical Journal. 2007;335:974.
  11. Facchinetti F, et al. Migraine is a risk factor for hypertensive disorders in pregnancy: A prospective cohort study. Cephalalgia: An International Journal of Headache. 2009;29:286.
  12. Steegers EA, et al. Pre-eclampsia. The Lancet. 2010;376:631.

REFERENCES ON THE GENETICS of PRE-ECLAMPSIA in

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3145161/?report=printable

1. Brown M.A., Lindheimer M.D., de Swiet M. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP) Hypertens Pregnancy. 2001;20:IX–XIV. [PubMed: 12044323]
2. Chesley L.C., Annitto J.E., Cosgrove R.A. The familial factor in toxemia of pregnancy. Obstet Gynecol. 1968;32:303–311. [PubMed: 5742111]
3. Thornton J.G., Macdonald A.M. Twin mothers, pregnancy hypertension and pre-eclampsia. Br J Obstet Gynaecol. 1999;106:570–575.[PubMed: 10426615]
4. O’Shaughnessy K.M., Ferraro F., Fu B. Identification of monozygotic twins that are concordant for preeclampsia. Am J Obstet Gynecol. 2000;182:1156–1157. [PubMed: 10819852]
5. Chappell S., Morgan L. Searching for genetic clues to the causes of pre-eclampsia. Clin Sci (Lond) 2006;110:443–458. [PubMed: 16526948]
6. Cnattingius S. The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res.2004;6(Suppl. 2):S125–140. [PubMed: 15203816]
7. Salonen Ros H., Lichtenstein P., Lipworth L. Genetic effects on the liability of developing pre-eclampsia and gestational hypertension. Am J Med Genet.2000;91:256–260. [PubMed: 10766979]
8. Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia. Science. 2005;308:1592–1594. [PubMed: 15947178]
9. Cooper D.W., Brennecke S.P., Wilton A.N. Genetics of pre-eclampsia. Hypertens Pregnancy. 1993;12:1–23.
10. Esplin M.S., Fausett M.B., Fraser A. Paternal and maternal components of the predisposition to preeclampsia. N Engl J Med. 2001;344:867–872.[PubMed: 11259719]
11. Skjaerven R., Vatten L.J., Wilcox A.J. Recurrence of pre-eclampsia across generations: exploring fetal and maternal genetic components in a population based cohort. BMJ. 2005;331:877. [PMCID: PMC1255793] [PubMed: 16169871]
12. Haig D. Genetic conflicts in human pregnancy. Q Rev Biol. 1993;68:495–532. [PubMed: 8115596]
13. GOPEC Disentangling fetal and maternal susceptibility for pre-eclampsia: a British multicenter candidate-gene study. Am J Hum Genet. 2005;77:127–131. [PMCID: PMC1226184] [PubMed: 15889386]
14. Mutze S., Rudnik-Schoneborn S., Zerres K. Genes and the preeclampsia syndrome. J Perinat Med. 2008;36:38–58. [PubMed: 18184097]
15. Colhoun H., McKeigue P., Davey Smith G. Problems of reporting genetic associations with comlex outcomes. Lancet. 2003;361:865–872.[PubMed: 12642066]
16. Wacholder S., Chanock S., Garcia-Closas M. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst. 2004;96:434–442. [PubMed: 15026468]
17. Isermann B., Sood R., Pawlinski R. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003;9:331–337.[PubMed: 12579195]
18. Brenner B. Thrombophilia and pregnancy loss. Thromb Res. 2002;108:197–202. [PubMed: 12617981]
19. Lin J., August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol. 2005;105:182–192. [PubMed: 15625161]
20. Dalmaz C.A., Santos K.G., Botton M.R. Relationship between polymorphisms in thrombophilic genes and preeclampsia in a Brazilian population. Blood Cells Mol Dis. 2006;37:107–110. [PubMed: 16963292]
21. Fabbro D., D’Elia A.V., Spizzo R. Association between plasminogen activator inhibitor 1 gene polymorphisms and preeclampsia. Gynecol Obstet Invest.2003;56:17–22. [PubMed: 12867763]
22. Gerhardt A., Goecke T.W., Beckmann M.W. The G20210A prothrombin-gene mutation and the plasminogen activator inhibitor (PAI-1) 5G/5G genotype are associated with early onset of severe preeclampsia. J Thromb Haemost. 2005;3:686–691. [PubMed: 15842353]
23. Shah N.C., Pringle S., Struthers A. Aldosterone blockade over and above ACE-inhibitors in patients with coronary artery disease but without heart failure.J Renin Angiotensin Aldosterone Syst. 2006;7:20–30. [PubMed: 17083070]
24. Medica I., Kastrin A., Peterlin B. Genetic polymorphisms in vasoactive genes and preeclampsia: a meta-analysis. Eur J Obstet Gynecol Reprod Biol.2007;131:115–126. [PubMed: 17112651]
25. Inoue I., Rohrwasser A., Helin C. A mutation of angiotensinogen in a patient with preeclampsia leads to altered kinetics of the renin-angiotensin system.J Biol Chem. 1995;270:11430–11436. [PubMed: 7744780]
26. Brennecke S.P., Gude N.M., Di Iulio J.L. Reduction of placental nitric oxide synthase activity in pre-eclampsia. Clin Sci (Lond) 1997;93:51–55.[PubMed: 9279203]
27. Banyasz I., Bokodi G., Vannay A. Genetic polymorphisms of vascular endothelial growth factor and angiopoietin 2 in retinopathy of prematurity. Curr Eye Res. 2006;31:685–690. [PubMed: 16877277]
28. Papazoglou D., Galazios G., Koukourakis M.I. Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. Mol Hum Reprod.2004;10:321–324. [PubMed: 14997002]
29. Foidart J., Hustin J., Dubois M. The human placenta becomes haemochorial at the 13th week of pregnancy. Int J Dev Biol. 1992;36:451–453.[PubMed: 1445791]
30. Jauniaux E., Watson A., Hempstock J. Onset of maternal arterial blood flow and placental oxidative stress. A possible factor in human early pregnancy failure. Am J Pathol. 2000;157:2111–2122. [PMCID: PMC1885754] [PubMed: 11106583]
31. Perkins A.V. Endogenous anti-oxidants in pregnancy and preeclampsia. Aust N Z J Obstet Gynaecol. 2006;46:77–83. [PubMed: 16638026]
32. Wickens D., Wilkins M.H., Lunec J. Free radical oxidation (peroxidation)products in plasma in normal and abnormal pregnancy. Ann Clin Biochem.1981;18:158–162. [PubMed: 7283366]
33. Canto P., Canto-Cetina T., Juarez-Velazquez R. Methylenetetrahydrofolate reductase C677T and glutathione S-transferase P1 A313G are associated with a reduced risk of preeclampsia in Maya-Mestizo women. Hypertens Res. 2008;31:1015–1019. [PubMed: 18712057]
34. Gebhardt G.S., Peters W.H., Hillermann R. Maternal and fetal single nucleotide polymorphisms in the epoxide hydrolase and gluthatione S-transferase P1 genes are not associated with pre-eclampsia in the Coloured population of the Western Cape, South Africa. J Obstet Gynaecol. 2004;24:866–872.[PubMed: 16147638]
35. Laasanen J., Romppanen E.L., Hiltunen M. Two exonic single nucleotide polymorphisms in the microsomal epoxide hydrolase gene are jointly associated with preeclampsia. Eur J Hum Genet. 2002;10:569–573. [PubMed: 12173035]
36. Ohta K., Kobashi G., Hata A. Association between a variant of the glutathione S-transferase P1 gene (GSTP1) and hypertension in pregnancy in Japanese: interaction with parity, age, and genetic factors. Semin Thromb Hemost. 2003;29:653–659. [PubMed: 14719182]
37. Descamps O.S., Bruniaux M., Guilmot P.F. Lipoprotein metabolism of pregnant women is associated with both their genetic polymorphisms and those of their newborn children. J Lipid Res. 2005;46:2405–2414. [PubMed: 16106048]
38. Kim Y.J., Williamson R.A., Chen K. Lipoprotein lipase gene mutations and the genetic susceptibility of preeclampsia. Hypertension. 2001;38:992–996.[PubMed: 11711487]
39. Atkinson K.R., Blumenstein M., Black M.A. An altered pattern of circulating apolipoprotein E3 isoforms is implicated in preeclampsia. J Lipid Res.2009;50:71–80. [PubMed: 18725658]
40. Hubel C.A., Roberts J.M., Ferrell R.E. Association of pre-eclampsia with common coding sequence variations in the lipoprotein lipase gene. Clin Genet.1999;56:289–296. [PubMed: 10636447]
41. Zhang C., Austin M.A., Edwards K.L. Functional variants of the lipoprotein lipase gene and the risk of preeclampsia among non-Hispanic Caucasian women. Clin Genet. 2006;69:33–39. [PubMed: 16451134]
42. Roberts J.M., Pearson G., Cutler J. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension.2003;41:437–445. [PubMed: 12623940]
43. Wang J.X., Knottnerus A.M., Schuit G. Surgically obtained sperm, and risk of gestational hypertension and pre-eclampsia. Lancet. 2002;359:673–674.[PubMed: 11879865]
44. Hiby S.E., Walker J.J., O’Shaughnessy K.M. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med. 2004;200:957–965. [PMCID: PMC2211839] [PubMed: 15477349]
45. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol. 2005;5:201–214. [PubMed: 15719024]
46. Moreau P., Contu L., Alba F. HLA-G gene polymorphism in human placentas: possible association of G*0106 allele with preeclampsia and miscarriage.Biol Reprod. 2008;79:459–467. [PubMed: 18509163]
47. Tan C.Y., Ho J.F., Chong Y.S. Paternal contribution of HLA-G*0106 significantly increases risk for pre-eclampsia in multigravid pregnancies. Mol Hum Reprod. 2008;14:317–324. [PubMed: 18353802]
48. LaMarca B.D., Ryan M.J., Gilbert J.S. Inflammatory cytokines in the pathophysiology of hypertension during preeclampsia. Curr Hypertens Rep.2007;9:480–485. [PubMed: 18367011]
49. Alexander B.T., Cockrell K.L., Massey M.B. Tumor necrosis factor-alpha-induced hypertension in pregnant rats results in decreased renal neuronal nitric oxide synthase expression. Am J Hypertens. 2002;15:170–175. [PubMed: 11863253]
50. Sharma A., Satyam A., Sharma J.B. Leptin, IL-10 and inflammatory markers (TNF-alpha, IL-6 and IL-8) in pre-eclamptic, normotensive pregnant and healthy non-pregnant women. Am J Reprod Immunol. 2007;58:21–30. [PubMed: 17565544]
51. Elahi M.M., Asotra K., Matata B.M. Tumor necrosis factor alpha -308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009;1792:163–172. [PubMed: 19708125]
52. Saarela T., Hiltunen M., Helisalmi S. Tumour necrosis factor-alpha gene haplotype is associated with pre-eclampsia. Mol Hum Reprod. 2005;11:437–440. [PubMed: 15901845]
53. Bombell S., McGuire W. Tumour necrosis factor (-308A) polymorphism in pre-eclampsia: meta-analysis of 16 case-control studies. Aust N Z J Obstet Gynaecol. 2008;48:547–551. [PubMed: 19133041]
54. Renaud S.J., Macdonald-Goodfellow S.K., Graham C.H. Coordinated regulation of human trophoblast invasiveness by macrophages and interleukin 10.Biol Reprod. 2007;76:448–454. [PubMed: 17151353]
55. Makris A., Xu B., Yu B. Placental deficiency of interleukin-10 (IL-10) in preeclampsia and its relationship to an IL10 promoter polymorphism. Placenta.2006;27:445–451. [PubMed: 16026832]
56. Daher S., Sass N., Oliveira L.G. Cytokine genotyping in preeclampsia. Am J Reprod Immunol. 2006;55:130–135. [PubMed: 16433832]
57. Goddard K.A., Tromp G., Romero R. Candidate-gene association study of mothers with pre-eclampsia, and their infants, analyzing 775 SNPs in 190 genes. Hum Hered. 2007;63:1–16. [PubMed: 17179726]
58. Kamali-Sarvestani E., Kiany S., Gharesi-Fard B. Association study of IL-10 and IFN-gamma gene polymorphisms in Iranian women with preeclampsia.J Reprod Immunol. 2006;72:118–126. [PubMed: 16863661]
59. Faisel F., Romppanen E.L., Hiltunen M. Polymorphism in the interleukin 1 receptor antagonist gene in women with preeclampsia. J Reprod Immunol.2003;60:61–70. [PubMed: 14568678]
60. Haggerty C.L., Ferrell R.E., Hubel C.A. Association between allelic variants in cytokine genes and preeclampsia. Am J Obstet Gynecol. 2005;193:209–215.[PubMed: 16021081]
61. Zusterzeel P.L., Peters W.H., Burton G.J. Susceptibility to pre-eclampsia is associated with multiple genetic polymorphisms in maternal biotransformation enzymes. Gynecol Obstet Invest. 2007;63:209–213. [PubMed: 17167268]
62. Buimer M., Keijser R., Jebbink J.M. Seven placental transcripts characterize HELLP-syndrome. Placenta. 2008;29:444–453. [PubMed: 18374411]
63. Raijmakers M.T., Roes E.M., Steegers E.A. The C242T-polymorphism of the NADPH/NADH oxidase gene p22phox subunit is not associated with pre-eclampsia. J Hum Hypertens. 2002;16:423–425. [PubMed: 12037698]
64. Rosta K., Molvarec A., Enzsoly A. Association of extracellular superoxide dismutase (SOD3) Ala40Thr gene polymorphism with pre-eclampsia complicated by severe fetal growth restriction. Eur J Obstet Gynecol Reprod Biol. 2009;142:134–138. [PubMed: 19108943]
65. Arngrimsson R., Sigurardo-ttir S., Frigge M.L. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet. 1999;8:1799–1805. [PubMed: 10441346]
66. Laivuori H., Lahermo P., Ollikainen V. Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am J Hum Genet.2003;72:168–177. [PMCID: PMC378622] [PubMed: 12474145]
67. Moses E.K., Lade J.A., Guo G. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am J Hum Genet. 2000;67:1581–1585. [PMCID: PMC1287935] [PubMed: 11035632]
68. Lachmeijer A.M., Arngrimsson R., Bastiaans E.J. A genome-wide scan for preeclampsia in the Netherlands. Eur J Hum Genet. 2001;9:758–764.[PubMed: 11781687]
69. Lander E., Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11:241–247.[PubMed: 7581446]
70. Zintzaras E., Kitsios G., Harrison G.A. Heterogeneity-based genome search meta-analysis for preeclampsia. Hum Genet. 2006;120:360–370.[PubMed: 16868762]
71. Akolekar R., Etchegaray A., Zhou Y. Maternal serum activin a at 11-13 weeks of gestation in hypertensive disorders of pregnancy. Fetal Diagn Ther.2009;25:320–327. [PubMed: 19776595]
72. Roten L.T., Johnson M.P., Forsmo S. Association between the candidate susceptibility gene ACVR2A on chromosome 2q22 and pre-eclampsia in a large Norwegian population-based study (the HUNT study) Eur J Hum Genet. 2009;17:250–257. [PMCID: PMC2696227] [PubMed: 18781190]
73. Fitzpatrick E., Johnson M.P., Dyer T.D. Genetic association of the activin A receptor gene (ACVR2A) and pre-eclampsia. Mol Hum Reprod.2009;15:195–204. [PMCID: PMC2647107] [PubMed: 19126782]
74. Riento K., Ridley A.J. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446–456. [PubMed: 12778124]
75. Kandabashi T., Shimokawa H., Miyata K. Inhibition of myosin phosphatase by upregulated rho-kinase plays a key role for coronary artery spasm in a porcine model with interleukin-1beta. Circulation. 2000;101:1319–1323. [PubMed: 10725293]
76. Ark M., Yilmaz N., Yazici G. Rho-associated protein kinase II (rock II) expression in normal and preeclamptic human placentas. Placenta. 2005;26:81–84. [PubMed: 15664415]
77. Johnson M.P., Roten L.T., Dyer T.D. The ERAP2 gene is associated with preeclampsia in Australian and Norwegian populations. Human Genetics.2009;126(5):655–666. PMCID: PMC2783187. [PMCID: PMC2783187] [PubMed: 19578876]
78. WTCCC Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007;447:661–678.[PMCID: PMC2719288] [PubMed: 17554300]
79. Bezerra P.C., Leao M.D., Queiroz J.W. Family history of hypertension as an important risk factor for the development of severe preeclampsia. Acta Obstet Gynecol Scand. 2010;89:612–617. [PubMed: 20423274]
80. Hatada I., Mukai T. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse. Nat Genet. 1995;11:204–206. [PubMed: 7550351]
81. Oudejans C.B., Mulders J., Lachmeijer A.M. The parent-of-origin effect of 10q22 in pre-eclamptic females coincides with two regions clustered for genes with down-regulated expression in androgenetic placentas. Mol Hum Reprod. 2004;10:589–598. [PubMed: 15208369]
82. Rigourd V., Chauvet C., Chelbi S.T. STOX1 overexpression in choriocarcinoma cells mimics transcriptional alterations observed in preeclamptic placentas. PLoS One. 2008;3:e3905. [PMCID: PMC2592700] [PubMed: 19079545]
83. Berends A.L., Bertoli-Avella A.M., de Groot C.J. STOX1 gene in pre-eclampsia and intrauterine growth restriction. BJOG. 2007;114:1163–1167.[PubMed: 17617193]
84. Iglesias-Platas I., Monk D., Jebbink J. STOX1 is not imprinted and is not likely to be involved in preeclampsia. Nat Genet. 2007;39:279–280. author reply 280–271. [PubMed: 17325670]
85. Kivinen K., Peterson H., Hiltunen L. Evaluation of STOX1 as a preeclampsia candidate gene in a population-wide sample. Eur J Hum Genet.2007;15:494–497. [PubMed: 17290274]
86. Yu L., Chen M., Zhao D. The H19 gene imprinting in normal pregnancy and pre-eclampsia. Placenta. 2009;30:443–447. [PubMed: 19342096]
87. Nussbaum R.L., McInnes R.R., Willard H.F. In: Genetics in medicine. 6th ed. Thompson and Thompson, editor. Saunders; Philadelphia: 2004. pp. 289–309.
88. Treloar S.A., Cooper D.W., Brennecke S.P. An Australian twin study of the genetic basis of preeclampsia and eclampsia. Am J Obstet Gynecol.2001;184:374–381. [PubMed: 11228490]
89. Ronningen K.S., Paltiel L., Meltzer H.M. The biobank of the Norwegian mother and child cohort study: a resource for the next 100 years. Eur J Epidemiol. 2006;21:619–625. [PMCID: PMC1820840] [PubMed: 17031521]
90. Kho E.M., McCowan L.M., North R.A. Duration of sexual relationship and its effect on preeclampsia and small for gestational age perinatal outcome. J Reprod Immunol. 2009;82:66–73. [PubMed: 19679359]

Read Full Post »

Transposon-mediated Gene Therapy improves Pulmonary Hemodynamics and attenuates Right Ventricular Hypertrophy: eNOS gene therapy reduces Pulmonary vascular remodeling and Arterial wall hyperplasia

Reporter: Aviva Lev-Ari, PhD, RN

 

Sleeping Beauty-mediated eNOS gene therapy attenuates monocrotaline-induced pulmonary hypertension in rats

  1. Li Liu*,
  2. Hanzhong Liu†,
  3. Gary Visner† and
  4. Bradley S. Fletcher‡,1

  1. *Department of Pharmacology and Therapeutics, College of Medicine, University of Florida, Gainesville, Florida, USA;

  2.  

  3. †Division of Pulmonary Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA; and

  4.  

  5. ‡Medical Research Service, Department of Veteran Affairs Medical Center, Gainesville, Florida, USA
  1. ↵Correspondence: 1Correspondence: Department of Pharmacology and Therapeutics, 1600 S.W. Archer Rd., Box 100267, University of Florida, College of Medicine, Gainesville, FL 32610-0267, USA. E-mail: bsf@pharmacology.ufl.edu

DISCUSSION

Despite the diverse origins of etiology of pulmonary hypertension, the various disorders share similar histological and pathological findings, including endothelial dysfunction and the proliferation of SMCs resulting in vascular remodeling, in situ thrombus formation with obliteration of distal arterioles, and an inflammatory type reaction (2)⇓ . Treatment strategies for PH have relied on the use of vasodilators (e.g., calcium-channel blockers, prostacyclin) or phosphodiesterase inhibitors (e.g., sildenafil), which promote smooth muscle relaxation (4)⇓ . While pharmacological agents can be effective, potential drawbacks include the need for continuous i.v. infusion of prostacyclin derivatives or the use of nonselective vasodilators with potential side effects (3)⇓ . Inhaled NO has also been used as a treatment in patients with PH (41)⇓ ; however, its shortcomings include minimal response rates (∼10%), expense, the need for sophisticated delivery systems, and rebound hypertension (42)⇓ . These obstacles limit the therapeutic potential of the pharmacological approaches and suggest that alternative treatment modalities should be investigated.

As an alternative to simply promoting vasodilatation, an ideal strategy would be to combat the pathological processes that drive the increased pulmonary vascular resistance and loss of pulmonary microvasculature. This includes SMC proliferation and vascular remodeling, oxidative stress, inflammatory responses, and abnormal levels of vasoconstrictive molecules such as endothelin-1 (ET-1) (43)⇓ and certain prostanoids (44⇓ , 45)⇓ .

Gene therapy, especially multigene delivery, offers the possibility to overcome some of these pathological factors by using proteins or other genetic elements, such as RNA interference (RNAi), which target key regulators of vascular tone and regeneration. A growing body of literature points to the importance of endothelial-derived NO in promoting endothelial health and regulating vascular tone and regeneration.

Therefore, overexpression of eNOS, potentially in combination with inhibitors of expression of vasoconstrictor molecules (such as ET-1), is a therapeutic strategy that may reverse some of the pathological changes associated with late-stage PH.

In the present study, a severe model of PH (monocrotaline-induced) was used to test the ability of a nonviral approach to alleviate the pathological events leading to PH. Intravenous gene delivery of plasmid DNA complexed to the synthetic polymer polyethylenimine tends to transfect endothelial cells and type II pneumocytes within the lung (31⇓ , 32⇓ , 46)⇓ . Although endothelial cells would be ideal targets, we chose to use a very active nonspecific promoter to obtain the highest level of eNOS expression possible within the lung tissue. Using the CMV-driven eNOS transposon, we could demonstrate increased eNOS protein and nitrate production in vivo following gene transfer. In theory, increased NO production should lead to SMC relaxation, vasodilatation, and a reduction in PABP, which was observed in the hemodynamic studies (Fig. 3)⇓ .

However, a key factor in PH progression is increased pulmonary resistance due to SMC proliferation, intimal wall hyperplasia, and increased wall thickness. The histological data suggest that transposon-based eNOS expression prevented this hyperplasia and vascular remodeling. As NO has the ability to both inhibit SMCs proliferation and induce apoptosis (15⇓ , 47⇓ , 48)⇓ , it was unclear if the improvement in vascular remodeling was the result of growth inhibition or apoptotic effects of NO on SMCs. Tunnel assays on the histological sections revealed no significant difference in the amount of apoptosis in gene therapy-treated animals (data not shown), suggesting the effect was more on inhibition of SMC proliferation. Taken together, these results suggest that the

transposon-based approach can increase pulmonary NO production, reduce PABP, and attenuate right ventricular hypertrophy by preventing SMC proliferation and vascular remodeling.

Although SB has been used in other animal paradigms, this is the first report of using SB-mediated gene delivery to treat PH. Benefits of this approach, compared with several previous studies using adenovirus, include its nonviral delivery method, lack of inflammatory responses to viral components, cost-effectiveness, and ability to promote sustained therapeutic transgene expression. Given that SB transposons integrate within the host genome, there is some concern this approach may induce tumorigenic mutations, as has been seen with retrovirus (49)⇓ . Although this concern may be valid, SB is still considered one of the safest integrating vectors because of its near-random nature of integration (50)⇓ .

The problems associated with SB-mediated insertional mutagenesis could be overcome through the development of transposases with site-specific integration (51)⇓ . Lastly, clinically relevant delivery methods of plasmid DNA are still needed. Although the polymer PEI has recently been used in humans (52)⇓ , the efficiency of nonviral gene transfer could be improved through the synthesis more effective liposomes (e.g., cationic polymers and lipid) or lipoplexes with reduced toxicity. These complexes must be stable within plasma, transfect the pulmonary vasculature efficiently, and be able to navigate the cytoplasm to deliver the plasmid cargo to the nucleus. Given that few long-term treatment options,

other than lung transplantation, are available for PH, the success of this nonviral gene-based approach to attenuate the pathological processes driving PH warrants further investigations.

REFERENCES

  1. ↵
    Machado, R. D., Pauciulo, M. W., Thomson, J. R., Lane, K. B., Morgan, N. V., Wheeler, L., Phillips, J. A., 3rd, Newman, J., Williams, D., Galie, N., et al (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am. J. Hum. Genet. 68,92-102Epub 2000 Dec 2012
  2. ↵
    Hampl, V., Herget, J. (2000) Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension. Physiol. Rev. 80,1337-1372
  3. ↵
    Michelakis, E. D. (2003) The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev. 8,5-21
  4. ↵
    Strange, J. W., Wharton, J., Phillips, P. G., Wilkins, M. R. (2002) Recent insights into the pathogenesis and therapeutics of pulmonary hypertension. Clin. Sci. (Lond). 102,253-268
  5. ↵
    Giaid, A., Saleh, D. (1995) Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.333,214-221
  6. ↵
    Tyler, R. C., Muramatsu, M., Abman, S. H., Stelzner, T. J., Rodman, D. M., Bloch, K. D., McMurtry, I. F. (1999) Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am. J. Physiol. 276,L297-L303
  7. ↵
    Champion, H. C., Bivalacqua, T. J., Greenberg, S. S., Giles, T. D., Hyman, A. L., Kadowitz, P. J. (2002) Adenoviral gene transfer of endothelial nitric-oxide synthase (eNOS) partially restores normal pulmonary arterial pressure in eNOS-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 99,13248-13253Epub 12002 Sep 13217
  8. ↵
    Kouyoumdjian, C., Adnot, S., Levame, M., Eddahibi, S., Bousbaa, H., Raffestin, B. (1994) Continuous inhalation of nitric oxide protects against development of pulmonary hypertension in chronically hypoxic rats. J. Clin. Invest. 94,578-584
  9. ↵
    Roberts, J. D., Jr, Chiche, J. D., Weimann, J., Steudel, W., Zapol, W. M., Bloch, K. D. (2000) Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups. Circ. Res. 87,140-145
  10. ↵
    Champion, H. C., Bivalacqua, T. J., D’Souza, F. M., Ortiz, L. A., Jeter, J. R., Toyoda, K., Heistad, D. D., Hyman, A. L., Kadowitz, P. J. (1999) Gene transfer of endothelial nitric oxide synthase to the lung of the mouse in vivo. Effect on agonist-induced and flow-mediated vascular responses. Circ. Res. 84,1422-1432
  11. ↵
    Budts, W., Pokreisz, P., Nong, Z., Van Pelt, N., Gillijns, H., Gerard, R., Lyons, R., Collen, D., Bloch, K. D., Janssens, S. (2000) Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 102,2880-2885
  12. ↵
    Champion, H. C., Bivalacqua, T. J., Toyoda, K., Heistad, D. D., Hyman, A. L., Kadowitz, P. J. (2000) In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation 101,923-930
  13. ↵
    Louzier, V., Eddahibi, S., Raffestin, B., Deprez, I., Adam, M., Levame, M., Eloit, M., Adnot, S. (2001) Adenovirus-mediated atrial natriuretic protein expression in the lung protects rats from hypoxia-induced pulmonary hypertension. Hum. Gene Ther. 12,503-513
  14. ↵
    Partovian, C., Adnot, S., Raffestin, B., Louzier, V., Levame, M., Mavier, I. M., Lemarchand, P., Eddahibi, S. (2000) Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am. J. Respir. Cell Mol. Biol. 23,762-771
  15. ↵
    Schmidt, H. H., Walter, U. (1994) NO at work. Cell 78,919-925
  16. ↵
    Von der Leyen, H. E., Dzau, V. J. (2001) Therapeutic potential of nitric oxide synthase gene manipulation. Circulation 103,2760-2765
  17. ↵
    Kay, M. A., Glorioso, J. C., Naldini, L. (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat. Med. 7,33-40
  18. ↵
    Thomas, C. E., Ehrhardt, A., Kay, M. A. (2003) Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4,346-358
  19. ↵
    Gong, F., Tang, H., Lin, Y., Gu, W., Wang, W., Kang, M. (2005) Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits. Pediatr. Int. 47,242-247
  20. ↵
    Tahara, N., Kai, H., Niiyama, H., Mori, T., Sugi, Y., Takayama, N., Yasukawa, H., Numaguchi, Y., Matsui, H., Okumura, K., Imaizumi, T. (2004) Repeated gene transfer of naked prostacyclin synthase plasmid into skeletal muscles attenuates monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Hum. Gene Ther. 15,1270-1278
  21. ↵
    Campbell, A. I., Zhao, Y., Sandhu, R., Stewart, D. J. (2001) Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 104,2242-2248
  22. ↵
    Zhao, Y. D., Campbell, A. I., Robb, M., Ng, D., Stewart, D. J. (2003) Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ. Res. 92,984-991Epub 2003 Apr 2010
  23. ↵
    Zhao, Y. D., Courtman, D. W., Ng, D. S., Robb, M. J., Deng, Y. P., Trogadis, J., Han, R. N., Stewart, D. J. (2006) Microvascular regeneration in established pulmonary hypertension by angiogenic gene transfer. Am. J. Respir. Cell Mol. Biol.16,16
  24. ↵
    Niidome, T., Huang, L. (2002) Gene therapy progress and prospects: nonviral vectors. Gene Ther. 9,1647-1652
  25. ↵
    Ivics, Z., Hackett, P. B., Plasterk, R. H., Izsvak, Z. (1997) Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 91,501-510
  26. ↵
    Ohlfest, J. R., Frandsen, J. L., Fritz, S., Lobitz, P. D., Perkinson, S. G., Clark, K. J., Nelsestuen, G., Key, N. S., McIvor, R. S., Hackett, P. B., Largaespada, D. A. (2005) Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 105,2691-2698Epub 2004 Dec 2692
  27. ↵
    Liu, L., Mah, C., Fletcher, B. S. (2006) Sustained FVIII expression and phenotypic correction of hemophilia a in neonatal mice using an endothelial-targeted Sleeping Beauty transposon. Mol. Ther. 3,3
  28. ↵
    Yant, S. R., Meuse, L., Chiu, W., Ivics, Z., Izsvak, Z., Kay, M. A. (2000) Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat. Genet. 25,35-41
  29. ↵
    Montini, E., Held, P. K., Noll, M., Morcinek, N., Al-Dhalimy, M., Finegold, M., Yant, S. R., Kay, M. A., Grompe, M. (2002) In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol. Ther. 6,759-769
  30. ↵
    Goula, D., Benoist, C., Mantero, S., Merlo, G., Levi, G., Demeneix, B. A. (1998) Polyethylenimine-based intravenous delivery of transgenes to mouse lung.Gene Ther. 5,1291-1295
  31. ↵
    Belur, L. R., Frandsen, J. L., Dupuy, A. J., Ingbar, D. H., Largaespada, D. A., Hackett, P. B., Scott McIvor, R. (2003) Gene insertion and long-term expression in lung mediated by the Sleeping Beauty transposon system. Mol. Ther. 8,501-507
  32. ↵
    Liu, L., Sanz, S., Heggestad, A. D., Antharam, V., Notterpek, L., Fletcher, B. S. (2004) Endothelial targeting of the Sleeping Beauty transposon within lung. Mol. Ther. 10,97-105
  33. ↵
    Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., Zeiher, A. M. (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399,601-605
  34. ↵
    Yew, N. S., Zhao, H., Przybylska, M., Wu, I. H., Tousignant, J. D., Scheule, R. K., Cheng, S. H. (2002) CpG-depleted plasmid DNA vectors with enhanced safety and long-term gene expression in vivo. Mol. Ther. 5,731-738
  35. ↵
    Baus, J., Liu, L., Heggestad, A. D., Sanz, S., Fletcher, B. S. (2005) Hyperactive transposase mutants of the sleeping beauty transposon. Mol. Ther.12,1148-1156Epub 2005 Sep 1148
  36. ↵
    Patel, J. M., Zhang, J., Block, E. R. (1996) Nitric oxide-induced inhibition of lung endothelial cell nitric oxide synthase via interaction with allosteric thiols: role of thioredoxin in regulation of catalytic activity. Am. J. Respir. Cell Mol. Biol. 15,410-419
  37. ↵
    Zhou, H., Liu, H., Porvasnik, S. L., Terada, N., Agarwal, A., Cheng, Y., Visner, G. A. (2006) Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension. Lab. Invest. 86,62-71
  38. ↵
    Guignabert, C., Raffestin, B., Benferhat, R., Raoul, W., Zadigue, P., Rideau, D., Hamon, M., Adnot, S., Eddahibi, S. (2005) Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation111,2812-2819
  39. ↵
    Dupuy, A. J., Clark, K., Carlson, C. M., Fritz, S., Davidson, A. E., Markley, K. M., Finley, K., Fletcher, C. F., Ekker, S. C., Hackett, P. B., et al (2002) Mammalian germ-line transgenesis by transposition. Proc. Natl. Acad. Sci. U. S. A.99,4495-4499Epub 2002 Mar 4419
  40. ↵
    Rudolph, C., Lausier, J., Naundorf, S., Muller, R. H., Rosenecker, J. (2000) In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J. Gene Med. 2,269-278
  41. ↵
    Ichinose, F., Roberts, J. D., Jr, Zapol, W. M. (2004) Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation109,3106-3111
  42. ↵
    Miller, O. I., Tang, S. F., Keech, A., Celermajer, D. S. (1995) Rebound pulmonary hypertension on withdrawal from inhaled nitric oxide. Lancet 346,51-52
  43. ↵
    Giaid, A., Yanagisawa, M., Langleben, D., Michel, R. P., Levy, R., Shennib, H., Kimura, S., Masaki, T., Duguid, W. P., Stewart, D. J. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med.328,1732-1739
  44. ↵
    Galie, N., Manes, A., Branzi, A. (2003) Prostanoids for pulmonary arterial hypertension. Am. J. Respir. Med. 2,123-137
  45. ↵
    Galie, N., Manes, A., Branzi, A. (2004) The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. 61,227-237
  46. ↵
    Goula, D., Becker, N., Lemkine, G. F., Normandie, P., Rodrigues, J., Mantero, S., Levi, G., Demeneix, B. A. (2000) Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Ther. 7,499-504
  47. ↵
    Chen, L., Daum, G., Forough, R., Clowes, M., Walter, U., Clowes, A. W. (1998) Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ. Res. 82,862-870
  48. ↵
    Pilane, C. M., LaBelle, E. F. (2004) NO induced apoptosis of vascular smooth muscle cells accompanied by ceramide increase. J. Cell Physiol. 199,310-315
  49. ↵
    Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J. L., Fraser, C. C., Cavazzana-Calvo, M., Fischer, A. (2003) A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348,255-256
  50. ↵
    Yant, S. R., Wu, X., Huang, Y., Garrison, B., Burgess, S. M., Kay, M. A. (2005) High-resolution genome-wide mapping of transposon integration in mammals. Mol. Cell Biol. 25,2085-2094
  51. ↵
    Thyagarajan, B., Olivares, E. C., Hollis, R. P., Ginsburg, D. S., Calos, M. P. (2001) Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol. Cell Biol. 21,3926-3934
  52. ↵
    Ohana, P., Gofrit, O., S, A., Al-Sharef, W., Mizrahi, A., Birman, T., Schneider, T., Matouk, I., de Groot, N., Tavdy, E., Ami Sidi, A., Hochberg, A. (2004) Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer.Gene Ther. Mol. Biol. 8,181-192

http://www.fasebj.org/content/20/14/2594.full

http://www.fasebj.org/cgi/doi/10.1096/fj.06-6254fje

Other related articles published on this Open Access OnLine Scientific Journal, include the following:

How mobile elements in “Junk” DNA promote cancer. Part 1: Transposon-mediated tumorigenesis.

Stephen J. Williams, Ph.D

http://pharmaceuticalintelligence.com/2012/10/31/how-mobile-elements-in-junk-dna-prote-cacner-part1-transposon-mediated-tumorigenesis/

Endothelial Dysfunction, Diminished Availability of cEPCs, Increasing CVD Risk for Macrovascular Disease –Therapeutic Potential of cEPCs

Aviva Lev-Ari, PhD, RN 8/27/2012

http://pharmaceuticalintelligence.com/2012/08/27/endothelial-dysfunction-diminished-availability-of-cepcs-increasing-cvd-risk-for-macrovascular-disease-therapeutic-potential-of-cepcs/

Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013

Lev-Ari, A. and L H Bernstein 3/7/2013

http://pharmaceuticalintelligence.com/2013/03/07/genomics-genetics-of-cardiovascular-disease-diagnoses-a-literature-survey-of-ahas-circulation-cardiovascular-genetics-32010-32013/

The Heart: Vasculature Protection – A Concept-based Pharmacological Therapy including THYMOSIN

Aviva Lev-Ari, PhD, RN 2/28/2013

http://pharmaceuticalintelligence.com/2013/02/28/the-heart-vasculature-protection-a-concept-based-pharmacological-therapy-including-thymosin/

Arteriogenesis and Cardiac Repair: Two Biomaterials – Injectable Thymosin beta4 and Myocardial Matrix Hydrogel

Aviva Lev-Ari, PhD, RN 2/27/2013

http://pharmaceuticalintelligence.com/2013/02/27/arteriogenesis-and-cardiac-repair-two-biomaterials-injectable-thymosin-beta4-and-myocardial-matrix-hydrogel/

Coronary artery disease in symptomatic patients referred for coronary angiography: Predicted by Serum Protein Profiles

Aviva Lev-Ari, PhD, RN 12/29/2012

http://pharmaceuticalintelligence.com/2012/12/29/coronary-artery-disease-in-symptomatic-patients-referred-for-coronary-angiography-predicted-by-serum-protein-profiles/

Peroxisome proliferator-activated receptor (PPAR-gamma) Receptors Activation: PPARγ transrepression for Angiogenesis in Cardiovascular Disease and PPARγ transactivation for Treatment of Diabetes

Aviva Lev-Ari, PhD, RN 11/13/2012

http://pharmaceuticalintelligence.com/2012/11/13/peroxisome-proliferator-activated-receptor-ppar-gamma-receptors-activation-pparγ-transrepression-for-angiogenesis-in-cardiovascular-disease-and-pparγ-transactivation-for-treatment-of-dia/

Clinical Trials Results for Endothelin System: Pathophysiological role in Chronic Heart Failure, Acute Coronary Syndromes and MI – Marker of Disease Severity or Genetic Determination?

Aviva Lev-Ari, PhD, RN 10/19/2012

http://pharmaceuticalintelligence.com/2012/10/19/clinical-trials-results-for-endothelin-system-pathophysiological-role-in-chronic-heart-failure-acute-coronary-syndromes-and-mi-marker-of-disease-severity-or-genetic-determination/

Endothelin Receptors in Cardiovascular Diseases: The Role of eNOS Stimulation

Aviva Lev-Ari, PhD, RN 10/4/2012

http://pharmaceuticalintelligence.com/2012/10/04/endothelin-receptors-in-cardiovascular-diseases-the-role-of-enos-stimulation/

Inhibition of ET-1, ETA and ETA-ETB, Induction of NO production, stimulation of eNOS and Treatment Regime with PPAR-gamma agonists (TZD): cEPCs Endogenous Augmentation for Cardiovascular Risk Reduction – A Bibliography

Aviva Lev-Ari, PhD, RN 10/4/2012

http://pharmaceuticalintelligence.com/2012/10/04/inhibition-of-et-1-eta-and-eta-etb-induction-of-no-production-and-stimulation-of-enos-and-treatment-regime-with-ppar-gamma-agonists-tzd-cepcs-endogenous-augmentation-for-cardiovascular-risk-reduc/

Positioning a Therapeutic Concept for Endogenous Augmentation of cEPCs — Therapeutic Indications for Macrovascular Disease: Coronary, Cerebrovascular and Peripheral

Aviva Lev-Ari, PhD, RN 8/29/2012

http://pharmaceuticalintelligence.com/2012/08/29/positioning-a-therapeutic-concept-for-endogenous-augmentation-of-cepcs-therapeutic-indications-for-macrovascular-disease-coronary-cerebrovascular-and-peripheral/

Cardiovascular Outcomes: Function of circulating Endothelial Progenitor Cells (cEPCs): Exploring Pharmaco-therapy targeted at Endogenous Augmentation of cEPCs

Aviva Lev-Ari, PhD, RN 8/28/2012

http://pharmaceuticalintelligence.com/2012/08/28/cardiovascular-outcomes-function-of-circulating-endothelial-progenitor-cells-cepcs-exploring-pharmaco-therapy-targeted-at-endogenous-augmentation-of-cepcs/

Vascular Medicine and Biology: CLASSIFICATION OF FAST ACTING THERAPY FOR PATIENTS AT HIGH RISK FOR MACROVASCULAR EVENTS Macrovascular Disease – Therapeutic Potential of cEPCs

Aviva Lev-Ari, PhD, RN 8/24/2012

http://pharmaceuticalintelligence.com/2012/08/24/vascular-medicine-and-biology-classification-of-fast-acting-therapy-for-patients-at-high-risk-for-macrovascular-events-macrovascular-disease-therapeutic-potential-of-cepcs/

Cardiovascular Disease (CVD) and the Role of agent alternatives in endothelial Nitric Oxide Synthase (eNOS) Activation and Nitric Oxide Production

Aviva Lev-Ari, PhD, RN 7/19/2012

http://pharmaceuticalintelligence.com/2012/07/19/cardiovascular-disease-cvd-and-the-role-of-agent-alternatives-in-endothelial-nitric-oxide-synthase-enos-activation-and-nitric-oxide-production/

Resident-cell-based Therapy in Human Ischaemic Heart Disease: Evolution in the PROMISE of Thymosin beta4 for Cardiac Repair

Aviva Lev-Ari, PhD, RN 4/30/2012

http://pharmaceuticalintelligence.com/2012/04/30/93/

Triple Antihypertensive Combination Therapy Significantly Lowers Blood Pressure in Hard-to-Treat Patients with Hypertension and Diabetes

Aviva Lev-Ari, PhD, RN 5/29/2012

http://pharmaceuticalintelligence.com/2012/05/29/445/

Macrovascular Disease – Therapeutic Potential of cEPCs: Reduction Methods for CV Risk

Aviva Lev-Ari, PhD, RN 7/2/2012

http://pharmaceuticalintelligence.com/2012/07/02/macrovascular-disease-therapeutic-potential-of-cepcs-reduction-methods-for-cv-risk/

Mitochondria Dysfunction and Cardiovascular Disease – Mitochondria: More than just the “powerhouse of the cell”

Aviva Lev-Ari, PhD, RN 7/9/2012

http://pharmaceuticalintelligence.com/2012/07/09/mitochondria-more-than-just-the-powerhouse-of-the-cell/

Bystolic’s generic Nebivolol – positive effect on circulating Endothelial Proginetor Cells endogenous augmentation

Aviva Lev-Ari, PhD, RN 7/16/2012

http://pharmaceuticalintelligence.com/2012/07/16/bystolics-generic-nebivolol-positive-effect-on-circulating-endothilial-progrnetor-cells-endogenous-augmentation/

Heart Remodeling by Design – Implantable Synchronized Cardiac Assist Device: Abiomed’s Symphony

Aviva Lev-Ari, PhD, RN 7/23/2012

http://pharmaceuticalintelligence.com/2012/07/23/heart-remodeling-by-design-implantable-synchronized-cardiac-assist-device-abiomeds-symphony/

Dilated Cardiomyopathy: Decisions on implantable cardioverter-defibrillators (ICDs) using left ventricular ejection fraction (LVEF) and Midwall Fibrosis: Decisions on Replacement using late gadolinium enhancement cardiovascular MR (LGE-CMR)

Aviva Lev-Ari, PhD, RN 3/10/2013
http://pharmaceuticalintelligence.com/2013/03/10/dilated-cardiomyopathy-decisions-on-implantable-cardioverter-defibrillators-icds-using-left-ventricular-ejection-fraction-lvef-and-midwall-fibrosis-decisions-on-replacement-using-late-gadolinium/

PCI Outcomes, Increased Ischemic Risk associated with Elevated Plasma Fibrinogen not Platelet Reactivity

Aviva Lev-Ari, PhD, RN 1/10/2013
http://pharmaceuticalintelligence.com/2013/01/10/pci-outcomes-increased-ischemic-risk-associated-with-elevated-plasma-fibrinogen-not-platelet-reactivity/

The ACUITY-PCI score: Will it Replace Four Established Risk Scores — TIMI, GRACE, SYNTAX, and Clinical SYNTAX

Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/01/03/the-acuity-pci-score-will-it-replace-four-established-risk-scores-timi-grace-syntax-and-clinical-syntax/

Heart Renewal by pre-existing Cardiomyocytes: Source of New Heart Cell Growth Discovered

Aviva Lev-Ari, PhD, RN 12/23/2012
http://pharmaceuticalintelligence.com/2012/12/23/heart-renewal-by-pre-existing-cardiomyocytes-source-of-new-heart-cell-growth-discovered/

Cardiovascular Risk Inflammatory Marker: Risk Assessment for Coronary Heart Disease and Ischemic Stroke – Atherosclerosis.

Aviva Lev-Ari, PhD, RN 10/30/2012
http://pharmaceuticalintelligence.com/2012/10/30/cardiovascular-risk-inflammatory-marker-risk-assessment-for-coronary-heart-disease-and-ischemic-stroke-atherosclerosis/

To Stent or Not? A Critical Decision

Aviva Lev-Ari, PhD, RN 10/23/2012
http://pharmaceuticalintelligence.com/2012/10/23/to-stent-or-not-a-critical-decision/

New Definition of MI Unveiled, Fractional Flow Reserve (FFR)CT for Tagging Ischemia

Aviva Lev-Ari, PhD, RN 8/27/2012
http://pharmaceuticalintelligence.com/2012/08/27/new-definition-of-mi-unveiled-fractional-flow-reserve-ffrct-for-tagging-ischemia/

Expected New Trends in Cardiology and Cardiovascular Medical Devices

Aviva Lev-Ari, PhD, RN 8/17/2012
http://pharmaceuticalintelligence.com/2012/08/17/expected-new-trends-in-cardiology-and-cardiovascular-medical-devices/

Coronary Artery Disease – Medical Devices Solutions: From First-In-Man Stent Implantation, via Medical Ethical Dilemmas to Drug Eluting Stents

Aviva Lev-Ari, PhD, RN 8/13/2012

http://pharmaceuticalintelligence.com/2012/08/13/coronary-artery-disease-medical-devices-solutions-from-first-in-man-stent-implantation-via-medical-ethical-dilemmas-to-drug-eluting-stents/

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

 

PCR is an organisation dedicated to education and information in the field of cardiovascular therapies, most notably for cardiolovascular intervention and interventional medicine.
Its activities cover a large spectrum, from the organisation of annual courses in Europe, Asia and the Middle East to editing a scientific journal, publishing textbooks as well as providing training seminars on thematic subjects.

[92] TUESDAY 21 MAY

Abstract & Case Corner
Complex and unusual interventions for structural heart disease 12:30 – 13:30
Congenital disease treatment in children and adults 13:30 – 15:00
Challenges during percutaneous balloon mitral valvuloplasty 15:00 – 16:30
Percutaneous treatment of mitral regurgitation 16:45 – 18:15
Interactive Case Corner
Interactive case corner #1 13:15 – 14:45
Interactive case corner #2 15:00 – 16:30
Interactive case corner #3 16:45 – 18:15
Main arena
Opening 10:00 – 13:00
2013 Great Debate: The burning issues – Bioresorbable scaffolds and dual antiplatelet therapy 
With an unrestricted educational grant from MEDTRONIC
13:00 – 14:30
Presentation of the 2013 Ethica award by Jean Fajadet & William Wijns 14:30 – 15:00
From late breaking trial to clinical practice 15:00 – 16:45
Moderated Poster Area
Moderated posters 1 16:45 – 18:15
PCR Sharing Centre
Understand what you see with the iPad Atlas of OCT – Interactive OCT image interpretation 14:00 – 15:30
Do you want to become comfortable with health economics? Practical example: is TAVI cost effective? 15:40 – 16:40
Peripheral Abstract & Case Corner
Renal artery stenting: what you cannot leave behind 12:30 – 14:00
Subclavian artery angioplasty: rare but real 14:00 – 15:30
In vascular disease, think global! 15:30 – 16:30
Room 241
Embolic stroke and cardiovascular interventions 13:30 – 15:00
RSICA@EuroPCR – Combined structural heart disease interventions 
With the collaboration of the Russian Scientific Society of Interventional Cardioangiology
15:00 – 16:30
Percutanous haemodynamic support in high-risk PCI and cardiogenic shock: your safety net in the cathlab 
With an unrestricted educational grant from ABIOMED
16:45 – 18:15
Room 242AB
How to decide between antegrade versus retrograde recanalisation of coronary chronic total occlusions? 12:30 – 13:30
Techniques for antegrade revascularisation of coronary chronic total occlusion 13:30 – 14:30
Techniques for retrograde coronary chronic total occlusion recanalisation 14:30 – 15:30
Coronary chronic total occlusion: from procedural success to long-term outcome 15:30 – 16:30
Coronary chronic total occlusion: set up your strategy to achieve success while keeping it simple 
With an unrestricted educational grant from ABBOTT VASCULAR
16:45 – 18:15
Room 243
A decade of experience with DES: insights from large registries and randomised clinical trials 12:30 – 14:00
DES: updated evidence from randomised clinical trials 14:00 – 15:00
Coronary perforation and interventional devices 15:00 – 16:30
Coronary dissection: management of rare and common cases 16:45 – 18:15
Room 251
Managing challenges during TAVI 12:30 – 14:00
Current and future technologies in the cathlab 14:00 – 15:30
TAVI update 15:30 – 16:30
Room 252AB
Renal denervation for resistant hypertension: procedural aspects, clinical effects and off-target indications 12:30 – 14:00
Selecting the right patient for catheter-based renal sympathetic denervation: a case-based discussion 14:00 – 15:30
Emerging technologies for transcatheter aortic valve therapies – Part I 
undefined
15:30 – 16:30
Catheter-based renal sympathetic denervation: long-term Symplicity clinical evidence, new data and future perspectives 
With an unrestricted educational grant from MEDTRONIC
16:45 – 18:15
Room 253
Interventional strategies for thrombus management in STEMI 12:30 – 14:00
Stent for Life and 2012 ESC STEMI guidelines implementation 14:00 – 15:30
Primary PCI for STEMI: prevention of thrombus embolism 15:30 – 16:30
Clot, too much clot, new clots: primary PCI for STEMI 16:45 – 18:15
Room 341
Outcome in contemporary coronary intervention 12:30 – 14:00
Cardiovascular Innovation Pipeline – New stents, scaffolds and drug-eluting balloons 14:00 – 15:30
Procedural factors determining outcome in high-risk patients 15:30 – 16:30
Novelties in peripheral interventions 16:45 – 17:45
Room 342A
Is there consensus in approach to coronary chronic total occlusion management? 
Under the auspices of the British Cardiovascular Intervention Society (BCIS) and the Cardiovascular Society of India
12:30 – 14:00
Patients in whom PCI is preferred over CABG 
Under the auspices of the Working Group on Interventional Cardiology of the Croatian Cardiac Society, the Working Group on Interventional Cardiology of the Cyprus Society of Cardiology, the South African Society of Cardiovascular Interventions (SASCI) and the Working Group on Interventional Cardiology of the Serbian Society of Cardiology
14:00 – 16:30
Mechanical device support during PCI: when, to whom and which device? 
With an unrestricted educational grant from MAQUET Cardiovascular GETINGE GROUP
16:45 – 18:15
Room 342B
Use of intravascular imaging during PCI 12:30 – 13:30
Impact of IVUS in a real-world practice 13:30 – 14:30
Use of adjunctive imaging during PCI in ACS 14:30 – 15:30
Use of adjunctive imaging during PCI 15:30 – 16:30
Unsettled issues with oral antiplatelet therapy: which one? How much? How long? 16:45 – 18:15
Room 343
Risk scores to aid decision making between CABG and PCI – Role of SYNTAX Score II 12:30 – 14:00
Intra-coronary haemodynamic parameters for evaluation of coronary lesion severity during cardiac catheterisation: how should we use them for clinical decision making? 
Under the auspices of the British Cardiovascular Intervention Society (BCIS) and the Working Group on Interventional Cardiology of the Netherlands Society of Cardiology (WIC)
14:00 – 15:30
Percutaneous interventions for congenital disease 15:30 – 16:30
Strategies in percutaneous management of left main stem stenosis 16:45 – 18:15
Room 351
TAVI results from worldwide registries 12:30 – 14:00
Overcoming TAVI challenges 14:00 – 15:30
Managing difficulties during TAVI 15:30 – 16:30
Transapical TAVI and other surgical transcatheter techniques 
With an unrestricted educational grant from EDWARDS LIFESCIENCES, JENAVALVE, MEDTRONIC and SYMETIS S.A.
16:45 – 18:15
Room 352A
You are facing a patient who needs a PCI: how to build your strategy and select your material? 14:00 – 15:30
Clinical impact of stent design – What’s new in 2013? 15:30 – 16:30
How to prevent distal embolisation during PCI of diseased saphenous vein graft 16:45 – 18:15
Room 352B
Various imaging techniques for TAVI procedures 12:30 – 14:00
TAVI nightmares 
Under the auspices of the British Cardiovascular Intervention Society (BCIS) and the Working Group on Interventional Cardiology (AGIK) of the German Society of Cardiology (DGK)
14:00 – 15:30
Percutaneous valve implantation for rare causes 15:30 – 16:30
TAVI: predictors of clinical outcomes 16:45 – 18:15
Room 353
Non-aortic transcatheter valvular interventions 12:30 – 13:30
All you need to know about interventions for mitral regurgitation 13:30 – 15:00
Percutaneous treatment options for degenerative mitral regurgitation 15:00 – 16:30
Atrial septal defect and left atrial appendage closure 16:45 – 18:15
Room Cordis
Training Village: Radial approach for coronary diagnostic and interventions – hands-on with the experts 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
13:00 – 15:00
Training Village: Catheter-based renal sympathetic denervation: introduction to an irrigated technology 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
15:30 – 16:30
Training Village: Catheter-based renal sympathetic denervation: introduction to an irrigated technology 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
16:30 – 17:30
Training Village: Femoral artery access and haemostasis 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
17:30 – 18:30
Room Maillot
Trials and innovations for peripheral interventions 13:00 – 14:00
Revascularisation strategies in patients with lower limb disease 14:00 – 16:30
Titanium-nitride-oxide active coated stents in renal applications: the true indications of renal stenting after ASTRAL and after the introduction of denervation 
With an unrestricted educational grant from HEXACATH
16:45 – 18:15
Room Medtronic Academia
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
13:00 – 14:30
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
14:45 – 16:15
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
16:30 – 18:00
Room St Jude Medical
Training Village: PCI optimisation – Focus on FFR 
With an unrestricted educational grant from ST. JUDE MEDICAL
14:00 – 15:00
Training Village: PCI optimisation – Focus on FFR 
With an unrestricted educational grant from ST. JUDE MEDICAL
15:15 – 16:15
Training Village: Left atrial appendage 
With an unrestricted educational grant from ST. JUDE MEDICAL
15:45 – 17:15
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
16:30 – 17:30
Theatre Bleu
NIC@EuroPCR – Interventional procedures complicated with fatal outcome 
With the collaboration of the National Intervention Council of India
14:00 – 16:30
Left main PCI using transradial approach 
With an unrestricted educational grant from TERUMO
16:45 – 18:45
Theatre Bordeaux
Expanding the indication for TAVI: who, why and when? 14:30 – 16:30
Tips and tricks on the four key steps of left atrial appendage closure: selection, planning, imaging, and guidance 
PHILIPS and ST JUDE MEDICAL
16:45 – 18:45
Theatre Havane
Learning bifurcations – How to successfully perform PCI in your patient presenting complex bifurcation lesions requiring two stents 14:00 – 15:30
Interactive case-based discussion on complex bifurcations 15:40 – 16:30
Incorporating bioresorbable vascular scaffolds in daily clinical practice: the time has come 
With an unrestricted educational grant from ABBOTT VASCULAR

 

[173] WEDNESDAY 22 MAY

Abstract & Case Corner
Left main treatment: dedicated stents, complex strategies and post-CABG situation 08:00 – 09:30
Left main PCI for left main disease intervention: outcome in 2013 09:45 – 10:45
Treatment of left main stem stenosis in high-risk patients 10:45 – 11:45
Fistula and haematoma during PCI 12:00 – 13:00
PCI challenges: just another day in the cathlab? 13:00 – 14:00
Retrieval techniques of lost ‘bits and pieces’ during PCI 14:10 – 15:40
Unusual causes of ACS 15:40 – 16:40
Stent deformation during PCI 16:45 – 18:15
Interactive Case Corner
Interactive case corner #4 08:00 – 09:30
Interactive case corner #5 09:45 – 11:15
Interactive case corner #6 12:00 – 13:30
Interactive case corner #7 14:10 – 15:40
Interactive case corner #8 16:45 – 18:15
Main arena
Complex cardiovascular interventions and new techniques – Master LIVE demonstrations by Jean Fajadet & Talib Majwal and expert panel discussion 08:00 – 11:45
Complex cardiovascular interventions and new techniques – Master LIVE demonstrations by Karl Heinz Kuck & Talib Majwal and expert panel discussion 14:10 – 16:45
Moderated Poster Area
Moderated posters 2 12:00 – 14:00
Moderated posters 3 16:45 – 18:15
Nurses and Technicians Corner
Moderated posters 12:00 – 13:00
PCR Sharing Centre
Do you want to become comfortable with pathophysiology? Practical example: hypertensive patients 08:00 – 09:00
Understand what you see with the iPad Atlas of OCT – Interactive OCT image interpretation 09:45 – 11:15
Do you want to become comfortable with health economics? Practical example: is renal denervation cost effective? 14:10 – 15:10
Do you want to become comfortable with data analysis? 15:40 – 16:40
Peripheral Abstract & Case Corner
Thoraco-abdominal aneurysm treatment 08:00 – 09:30
Endovascular aortic aneurysm repair: an evergrowing story 09:45 – 10:45
Aortic aneurysms: fundamentals to innovation 10:45 – 11:45
Renal artery stenting: challenging but rewarding cases 12:00 – 13:00
How to manage aorto-renal rupture and dissection 13:00 – 14:00
Aneurysm and false aneurysm management for superficial femoral artery and popliteal artery 14:10 – 15:40
Multilevel vascular interventions 15:40 – 16:40
Complications and great saves on carotid interventions 16:45 – 17:45
Room 241
Percutaneous mitral valve repair with the MitraClip system: determinants of outcome 08:00 – 09:30
Technical and approach issues in renal artery stenting 
Under the auspices of the Working Group on Interventional Cardiology of the Bulgarian Society of Cardiology, the Working Group on Interventional Cardiology of the Macedonian Society of Cardiology and the Working Group on Interventional Cardiology of the Romanian Society of Cardiology
09:45 – 11:45
Chronic total occlusion and multivessel disease: can novel imaging help to reduce risks? 
With an unrestricted educational grant from PHILIPS and INFRAREDX
12:00 – 13:00
Cardioprotective strategies to reduce ischaemic injury during PCI 
With an unrestricted educational grant from MENARINI
13:05 – 14:05
How to avoid patient-prosthesis mismatch and aortic regurgitation after aortic valve interventions 14:10 – 15:40
Hot Line – First-in-man in valvular heart disease 15:40 – 16:40
New frontiers – Exploring reduced contrast volume and fluoroscopy time with the GPSCath balloon dilatation catheter for complex percutaneous transluminal angioplasty procedures 
With an unrestricted educational grant from TELEFLEX
16:45 – 18:15
Room 242AB
Innovative stents and scaffolds 08:00 – 09:40
Emerging technologies for transcatheter aortic valve therapies – Part II 09:45 – 11:45
Real-world considerations for selecting antiplatelet therapy in high-risk ACS patients: putting evidence into clinical practice 
This educational programme is accredited by EBAC for one hour of External CME credit – Programme supported by an unrestricted educational grant from ASTRAZENECA
12:00 – 13:30
Hot Line – Trial updates and registries 14:10 – 15:10
Managing patients with unprotected left main coronary artery disease 
With the collaboration of China Interventional Therapeutics (CIT)
15:10 – 16:40
Catheter-based renal sympathetic denervation – Building momentum with the next generation Vessix system 
With an unrestricted educational grant from BOSTON SCIENTIFIC
16:45 – 18:15
Room 243
Challenging coronary artery intervention in ACS 
Under the auspices of the Iranian Society of Interventional Cardiology (ISOIC) and the Russian Society of Interventional Cardioangiology (RSICA)
08:00 – 09:30
Hot Line – First-in-man & novel DES and scaffolds 09:45 – 11:45
Management of complex coronary disease in Asia Pacific 
With an unrestricted educational grant from MEDTRONIC
12:00 – 13:30
Complex cardiovascular intervention in patients primarily reported as ACS 
Under the auspices of the Working Group on Interventional Cardiology of the Czech Society of Cardiology and the Working Group on Interventional Cardiology of the Slovak Society of Cardiology
14:10 – 15:40
How to improve the STEMI treatment in large territories like Russia? 15:40 – 16:40
Impact of thrombus aspiration device on the results of primary PCI 16:45 – 18:15
Room 251
Primary PCI in complex STEMI with cardiogenic shock 08:00 – 09:30
Learning FFR – Assisting for FFR measurement in the cathlab 09:45 – 11:15
Synchronising polymer absorption and drug elution with the Synergy stent. Implications for healing and dual antiplatelet therapy duration 
With an unrestricted educational grant from BOSTON SCIENTIFIC
12:00 – 13:00
The Direct Flow valve: innovation for improving outcomes in TAVI 
With an unrestricted educational grant from DIRECT FLOW MEDICAL
13:05 – 14:05
Assisting for PCI through radial approach 14:10 – 15:40
Pre-procedure risk assessment to prevent complications after/during PCI 15:40 – 16:40
Clinical value of anti-restenosis and pro-healing Combo stent 
With an unrestricted educational grant from ORBUSNEICH
16:45 – 18:15
Room 252AB
How to treat a patient with complex multivessel disease and/or left main disease 
Under the auspices of the Argentine College of Interventional Cardioangiologist (CACI) and the Atheroma Coronary and Interventional Cardiology Group (GACI)
08:00 – 09:30
GRCI@EuroPCR – Challenging cases in the catheterisation laboratory: international viewpoint Gestion de cas complexes en salle de cathétérisme: approche internationale 
Bilingual session in collaboration with the GRCI (Groupe de Réflexion sur la Cardiologie Interventionnelle) Session bilingue en collaboration avec le GRCI (Groupe de Réflexion sur la Cardiologie Interventionnelle)
09:45 – 11:15
Advancing innovations in catheter-based renal sympathetic denervation 
CORDIS, JOHNSON & JOHNSON
12:00 – 13:30
Device-based interventions in heart failure: targeting deleterious mechanisms of heart failure progression 14:10 – 15:40
Novel devices for acute or chronic heart failure 15:40 – 16:40
DES and dual antiplatelet therapy: customising treatment duration to your patient 
With an unrestricted educational grant from ABBOTT VASCULAR
16:45 – 18:15
Room 253
Transradial approach for complex coronary interventions in patients with ACS 
Under the auspices of the Working Group on Interventional Cardiology of the Hungarian Society of Cardiology and the Working Group on Interventional Cardiology of the Macedonian Society of Cardiology
08:00 – 09:30
How to write a scientific manuscript and get it published! 09:45 – 10:45
From bench to cathlab: clinical implication of stent design 10:45 – 11:45
Conduction disturbances after TAVI 12:00 – 13:00
Overcoming TAVI challenges 13:00 – 14:00
Planning is the key to avoiding TAVI complications 
Under the auspices of the Association of Cardiovascular Interventions (ACVI) of the Polish Cardiac Society and the South African Society of Cardiovascular Intervention (SASCI)
14:10 – 15:40
How to write a scientific abstract and get it accepted! 15:40 – 16:40
Use of DES in specific subsets of patients/lesions 16:45 – 18:15
Room 341
Tough calls in primary PCI: STEMI and multivessel disease 
Under the auspices of the Working Group on Interventional Cardiology of the Israeli Heart Society and the Working Group on Interventional Cardiology of the Slovenian Society of Cardiology
08:00 – 09:30
Antegrade or retrograde strategy for coronary chronic total occlusion recanalisation? 09:45 – 10:45
Complicated coronary chronic total occlusion recanalisation 10:45 – 11:45
Resistant hypertension and its treatment across the world 
With an unrestricted educational grant from TERUMO
12:00 – 13:00
Coronary intervention in the elderly population 13:00 – 14:00
PCI in the elderly: when to stop, when to intervene 
Under the auspices of the Working Group on Interventional Cardiology of the Dutch Society of Cardiology and the Working Group on Interventional Cardiology (GTCI) of the Tunisian Society of Cardiology and Cardiovascular Surgery
14:10 – 15:40
Percutaneous revascularisation from coronary chronic total occlusion: results from registries 15:40 – 16:40
Single-guide catheter techniques for retrograde recanalisations for coronary chronic total occlusions 16:45 – 18:15
Room 342A
Intravascular diagnostics – Does it really change our treatment strategy? 
Under the auspices of the Working Group on Interventional Cardiology of the Danish Society of Cardiology and the Working Group on Interventional Cardiology of the Norwegian Society of Cardiology
08:00 – 09:30
Multivessel disease: “a tale of two cities” 
Under the auspices of the British Cardiovascular Intervention Society (BCIS) and the Working Group on Interventional Cardiology of the Cyprus Society of Cardiology
09:45 – 11:15
Self-expanding stents: a NEW solution for patients presenting with atypical coronary anatomy 
With an unrestricted educational grant from STENTYS
12:00 – 13:30
Complex primary PCI in high-risk STEMI patients 14:10 – 15:40
Non-left main bifurcation stenting: tips and tricks 15:40 – 16:40
Ischaemia-driven revascularisation: the evolution of FFR in daily practice 
With an unrestricted educational grant from ST. JUDE MEDICAL
16:45 – 18:15
Room 342B
Unusual causes of STEMI in young women 08:00 – 09:30
Different approaches for thrombus removal during primary PCI 09:45 – 10:45
Primary PCI for STEMI when stent is not the solution 10:45 – 11:45
Revascularisation strategies for multivessel disease patients: stents, bypasses or both? 12:00 – 13:00
Complex PCI in patients with multivessel disease 13:00 – 14:00
Challenging cases from Turkey 
With the collaboration of the Turkish Society of Cardiology’s Association of Percutaneous Cardiovascular Interventions
14:10 – 15:10
Individualised antiplatelet therapy based on testing or genotyping: idea from the past or solution for the future 15:40 – 16:40
Real life use of bioabsorbable vascular scaffold in coronary disease 16:45 – 18:15
Room 343
Patent foramen ovale closure in patients with cryptogenic stroke – Timed out or role respected? 
Under the auspices of the British Cardiovascular Intervention Society (BCIS) and the Working Group on Interventional Cardiology of the Danish Society of Cardiology
08:00 – 09:30
Multislice computed tomography: emerging indication in interventional cardiology 09:45 – 10:45
The role of non-invasive imaging to guide percutaneous coronary revascularisation procedures 10:45 – 11:45
FFR in the real world 12:00 – 13:00
FFR are we working with the best threshold? 13:00 – 14:00
STEMI and multivessel disease 
Under the auspices of the Working Group on Interventional Cardiology of the Georgian Society of Cardiology and the Working Group on Interventional Cardiology of the Kazakhstanese Society of Cardiology
14:10 – 15:40
Coronary aneurysms and ACS 15:40 – 16:40
Left ventricular assistance devices in acute ischaemic heart failure 16:45 – 18:15
Room 351
All you need to know about TAVI 08:00 – 09:30
New devices for TAVI 09:45 – 10:45
Percutaneous valve implantation: new valves and new indications 10:45 – 11:45
Complex patients today and tomorrow: Medtronic DES solutions from Resolute Integrity to bioresorbable stents 
With an unrestricted educational grant from MEDTRONIC
12:00 – 13:30
All you need to know about OCT 14:10 – 15:40
Use of OCT during PCI 15:40 – 16:40
The Medtronic transcatheter valve programmes – Recapturability, transapical technology and mitral solutions 
With an unrestricted educational grant from MEDTRONIC
16:45 – 18:15
Room 352A
You are facing an elderly patient presenting with high risk NSTE-ACS: how do you successfully perform PCI? 08:00 – 09:30
Radial approach – Fundamental rules 09:45 – 10:40
Radial approach – Navigation from radial to brachial 10:50 – 11:45
Radial access: anything new? 12:00 – 13:00
When there is no access site, remember that the arteries lead to the heart 13:00 – 14:00
You are facing a patient presenting with an acute STEMI: how do you successfully perform PCI? 14:10 – 15:40
Radial approach – Navigation from brachial artery to ascending aorta 15:45 – 16:40
Radial access: a gold standard worldwide? 16:45 – 18:15
Room 352B
TAVI: typical and atypical complications 
Under the auspices of the Association of Cardiovascular Interventions (ACVI) of Polish Cardiac Society and the Saudi Arabia Cardiology Interventional Group (SACIG) of the Saudia Heart Association
08:00 – 09:30
AICT@EuroPCR – How Asia performs PCI of coronary chronic total occlusion 
With the collaboration of the Asian Interventional Cardiovascular Therapeutics (AICT)
09:45 – 11:15
Titanium-nitride-oxide bioactive stent: the evidence-based choice in STEMI and NSTEMI patients 
With an unrestricted educational grant from HEXACATH
12:00 – 13:30
TAVI and coronary artery disease: what is the best treatment strategy? 
Under the auspices of the Working Group on Interventional Cardiology of the Latvian Society of Cardiology and the Russian Society of Interventional Cardioangiology
14:10 – 15:40
TAVI and coronary artery disease 15:40 – 16:40
A new combination of factor Xa inhibition and standard antiplatelet therapy to prevent more recurrent cardiovascular events in ACS 
With an unrestricted educational grant from BAYER HEALTHCARE PHARMACEUTICALS
16:45 – 18:15
Room 353
Czech Republic shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Czech Society of Cardiology
08:00 – 08:45
India shares its most educational cases 
Under the auspices of the Cardiovascular Society of India
08:45 – 09:30
Hungary shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Hungarian Society of Cardiology
09:45 – 10:30
Saudi Arabia shares its most educational cases 
Under the auspices of the Saudi Arabia Cardiology Interventional Society (SACIS) of the Saudia Heart Association
10:30 – 11:15
South Africa shares its most educational cases 
Under the auspices of the South African Society of Cardiovascular Intervention (SASCI)
11:15 – 12:00
Diabetes and coronary artery disease: a bad association! 12:00 – 13:00
Renal function and clinical outcome after PCI 13:00 – 14:00
Switzerland shares its most educational cases 
Under the auspices of the Working Goup on Interventional Cardiology and ACS of the Swiss Society of Cardiology
14:10 – 14:55
United Kingdom shares its most educational cases 
Under the auspices of the British Cardiovascular Intervention Society (BCIS)
14:55 – 15:40
Serbia shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Serbian Society of Cardiology
15:40 – 16:25
Iran shares its most educational cases 
Under the auspices of the Iranian Society of Interventional Cardiology (ISOIC)
16:45 – 17:30
Germany shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology (AGIK) of the German Society of Cardiology (DGK)
17:30 – 18:15
Room Cordis
Training Village: Radial approach for coronary diagnostic and interventions – hands-on with the experts 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
09:00 – 11:00
Training Village: Catheter-based renal sympathetic denervation: introduction to an irrigated technology 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
14:00 – 15:00
Training Village: Advanced tips and tricks: vessel preparation and post dilation 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
15:30 – 16:30
Room Maillot
Carotid LIVE session: the “state-of-the-art” of stroke prevention 08:00 – 09:55
Access is key for carotid artery stenting in complex aortic arches 10:00 – 10:50
Embolic protection devices for carotid artery stenting 10:50 – 11:45
Access is critical 
With an unrestricted educational grant from COOK MEDICAL
12:00 – 13:30
Visceral and renal artery interventions 14:10 – 15:40
Guest lectures: how I survived the peripheral endovascular battle? 15:40 – 16:40
The evolving evidence of IN.PACT drug-eluting balloon in claudication and critical limb ischaemia 
With an unrestricted educational grant from MEDTRONIC
16:45 – 18:15
Room Medtronic Academia
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
09:00 – 10:30
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
10:30 – 12:00
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
12:30 – 14:00
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
14:15 – 15:45
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
16:00 – 17:30
Room St Jude Medical
Training Village: Left atrial appendage 
With an unrestricted educational grant from ST. JUDE MEDICAL
09:00 – 10:30
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
10:15 – 11:15
Training Village: Left atrial appendage 
With an unrestricted educational grant from ST. JUDE MEDICAL
10:45 – 12:15
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
11:30 – 12:30
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
14:00 – 15:00
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
15:15 – 16:15
Training Village: Left atrial appendage 
With an unrestricted educational grant from ST. JUDE MEDICAL
15:45 – 17:15
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
16:30 – 17:30
Talk ‘LIVE’ Corner
Talk ‘LIVE’ 17:00 – 18:30
Theatre Bleu
Structured care pathways for NSTE-ACS: best practice examples 08:00 – 09:30
Complex bifurcation stenting: LIVE demonstration of emerging techniques 09:45 – 11:45
Do we really need dedicated stents to treat bifurcation lesions? 
With an unrestricted educational grant from BIOSENSORS INTERNATIONAL
12:00 – 14:00
Bioresorbable coronary scaffolds in practice 14:10 – 16:10
Acurate positioning of transapical and transfemoral aortic valves with self-seating and self-sealing design 
With an unrestricted educational grant from SYMETIS S.A.
16:45 – 18:45
Theatre Bordeaux
The best way to diagnose ischaemia in my patient? Convince me! Personal views from interventional cardiologists 08:00 – 09:30
Can left atrial appendage or patent foramen ovale closure prevent embolic stroke? 09:45 – 11:45
Optimising PCI outcomes using OCT and FFR in patients with stable and acute coronary artery disease 
With an unrestricted educational grant from ST. JUDE MEDICAL
12:00 – 14:00
What to do with coronary artery disease in TAVI candidates? 14:10 – 16:10
The next frontier for catheter-based renal sympathetic denervation for patients with resistant hypertension 
With an unrestricted educational grant from COVIDIEN
16:45 – 18:45
Theatre Havane
Learning access for TAVI – Access options for TAVI 08:00 – 09:30
Learning transseptal puncture and mitral balloon valvuloplasty – Transseptal puncture and mitral balloon valvuloplasty made easy 10:15 – 11:45
An in-depth look into the BIOFLOW trials: a modern limus-eluting stent with bioabsorbable polymer 
With an unrestricted educational grant from BIOTRONIK
12:00 – 13:30
Learning atrial closure procedures – Patent foramen ovale and left atrial appendage closure made easy 14:10 – 15:40
Interactive case-based discussion – complications on atrial closure procedures 15:45 – 16:40
Interventional management of high-risk ACS and STEMI: don’t just do it… do it right! 
With an unrestricted educational grant from TERUMO and THE MEDICINES COMPANY
16:45 – 18:15

[172] THURSDAY 23 MAY

Abstract & Case Corner
FFR or IVUS to guide coronary revascularisation? Do you believe in morphology or function? 08:00 – 09:30
Role of imaging in in-stent restenosis 09:45 – 10:45
Diagnostics and management of stent fracture 10:45 – 11:45
PCI of totally occluded saphenous vein graft 12:00 – 13:00
Interventional management of unusual causes of angina 13:00 – 14:00
The role of drug-eluting balloons in contemporary coronary intervention 14:10 – 15:40
Management of late in-stent restenosis 15:40 – 16:40
Coronary perforation management 16:45 – 17:45
Interactive Case Corner
Interactive case corner #9 08:00 – 09:30
Interactive case corner #10 09:45 – 11:15
Interactive case corner #11 12:00 – 13:30
Interactive case corner #12 14:10 – 15:40
Interactive case corner #13 16:45 – 18:15
Main arena
Complex cardiovascular interventions and new techniques – Master LIVE demonstrations by Corrado Tamburino, Martyn Thomas & Simon Redwood and expert panel discussion 08:00 – 11:45
Complex cardiovascular interventions and new techniques – Master LIVE demonstrations by Christian Hamm & Corrado Tamburino and expert panel discussion 14:10 – 16:45
Moderated Poster Area
Moderated posters 4 12:00 – 14:00
Moderated posters 5 16:45 – 18:15
PCR Sharing Centre
Understand what you see with the iPad Atlas of OCT – Interactive OCT image interpretation 08:00 – 09:30
Do you want to be more confident when developing and delivering PowerPoint presentations? 14:10 – 15:10
Do you want to become comfortable with data analysis? 15:40 – 16:40
Peripheral Abstract & Case Corner
Tips and tricks in carotid artery stenting 08:00 – 09:30
Carotid artery stenting: clinical outcome 09:45 – 10:45
Acute procedural events in carotid artery stenting 10:45 – 11:45
Carotid artery stenting: novelties in risk assessment 12:00 – 13:00
Carotid artery stenting: challenging scenarios 13:00 – 14:00
Aorto-iliac angioplasty: what is new in 2013 14:10 – 15:40
Iliac angioplasty 15:40 – 16:40
Complex aortic interventions 
With the collaboration of the International Society of Endovascular Specialists
16:45 – 18:15
Room 241
How I treat complications after peripheral endovascular intervention 
Under the auspices of the Italian Society for Vascular and Endovascular Surgery (SICVE) and the Vascular Surgery Society of Southern Africa (VASSA)
08:00 – 09:30
Cardiovascular Innovation Pipeline – New valves and devices 09:45 – 10:45
Radiation safety during PCI 10:45 – 11:45
Innovating vascular restoration: paving the way for the DESolve scaffold platform 
With an unrestricted educational grant from ELIXIR MEDICAL
12:00 – 13:30
How to prevent and treat ilio-femoral complications of TAVI? 14:10 – 15:40
Emerging technologies for transcatheter mitral valve therapies 2013 – Part I: transcatheter mitral valve repair devices 15:40 – 16:40
Tryton growing clinical experience and data displacing provisional stenting? 
With an unrestricted educational grant from TRYTON MEDICAL
16:45 – 18:15
Room 242AB
Challenges in complex percutaneous valve treatment: the combination of aortic stenosis and significant functional mitral regurgitation 08:00 – 09:30
Preclinical studies of upcoming bioresorbable scaffolds 09:45 – 11:45
The Embolic Protection Stent – Beyond current techniques: a more effective solution in STEMI primary PCI 
With an unrestricted educational grant from INSPIRE MD
12:00 – 13:30
Effect of catheter-based renal sympathetic denervation: is there a role beyond resistant hypertension? 14:10 – 15:40
Contribution of renal denervation to the treatment of resistant hypertension: a health technology assessment perspective 15:40 – 16:40
Edwards TAVI: a predictable procedure with sustained clinical results 
With an unrestricted educational grant from EDWARDS LIFESCIENCES
16:45 – 18:15
Room 243
PCI of bifurcation lesions: results from registries and new dedicated stents 08:00 – 09:30
Non-left main bifurcation stenting: tips and tricks 09:45 – 10:45
Non-left main bifurcation lesions: tips and tricks 10:45 – 11:45
Stent thrombosis: management challenges 12:00 – 13:00
Very late stent thrombosis 13:00 – 14:00
Innovations in Cardiovascular Interventions@EuroPCR 2013 
With the collaboration of Innovations in Cardiovascular Interventions (ICI)
14:10 – 15:40
Intervention for prevention of stroke 15:40 – 16:40
Stent thrombosis: new evidence from clinical trials and registries 16:45 – 18:15
Room 251
Best clinical abstract presentations 08:00 – 09:30
Best nurse research abstract session 09:45 – 11:15
Nurses and Technicians best presentation award and closing ceremony 11:15 – 11:45
The Portico TAVI system – How new design translates into clinical results 
With an unrestricted educational grant from ST. JUDE MEDICAL
12:00 – 13:00
Emerging clinical use of drug-eluting balloons in challenging atherosclerotic lesions 
With an unrestricted educational grant from BIOTRONIK
13:05 – 14:05
Challenging cases from Taiwan 
With the collaboration of the Taiwan Society of Cardiovascular Interventions
14:10 – 15:40
Left main dissection during PCI 15:40 – 16:40
Cre8: welcome back confidence in short dual antiplatelet therapy with effective DES 
With an unrestricted educational grant from CID
16:45 – 18:15
Room 252AB
All you need to know about catheter-based renal sympathetic denervation 08:00 – 09:30
Antiplatelet and antithrombotic therapy in PCI: a balancing act 09:45 – 11:15
Clinical update on EnligHTN, the original multi-electrode catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from ST. JUDE MEDICAL
12:00 – 13:30
Up-to-date primary PCI technique 14:10 – 15:40
GPIIbIII inhibitors : still useful in 2013? 15:40 – 16:40
What do YOU think? A case-based discussion on biodegradable versus durable polymer DES in complex patients 
With an unrestricted educational grant from BIOSENSORS INTERNATIONAL
16:45 – 18:15
Room 253
Restenosis after failure of CABG and PCI 
Under the auspices of the Working Group on Interventional Cardiology of the Danish Society of Cardiology and the Working Group on Interventional Cardiology of the Finnish Society of Cardiology
08:00 – 09:30
How to write a scientific manuscript and get it published! 09:45 – 10:45
ABC for biotechnology innovators@EuroPCR 
With the collaboration of Innovations in Cardiovascular Interventions (ICI)
10:45 – 11:45
Tools and techniques for PCI of coronary chronic total occlusion 12:00 – 13:00
How to treat coronary chronic total occlusion with limited resources and material? 13:00 – 14:00
New challenges for high-risk primary PCI in 2013 
Under the auspices of the Association of Cardiovascular Interventions (ACVI) of the Polish Cardiac Society and the Working Group of Acute Cardiology of the Slovenian Society of Cardiology
14:10 – 15:40
The unusual coronary chronic total occlusion: recanalisation in bypass patients, acute myocardial infarction and anomalous coronaries 15:40 – 16:40
New generation DES: comparison with older DES 16:45 – 18:15
Room 341
Prevention and management of complications after TAVI 
Under the auspices of the Portuguese Association for Interventional Cardiology (APIC) and the Working Group on Interventional Cardiology of the Spanish Society of Cardiology
08:00 – 09:30
Incidence and prevention of cerebrovascular events after TAVI 09:45 – 10:45
Challenges before, during and after TAVI 10:45 – 11:45
TAVI and bleeding complication 12:00 – 13:00
TAVI and kidney injury 13:00 – 14:00
TAVI with coronary artery disease 
Under the auspices of the Working Goup on Interventional Cardiology (EWGIC) of the Egyptian Society of Cardiology and the Working Group on Interventional Cardiology of the Lebanese Society of Cardiology
14:10 – 15:40
TAVI in unique clinical scenarios 15:40 – 16:40
TAVI technical issues 16:45 – 18:15
Room 342A
How to treat a patient with significant paravalvular leak after TAVI 
Under the auspices of the British Cardiovascular Intervention Society (BCIS) and the Atheroma Coronary and Interventional Cardiology Group (GACI)
08:00 – 09:30
Interventional treatment of acute ischaemic stroke: which role for STEMI networks? 09:45 – 11:45
Self-expanding stents: a NEW solution to optimise primary PCI beyond the open artery 
With an unrestricted educational grant from STENTYS
12:00 – 13:30
Cardiovascular Innovation Pipeline – Treatment of resistant hypertension 14:10 – 15:40
Hot Line – Registries and first-in-man for structural heart disease 15:40 – 16:40
Patient with STEMI: learn the best from East and West 
With an unrestricted educational grant from TERUMO
16:45 – 18:15
Room 342B
Determinants of outcome in STEMI patients 08:00 – 09:30
Resuscitated cardiac arrest – Burning interventional questions 09:45 – 11:45
Updates on contrast-induced nephropathy 12:00 – 13:00
Updates on myocardial revascularisation in patients with chronic kidney disease and haemodialysis 13:00 – 14:00
Unusual causes of STEMI 14:10 – 15:40
You cannot miss this great session on Rotablator! 15:40 – 16:40
Rotational atherectomy in complex coronary cases 16:45 – 18:15
Room 343
Challenges in acute myocardial infarction 
Under the auspices of the Working Group on Interventional Cardiology of the Austrian Society of Cardiology and the Working Goup on Interventional Cardiology and ACS of the Swiss Society of Cardiology
08:00 – 09:30
New methods for physiological assessment of coronary stenosis? 09:45 – 10:45
Complex PCI: which role for self-expanding stents? 10:45 – 11:45
Clinical value of IVUS during ACS: when you lose your way 12:00 – 13:00
Clinical value of IVUS: what others don’t tell 13:00 – 14:00
Challenging prosthetic mitral valve malfunction 
Under the auspices of the Working Group on Interventional Cardiology (AGIK) of the German Cardiac Society (DGK) and the Working Group on Invasive Cardiology of the Italian Society of Invasive Cardiology (SICI-GISE)
14:10 – 15:40
Clinical value of IVUS during coronary chronic total occlusion PCI: with a little help from your friend 15:40 – 16:40
Room 351
All you need to know about bioresorbable scaffolds 08:00 – 09:30
Hot Line – Evolving procedural strategies 09:45 – 11:45
Treating complex lesions and patients with bioresorbable vascular scaffolds 
With an unrestricted educational grant from ABBOTT VASCULAR
12:00 – 13:30
Bioresorbable vascular scaffolds in chronic total occlusions and calcified lesions 14:10 – 15:40
Bioresorbable scaffolds: clinical results 15:40 – 16:40
Complex cases of mitral regurgitation: how far can you go with MitraClip? 
With an unrestricted educational grant from ABBOTT VASCULAR
16:45 – 18:15
Room 352A
You are a practitioner who wishes to successfully start a peripheral percutaneous transluminal angioplasty (PTA) programme 08:00 – 09:30
Radial approach – Cannulation of the targeted vessels ostia 09:45 – 10:40
Forum on radial approach 10:50 – 11:45
Difficult diagnosis and management of ACS 12:00 – 13:00
Acute heart failure due to ACS 13:00 – 14:00
Cardiovascular Innovation Pipeline – Novel interventional approaches for heart failure 15:40 – 16:40
Radial access: problem or solution? 16:45 – 18:15
Room 352B
All you need to know about treatment of coronary chronic total occlusion 08:00 – 09:30
Renal denervation: novel approaches and first-in-man results 09:45 – 10:45
Management of intra-coronary thrombus during primary PCI 10:45 – 11:45
Provisional treatment approach of a distal left main and true bifurcation lesion: combination of a dedicated stent in the main branch and drug-eluting balloon in the side branch 
With an unrestricted educational grant from MINVASYS
12:00 – 13:30
EuroIntervention / European Heart Journal@EuroPCR 14:10 – 15:40
Unusual presentation of coronary aneurysms 15:40 – 16:40
How to treat aorto-ostial coronary dissection 16:45 – 18:15
Room 353
Tunisia shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology (GTCI) of the Tunisian Society of Cardiology and Cardiovascular Surgery
08:00 – 08:45
Italy shares its most educational cases 
Under the auspices of the Working Group on Invasive Cardiology of the Italian Society of Invasive Cardiology (SICI-GISE)
08:45 – 09:30
Egypt shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology (EWGIC) of the Egyptian Society of Cardiology
09:45 – 10:30
Kazakhstan shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Association of Cardiologists of Kazakhstan
11:15 – 12:00
Stent dislodgement during PCI 12:00 – 13:00
Aortic damage during percutaneous intervention 13:00 – 14:00
Spain shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Spanish Society of Cardiology
14:10 – 14:55
Sweden shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Swedish Society of Cardiology
14:55 – 15:40
Argentina shares its most educational cases 
Under the auspices of the Argentine College of Interventional Cardioangiologist (CACI)
15:40 – 16:25
Portugal shares its most educational cases 
Under the auspices of the Portuguese Association for Interventional Cardiology (APIC)
16:45 – 17:30
Greece shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Hellenic Cardiological Society
17:30 – 18:15
Room Cordis
Training Village: Endovascular complication management: renal access 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
09:00 – 10:00
Training Village: Catheter-based renal sympathetic denervation: introduction to an irrigated technology 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
10:30 – 11:30
Training Village: Radial approach for coronary diagnostic and interventions – hands-on with the experts 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
13:00 – 15:00
Training Village: Advanced Exoseal: achieving haemostasis and managing access site complications 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
15:30 – 16:30
Training Village: Importance of vessel pre- and post- dilatation for better patient outcomes 
With an unrestricted educational grant from CORDIS CARDIAC & VASCULAR INSTITUTE
16:45 – 18:00
Room Maillot
Solutions for complex abdominal aortic aneurysm 08:00 – 09:55
Therapeutic embolisation – Part I: tools and techniques for coronary and peripheral arteries 10:00 – 11:45
Left atrial appendage closure for stroke prevention: what every interventional cardiologist should know 
With an unrestricted educational grant from BOSTON SCIENTIFIC
12:00 – 13:00
New hopes for critical limb ischaemia 
With an unrestricted educational grant from TERUMO
13:05 – 14:05
Solutions for complex thoracic aortic disease 14:10 – 15:40
Therapeutic embolisation – Part II: clinical applications for coronary and peripheral arteries 15:40 – 16:40
Titanium-nitride-oxide active stent in ACS patients with or without bleeding risks 
With an unrestricted educational grant from HEXACATH
16:45 – 18:15
Room Medtronic Academia
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
09:00 – 10:30
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
10:30 – 12:00
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
12:30 – 14:00
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
14:15 – 15:45
Training Village: Hands-on introduction to the new Symplicity Spyral catheter-based renal sympathetic denervation system 
With an unrestricted educational grant from MEDTRONIC ACADEMIA
16:00 – 17:30
Room St Jude Medical
Training Village: PCI optimisation – Focus on OCT 
With an unrestricted educational grant from ST. JUDE MEDICAL
09:00 – 10:00
Training Village: PCI optimisation – Focus on OCT 
With an unrestricted educational grant from ST. JUDE MEDICAL
10:15 – 11:15
Training Village: Left atrial appendage 
With an unrestricted educational grant from ST. JUDE MEDICAL
10:45 – 12:15
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
11:30 – 12:30
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
14:00 – 15:00
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
15:15 – 16:15
Training Village: Left atrial appendage 
With an unrestricted educational grant from ST. JUDE MEDICAL
15:45 – 17:15
Training Village: TAVI 
With an unrestricted educational grant from ST. JUDE MEDICAL
16:30 – 17:30
Talk ‘LIVE’ Corner
Talk ‘LIVE’ 17:00 – 18:30
Theatre Bleu
Revascularisation in a patient with ischaemic heart failure and reduced left ventricular function 08:00 – 09:30
Treatment of coronary chronic total occlusion: Japan meets Europe 
With the collaboration of Complex Cardiovascular Therapeutics (CCT)
09:45 – 11:45
Left main and complex bifurcation stenting 
With an unrestricted educational grant from TERUMO
12:00 – 14:00
Am I treating the right lesion? Angiography versus ischaemia-based coronary revascularisation in stable coronary artery disease patients 14:10 – 16:10
Catheter-based renal sympathetic denervation: introducing the new Symplicity Spyral and Flex systems 
With an unrestricted educational grant from MEDTRONIC
16:45 – 18:45
Theatre Bordeaux
Enabling technologies for TAVI 08:00 – 09:30
Percutaneous treatment options for functional mitral regurgitation 09:45 – 11:45
Optimising TAVI procedures and patients outcomes: Medtronic’s new technologies and valve-in-valve procedure with Evolut 
With an unrestricted educational grant from MEDTRONIC
12:00 – 14:00
Valve-in-valve 14:10 – 16:10
Physiological stenosis assessment with FFR and instant wave-free ratio: we need both! 
With an unrestricted educational grant from VOLCANO
16:45 – 18:45
Theatre Havane
Optimal management of your NSTE-ACS patient with complex multivessel disease 08:00 – 09:30
Learning renal denervation – Critical appraisal on device-based therapies targeting the sympathetic system 09:45 – 11:45
Contemporary ACS antithrombotic therapy 
With an unrestricted educational grant from THE MEDICINES COMPANY
12:00 – 13:30
Learning ostial PCI – How to successfully perform PCI in a patient presenting ostial left main and ostial right coronary artery 14:10 – 15:40
Interactive case-based discussion – complications on ostial PCI 15:45 – 16:40
Contemporary coronary chronic total occlusion PCI: integrating the hybrid approach to your practice 
With an unrestricted educational grant from BOSTON SCIENTIFIC
16:45 – 18:15

 

 

 

[59] FRIDAY 24 MAY

Abstract & Case Corner
How to close paravalvular leak 09:00 – 10:30
Cases you have never seen 10:45 – 11:45
Unusual cases in the cathlab: diagnostic challenges 11:45 – 12:45
Interactive Case Corner
Interactive case corner #14 09:00 – 10:30
Interactive case corner #15 10:45 – 12:15
Main arena
Complex cardiovascular interventions and new techniques – Master LIVE demonstrations by Farrel Hellig, Martyn Thomas & Simon Redwood and expert panel discussion 09:00 – 13:00
PCR Sharing Centre
Do you want to be more confident when developing and delivering PowerPoint presentations? 09:00 – 10:00
Peripheral Abstract & Case Corner
Femoro-popliteal angioplasty : could new devices improve mid-term follow-up? 09:00 – 10:30
Chronic total occlusion revascularisation for superficial femoral artery 10:45 – 12:15
Room 241
Bioresorbable versus durable polymer coatings for DES 09:00 – 10:30
All you need to know about drug-coated balloons in coronary and peripheral vascular disease 10:45 – 12:15
Room 242A
Fully-absorbable jacket, in-stent restenosis and bypasses: new avenues for bioabsorbable vascular scaffolds? 09:00 – 10:30
Bioresorbable scaffolds: lessons learned from intracoronary imaging 10:45 – 11:45
Managing difficult stent cases 11:45 – 12:45
Room 242B
Challenging cases of saphenous vein graft interventions 09:00 – 10:30
Overcoming challenges during PCI 10:45 – 11:45
Helpful techniques during “extreme” PCI 11:45 – 12:45
Room 243
Predictors of in-stent restenosis and stent thrombosis after DES implantation 09:00 – 10:30
Stent thrombosis: overcoming challenging scenarios 10:45 – 12:15
Room 251
Emerging technologies for transcatheter mitral valve therapies 2013 – Part II: transcatheter replacement technologies 09:00 – 11:00
Novel catheter-based therapies of mitral regurgitation 11:00 – 12:00
Room 252A
Developments in percutaneous closure of the left atrial appendage 09:00 – 10:30
Percutaneous treatment of complex coronary aneurysms 10:45 – 11:45
Percutaneous management of complex coronary aneurysms 11:45 – 12:45
Room 252B
Primary PCI when the left main is the culprit 09:00 – 10:30
Primary PCI when the left main is the culprit 10:45 – 11:45
Left main dissection during PCI 11:45 – 12:45
Room 253
Below-the-knee angioplasty: risk stratification and DES benefits 09:00 – 10:00
Severe aortic stenosis combined with coronary artery disease in high-risk patient 
Under the auspices of the Working Group on Interventional Cardiology of the Hellenic Cardiological Society and the Working Group on Interventional Cardiology of the Israeli Heart Society
10:45 – 12:15
Room 341
Slow flow and no flow in PCI, not only in ACS: how to prevent and how to treat it? 
Under the auspices of the Working Group on Interventional Cardiology of the Danish Society of Cardiology and the Working Group on Interventional Cardiology of the Swedish Society of Cardiology
09:00 – 10:30
Renal denervation for resistant hypertension 10:45 – 12:15
Room 342A
Cardiogenic shock and intra-aortic balloon pump 
Under the auspices of the Luxembourg Society of Cardiology and the Working Group on Interventional Cardiology of the Norwegian Society of Cardiology
09:00 – 10:30
PCI of bifurcation lesions: impact of procedural techniques on clinical outcome 10:45 – 11:45
Bifurcation lesion: problems and solutions 11:45 – 12:45
Room 342B
TAVI or not TAVI: that is the question 
Under the auspices of the British Cardiovascular Intervention Society (BCIS) and the Working Group on Interventional Cardiology of the Spanish Society of Cardiology
09:00 – 10:30
Unfrequent indications for TAVI 10:45 – 11:45
TAVI in patients with previous cardiac valve operations 11:45 – 12:45
Room 343
Insights from OCT 09:00 – 10:30
Importance of OCT during PCI today 10:45 – 12:15
Room 351
Primary PCI for STEMI 
Under the auspices of the Working Group on Interventional Cardiology (BWGIC) of the Belgium Society of Cardiology and the Working Group on Interventional Cardiology of the Scottish Cardiac Society
09:00 – 10:30
All you need to know about radial approach for PCI 10:45 – 12:15
Room 352A
Learning rotablator – How to easily and successfully use rotational atherectomy 09:00 – 10:30
Novel techniques using rotational atherectomy 10:45 – 12:15
Room 352B
All you need to know about antiplatelet and antithrombotic pharmacology for PCI: NSTEMI and STEMI 09:00 – 10:30
Management of acute coronary artery occlusion during PCI 10:45 – 11:45
Retrieval of ‘things’ left behind during PCI 11:45 – 12:45
Room 353
Israel shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Israeli Heart Society
09:00 – 09:45
Macedonia shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Macedonian Society of Cardiology
09:45 – 10:30
Cyprus shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Cyprus Society of Cardiology
10:45 – 11:30
Austria shares its most educational cases 
Under the auspices of the Working Group on Interventional Cardiology of the Austrian Society of Cardiology
11:30 – 12:15
Room Maillot
Hybrid angio suite 09:00 – 10:30
Large size percutaneous access for endoaortic procedures 10:45 – 12:45
Theatre Bleu
Coronary perforation: management and implications 09:00 – 10:30
Device-based left ventricular cavity reduction in heart failure 10:45 – 12:15
Theatre Bordeaux
SOLACI@EuroPCR 
With the collaboration of the Sociedad Latino Americana de Cardiologia Intervencionista (SOLACI)
09:00 – 10:30
Tips and tricks for a successful catheter-based renal sympathetic denervation in difficult anatomies 10:45 – 12:45
Theatre Havane
Optimal management of your patient with coronary chronic total occlusion 09:00 – 10:30
The ‘undefeatable’ coronary chronic total occlusion: warriors at work 10:45 – 11:45
Challenging retrograde recanalisations of coronary chronic total occlusion 11:45 – 12:45
 SOURCE:

 

Read Full Post »

Imaging Biomarker for Arterial Stiffness: Pathways in Pharmacotherapy for Hypertension and Hypercholesterolemia Management

Author, and Content Consultant to e-SERIES A: Cardiovascular Diseases: Justin Pearlman, MD, PhD, FACC

and

Article Curator: Aviva Lev-Ari, PhD, RN

This article has Four Parts:

Part 1:

Quantification of Arterial Stiffness selected for its Predictive Value for Cardiovascular (CV) Events.

Arterial stiffness can predict cardiovascular adverse events such as stroke and heart attack. While there are various ways to define and estimate arterial stiffness, relatively simple surrogates have clinical advantages and favorable reports regarding predictive accuracy. This article will review in particular carotid-femoral pulse wave velocity (cfPWV) as an imaging-based biomarker of arterial stiffness.

Part II:

Results for Advances and Recent Clinical Trials in Hypertension Management

Caution is required in the interpretation of trial results, due to the Hawthorne Effect: participation in a trial confers benefits to all groups. Usually the Hawthorne effect is attributed to the close attention and is considered transient, but it can have lasting impact. In a retrospective cohort study, the benefits of participation in clinical trials irrespective of the treatment allocation were illustrated by better persistence and adherence to prescribed medication long term.

  • Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study.

Hypertension . 2011 ; 58 : 573 – 578 .

  • It is proving more and more difficult to show incremental benefit of new therapies over standard therapy in control groups that are on background therapy marked by high statin, antiplatelet, and other antihypertensive therapy rates, as well as more overweight and obesity and less tobacco use than in the past.

Participation in a Clinical Trial Enhances Adherence and Persistence to Treatment, A Retrospective Cohort Study Chronobiol Int . 2011 ; 28 : 601 – 610.

 Cardiorenal end points in a trial of Aliskiren for type 2 diabetes. N Engl J Med . 2012 ; 367 : 2204 – 2213.

Part III:

Pharmacotherapy for Hypertension and Hypercholesterolemia Management: Mechanism of Action of Top 10 Cardio Drugs 2012, published on May 16, 2013. FiercePharma reports the top 10 drugs from expenditure standpoint:

Part IV: Management Aspects of the Global Pharmaceutical Industry

The 20 Highest-Paid Biopharma CEOs of 2012 are also reported by FiersePharma.

Part 1:

Quantification of Arterial Stiffness selected for its Predictive Value for Cardiovascular (CV) Events.

based on

Stéphane Laurent, Elie Mousseaux and Pierre Boutouyrie, Arterial Stiffness as an Imaging Biomarker : Are All Pathways Equal?

http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.01372.citation

In a recent meta-analysis,2 Seventeen longitudinal studies totalizing 15,877 subjects with a mean follow-up of 7.7 years showed, for 1 SD increase in PWV, a risk ratio of 1.47 (1.31–1.64) for total mortality, 1.47 (1.29–1.66) for CV mortality, and 1.42 (1.29–1.58) for all-cause mortality.

Aortic stiffness, measured through cfPWV, can thus be considered as a novel imaging biomarker for predicting CV events, although its value as a true surrogate end point requires a large intervention trial to demonstrate that the reduction in arterial stiffness translates into a reduction in CV events.

Prediction of Occurrence of Cardiovascular Events Independently of Left Ventricular Mass in Hypertensive Patients: Monitoring of Timing of Korotkoff Sounds as Indicator of Arterial Stiffness

In this article by Gosse et al7 published in the present issue of Hypertension, the Authors provides an important contribution with regard to the predictive value of arterial stiffness for CV events for the following reasons:

  • First, the authors reported that arterial stiffness, measured in a population of 793 patients with hypertension with a mean follow-up of 97 months, was independently related to all CV events, major CV events, and total mortality. Interestingly, the predictive value was significant in all subgroups of CV risk, defined by a low, medium, or high SCORE risk. These findings confirmed those of previous studies.
  • Second, the authors took advantage of the simultaneous measurement of 24-hour blood pressure (BP) to include 24-hour mean BP in the multivariate Cox analysis, and this is a novelty. Thus, they were able to provide the demonstration that the predictive value of arterial stiffness is not only independent of office BP, as shown in most epidemiological studies, but also of 24-hour mean BP and pulse pressure (or alternatively 24-hour systolic and diastolic BPs) simultaneously measured.
  • Third, among the 793 patients, 519 patients had baseline measurements of arterial stiffness before any antihypertensive treatment, and the remaining 274 patients had measurement during the follow- up period. The independent predictive value of arterial stiffness was significant whether measured before or after the administration of antihypertensive treatment.
  • Finally, Gosse et al 7 showed, in a subgroup of 523 patients who had a measurement of left ventricular mass index, that the predictive value of arterial stiffness for major CV events was independent of left ventricular mass index. The authors thus confirmed the very few epidemiological studies which analyzed the predictive value of biomarkers of target organ damages (ie, left ventricular mass index, urinary albumin excretion rate, carotid intimamedia thickness, and arterial stiffness) and found that arterial stiffness retained a significant predictive value when adjusted either to left ventricular mass index6 or carotid intima-media thickness.5
  • The method which has been used to determine arterial stiffness. Indeed, Gosse et al 8 proposed, 2 decades ago, to take advantage of an ambulatory measurement of BP and continuous monitoring of ECG >24 hours, to calculate the QKD interval. QKD is the time between the onset of the QRS on the ECG and the detection of the last Korotkoff sound by the microphone placed on the brachial artery. It has 2 components:
  1. the pre-ejection time, which is influenced by heart rate and
  2. the pulse transmission time, which is inversely related to PWV, and arterial stiffness.
  • BP and QKD are measured repeatedly, and a stiffness parameter is derived from the linear regression of all the measurements of QKD, heart rate, and systolic BP >24 hours. The QKD interval is calculated for a 100-mm Hg BP, thus it gives an isobaric value of arterial stiffness, and for a 60-beats/min heart rate to reduce the influence of the pre-ejection time.
  • Most importantly, the arterial pathway of pulse wave transmission includes the ascending aorta, the aortic arch, and muscular arteries (subclavian and brachial), and thus,
  • differs from the carotid-femoral pathway of the cfPWV measurement, considered as gold standard for arterial stiffness.9
  • cfPWV is calculated as the ratio of the transit time between the feet of the carotid and femoral pressure waveforms, and the carotid-femoral distance, a ratio which is undisputedly recognized as a stiffness parameter. Several studies and a consensus statement have determined the correction factor, which should be applied to the carotid-femoral distance, to take into account the fact that, when the pressure wave is recorded at the carotid level, it has already reached the descending thoracic aorta.
  • The pressure wave travels mostly along an aortic segment, including the thoracic descending aorta and the abdominal aorta, and ultimately travels along the iliac and common femoral arteries. This is well exemplified by the Figure, which superimposes the trajectory of the pressure pulse wave on a normal angiogram obtained by magnetic resonance imaging.

VIEW FIGURE

The trajectories of the pressure pulse waves along the arterial segments are superimposed onto an angiogram obtained by computed tomography scan (left anterior oblique). The carotid-femoral pathway is described as dotted line, and the QKD pathway is described as dashed line.

pap62

FIGURE SOURCE:

http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.01372.citation

The method developed by Gosse et al 7,8 measures the time delay between the onset of the QRS on the ECG and the detection of the last Korotkoff sound by the microphone placed on the brachial artery. Thus, the pressure pulse wave travels first along the ascending aorta and the aortic arch (ie, a short pathway of elastic arteries) and then along the subclavian and brachial arteries (ie, a much longer pathway of muscular arteries).

Because the stiffness of muscular arteries is little influenced by age and hypertension, Gosse et al8 attributed the difference in QKD duration to ascending aorta and aortic arch. However, a closer look at the Figure shows that the length of the ascending and aortic arch pathway represents a very small part of the total pathway and casts doubt about this statement.

Furthermore, in magnetic resonance imaging studies, the transit time of flow wave along the aortic arch (average 120 mm length) is often found ≈35 ms in young healthy subjects,10 a value which is far from the mean 206 ms QKD duration found in the present study. Thus, part of that QFD duration has to be further explained by both the preejection period and the transit time within muscular arteries.

Alternative Devices

  • 2008 – The arteriograph system estimates PWV from a single-site determination of the suprasystolic waveform at the brachial artery site, and measures the time elapsed between the first wave ejected from the left ventricle to the aortic root, and its reflection from the bifurcation as the second systolic wave, with subtraction of the brachial artery transit time.
  • 2010 – The Mobil-O-Graph system uses oscillometric recording of brachial artery pressure waveform and reconstructs the central pulse wave by applying a transfer function. Central pulse wave is then decomposed into forward and backward waves, and PWV isestimated from their time difference.
  • Device |Method |Arterial Pathway |Predictive Value for CV Events | (Year of First Publication)

1984 Complior Mechanotransducer Carotid-femoral Yes (1999)

1990 Sphygmocor Tonometer Carotid-femoral Yes (2011)

1994 QKD ECG + Korotkoff sounds Aorta + brachial Yes (2005)

1997 Cardiov. Eng. Inc Tonometer Carotid-femoral Yes (2010)

2002 Doppler probes Doppler probe Aortic arch + descending aorta Yes (2002)

2002 VP-1000 Omron Brachial and ankle pressure cuffs Aorta + brachial + lower limbs Yes (2005)

2004 PulsePen Tonometer Carotid-femoral No

2006 CAVI-VaSera ECG + Brachial and ankle pressure cuffs Aorta + brachial + lower limbs No

2008 Arteriograph Arm pressure cuff Aorta + brachial No

2009 MRI-ArtFun MRI Aortic arch No

2009 Vicorder Cuffs Carotid-femoral No

2010 Mobil-O-Graph Arm pressure cuff Aorta No

Conclusions

The measurement of arterial stiffness is increasingly popular among physicians and researchers mainly because its predictive value for cardiovascular (CV) events has been well demonstrated. The largest amount of evidence has been given for aortic stiffness, measured through carotid-femoral pulse wave velocity (cfPWV). This has been initially reported in the late 1990s or early 2000s.1

Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241.

European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27:2588–2605.

Arterial Stiffness as an Imaging Biomarker : Are All Pathways Equal? http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.01372.citation

References for Imaging Biomarker for Arterial Stiffness, at the end of the paper

Part II:

Results for Advances and Recent Clinical Trials in Hypertension Management

Based on

Garry L.R. Jennings, Recent Advances in Hypertension:Recent Clinical Trials of Hypertension Management http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.00863.citation

Trends: tended to drive interest toward equivalence rather than efficacy studies (ie, trials designed to show an investigational agent is as good as, not better than, existing treatment), surrogate end points, including new blood pressure (BP) variables, and studies of combinations and algorithms rather than single interventions. Population studies around the world, however, continue to show that large numbers of people have hypertension that is not treated satisfactorily and are not achieving the goals set by the major national guidelines. These guidelines themselves are under continual scrutiny on the basis of recent data casting doubt on the validity of present BP goals. Guideline committees also face the issue that evidence based on expensive large-scale clinical trials is more often funded by the pharmaceutical or device industries than by government, leaving large evidence gaps in areas of public importance but no direct interest to industry funders. The purpose of the present article is to briefly review clinical trials of interventions in hypertension during the past 2 years.

Subject categories of Last Decade Clinical Trials on Hypertension

  • Resistant Hypertension
  • Resistant Hypertension and the Sympathetic
  • Nervous System
  • Trials of Pharmacotherapy
  • Old Ground, New Findings
  • Are Chlorthalidone and Nonthiazides the Best Diuretics for Treatment of Hypertension?
  • BP Targets and Treatment
  • Lifestyle and Nonpharmacological Approaches to Hypertension
  1.  Sodium
  2. Trials of Nutrition and BP
  • Resistance Exercise and BP

What Can Be Learned From Clinical Trials Reported in the Present Decade?

  • Systems for blood pressure management in the community can be improved because a large treatment gap remains.
  • Drug combinations from different classes with different modes of action are useful.
  • Drug combinations that include drugs with similar mode of action do not generally enhance efficacy and come at a cost in adverse events.
  • Small but important nutritional effects on blood pressure demand further examination.
  • The sympathetic nervous system has returned as an important target for therapy of hypertension.
  • Blood pressure targets and goals need refining, preferably on the basis of specifically designed clinical trials.

The scene for clinical trials of hypertension management is in transition. The era of mega trials may not be over but is certainly in decline, and in the past 2 years there have been no studies reporting primary outcome data the scale of the

  • Antihypertensive and
  • Lipid-Lowering Treatment
  1. Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),
  2. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET),
  3. Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), and other
  4. major studies that marked clinical trial activity and informed guideline committees during the past 2 to 3 decades.

This reflects in part the view that the

  • present benchmark pharmacological agents for treating hypertension are difficult to improve,
  • some systemic issues affecting the pharmaceutical industry influencing the ability to make the large investment required to perform mega trials and
  • the quality of the antihypertensive drug pipeline.

http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.00863.citation

References for Clinical Trial on Hypertension, at the end of the paper

Part III:

Mechanism of Action of Top 10 Cardio Drugs 2012, published on May 16, 2013

The top 10 Cardio Drugs in 2012 belong to two drug classes

  • Antihypertensive and
  • Lipid-Lowering Treatment

Sales % Change 2012 vs 2011 by Drug Class

MOA

By

Drug Class

Drug Name

2011 Sales billion

2012 Sales billion

% change

Statins

Crestor

6.622

6.253

-6%

Lipitor

9.577

3.948

-59%

Zetia

2.428

2.567

+6%

Vytorin

1.882

1.747

-7%

Total Sales and % change Statins

 20,509  14,515  -29.2%

ARB

Diovan

5.665

4.417

-22%

ACEII

Benicar

2.602

2.446

-6%

ACEI

Micardis

2.217

2.098

-5%

ARB

Avapro

1.797

1.422

-30% (BMS)

ARB

Blopress

1.808

1.643

-9%

PAH

Tracleer

1.721

1.6

-7%

Total Sales and % change AntiHTN

 15,810  13,626  -13.8%

Data Source:

http://www.fiercepharma.com/special-reports/top-10-cardio-drugs-2012#ixzz2U9Axh8X4 

1 Crestor

Crestor (AstraZeneca)
Patent expiry: July 2016

2012 sales: $6.253 billion
2011 sales: $6.622 billion
Change: (6%)

Crestor – FiercePharma http://www.fiercepharma.com/special-reports/crestor-0#ixzz2UACLZyaa 

(rosuvastatin calcium) is indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, non-HDL-C, and triglycerides, and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia and to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.1

2 Diovan

Diovan (Novartis)
Patent expiry: September 2012

2012 sales: $4.417 billion
2011 sales: $5.665 billion
Change: (22%)

Diovan – FiercePharma http://www.fiercepharma.com/special-reports/diovan#ixzz2UACdBCtZ 

Valsartan (Angiotan or Diovan) is an angiotensin II receptor antagonist (more commonly called an “ARB”, or angiotensin receptor blocker), with particularly high affinity for the type I (AT1) angiotensin receptor. By blocking the action of angiotensin, valsartan dilates blood vessels and reduces blood pressure.[1] In the U.S., valsartan is indicated for treatment of high blood pressure, congestive heart failure (CHF), or post-myocardial infarction (MI).[2]

3 Lipitor

Lipitor (Pfizer)
Patent expiry: November 2011

2012 sales: $3.948 billion
2011 sales: $9.577 billion
Change: (59%)

Lipitor – FiercePharma http://www.fiercepharma.com/special-reports/lipitor-2#ixzz2UACsJ2Y2 

(atorvastatin calcium) tablets are a prescription medicine that is used along with a low-fat diet. It lowers the LDL (“bad”) cholesterol and triglycerides in your blood. It can raise your HDL (“good”) cholesterol as well. LIPITOR can lower the risk for heart attack, stroke, certain types of heart surgery, and chest pain in patients who have heart disease or risk factors for heart disease such as age, smoking, high blood pressure, low HDL, or family history of early heart disease. LIPITOR can lower the risk for heart attack or stroke in patients with diabetes and risk factors such as diabetic eye or kidney problems, smoking, or high blood pressure.

LIPITOR is a member of the drug class known as statins, used for lowering blood cholesterol. It also stabilizes plaque and prevents strokes through anti-inflammatory and other mechanisms. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body.

Atorvastatin was first synthesized in 1985 by Bruce Roth of Parke-Davis Warner-Lambert Company (now Pfizer). The best selling drug in pharmaceutical history, sales of Lipitor since it was approved in 1996 exceed US$125 billion, and the drug has topped the list of best-selling branded pharmaceuticals in the world for nearly a decade

4 Zetia

Zetia (Merck)
Patent expiry: December 2016

2012 sales: $2.567 billion
2011 sales: $2.428 billion
Change: 6%

Zetia – FiercePharma http://www.fiercepharma.com/special-reports/zetia#ixzz2UADFaGJ0 

Ezetimibe (pron.: /ɛˈzɛtɨmɪb/) is a drug that lowers plasma cholesterol levels. It acts by decreasing cholesterol absorption in the intestine. It may be used alone (marketed as Zetia or Ezetrol), when other cholesterol-lowering medications are not tolerated, or together withstatins (e.g., ezetimibe/simvastatin, marketed as Vytorin and Inegy) when statins alone do not control cholesterol.

Ezetimibe decreases cholesterol levels, but has not been shown to improve outcomes in cardiovascular disease patients by decreasing atherosclerotic or vascular events compared to placebo. Ezetimibe is endorsed in the Canadian Lipid Guidelines and is considered a well-tolerated option for an add-on agent to statin, to help patients achieve their LDL (or bad cholesterol) targets. [1] Ezetimibe is the only add-on to statin therapy that has successfully shown cardiovascular benefit when combined with statin, but has not been proven to have an incremental benefit compared to statins alone. [2] Britain’s NICE statement, published in 2007, endorses its use for monotherapy if statins are not tolerated or as add-on therapy.[3]

5 Benicar

Benicar (Daiichi Sankyo)
Patent expiry: October 2016

2012 sales: $2.446 billion
2011 sales: $2.602 billion
Change: (6%)

Benicar – FiercePharma http://www.fiercepharma.com/special-reports/benicar#ixzz2UADYvld5 

BENICAR and BENICAR HCT are prescription medicines used to lower high blood pressure (hypertension). They may be used alone or with other medicines used to treat high blood pressure. BENICAR HCT is not for use as the first medicine to treat high blood pressure.

 Olmesartan medoxomil is an angiotensin II receptor antagonistused to treat high blood pressure.

Olmesartan is a prodrug that works by blocking the binding of angiotensin II to the AT1 receptors in vascular muscle; it is therefore independent of angiotensin II synthesis pathways, unlike ACE inhibitors. By blocking the binding rather than the synthesis of angiotensin II, olmesartan inhibits the negative regulatory feedback on renin secretion. As a result of this blockage, olmesartan reduces vasoconstriction and the secretion of aldosterone. This lowers blood pressure by producing vasodilation, and decreasing peripheral resistance.

6 Micardis

Micardis (Boehringer Ingelheim)
Patent Expiry: January 2014

2012 Sales: $2.098 billion
2011 Sales: $2.217 billion
Change: (5%)

Micardis – FiercePharma http://www.fiercepharma.com/special-reports/micardis#ixzz2UADpDZeO 

Micardis® (telmisartan) tablets are a prescription medicine used to treat high blood pressure (hypertension). Additionally, MICARDIS 80 mg tablets are used in certain high-risk people aged 55 years and older who are unable to take a medicine called an angiotensin converting enzyme inhibitor (ACE-I) to help lower their risk of having certain cardiovascular problems such as stroke, heart attack, or death.

Micardis® (telmisartan) tablets are a prescription medicine used to treat high blood pressure (hypertension).

Telmisartan (INN) (pron.: /tɛlmɪˈsɑrtən/) is an angiotensin II receptor antagonist (angiotensin receptor blocker, ARB) used in the management of hypertension. It is marketed under thetrade name Micardis (by Boehringer Ingelheim), among others.

Telmisartan is an angiotensin II receptor blocker that shows high affinity for the angiotensin II receptor type 1 (AT1), with a binding affinity 3000 times greater for AT1 than AT2. It has the longest half-life of any ARB (24 hours)[1][4] and the largest volume of distribution.

In addition to blocking the RAs, telmisartan acts as a selective modulator of peroxisome proliferator-activated receptor gamma (PPAR-γ), a central regulator of insulin and glucose metabolism. It is believed that telmisartan’s dual mode of action may provide protective benefits against the vascular and renal damage caused by diabetes and cardiovascular disease (CVD).[4]

Telmisartan’s activity at the PPAR-γ receptor has prompted speculation around its potential as a sport doping agent as an alternative to GW 501516.[5] Telmisartan activates PPARδ receptors in several tissues. [6][7][8][9]

7 Avapro

Avapro (Sanofi)
Patent expiry: March 2012

Total 2012 sales: $1.925 billion
2012 sales Sanofi: $1.422 billion
2012 sales BMS: $503 million

Total 2011 sales: $2.749 billion
2011 sales Sanofi: $1.797 billion
2011 sales BMS: $952 million
Total Change: (30%)

Avapro – FiercePharma http://www.fiercepharma.com/special-reports/avapro#ixzz2UAE9iB2E 

rbesartan (INN) (pron.: /ɜrbəˈsɑrtən/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part ofsanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.

As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment ofhypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,[1]hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).[2]

 A large randomized trial following 4100+ men and women with heart failure and normal ejection fraction (>=45%) over 4+ years found no improvement in study outcomes or survival with irbesartan as compared to placebo.[3]

8 Vytorin

Vytorin (Merck)
Patent Expiry: April 2017

2012 sales: $1.747 billion
2011 sales: $1.882 billion
Change: (7%)

Vytorin – FiercePharma http://www.fiercepharma.com/special-reports/vytorin#ixzz2UAEQVcQr 

Ezetimibe/simvastatin (pron.: /ɛˈzɛtɨmɪb ˌsɪmvəˈstætɨn/) is a drug combination used for the treatment of dyslipidemia. It is a combination of ezetimibe (best known as Zetia in the United States and Ezetrol elsewhere) and the statin drug simvastatin (best known as Zocor in the U.S.). The combination preparation is marketed by Merck & Co./Schering-PloughPharmaceuticals (joint venture) under the trade names Vytorin and Inegy.

Ezetimibe reduces blood cholesterol by inhibiting absorption of cholesterol by the small intestine by acting at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver.

Simvastatin is an HMG-CoA reductase inhibitor or statin. It works by blocking an enzymethat is necessary for the body to make cholesterol.

Even though ezetimibe decreases cholesterol levels, as of 2009 it has not been found to lead to improvement in real world outcomes.[1] The combination of simvastatin and ezetimibe has not been found to be any better than simvastatin alone. A panel of experts thus concluded in 2008 that it should “only be used as a last resort”.[2]

9 Blopress

Blopress (Takeda Pharmaceutical)
Patent expiry: June 2012

2012 sales: $1.643 billion
2011 sales: $1.808 billion
Change: (9%)

Blopress – FiercePharma http://www.fiercepharma.com/special-reports/blopress#ixzz2UAEnxyWy

Candesartan (rINN) (pron.: /ˌkændɨˈsɑrtən/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. The prodrug candesartan cilexetil is marketed by AstraZeneca and Takeda Pharmaceuticals, commonly under the trade names Blopress,Atacand, Amias, and Ratacand

As all angiotensin II receptor antagonists, candesartan is indicated for the treatment of hypertension. Results from the CHARM study in the early 2000s demonstrated the morbidity and mortality reduction benefits of candesartan therapy in congestive heart failure.[1] Thus, while ACE inhibitors are still considered first-line therapy in heart failure, candesartan can be used in combination with an ACE to achieve improved mortality and morbidity vs. an ACE alone and additionally is an alternative in patients intolerant of ACE inhibitor therapy.

Prehypertension

In a four-year randomized controlled trial, candesartan was compared to placebo to see whether it could prevent or postpone the development of full-blown hypertension in people with so-called prehypertension. During the first two years of the trial, half of participants were given candesartan, and the others received placebo; candesartan reduced the risk of developing hypertension by nearly two-thirds during this period. In the last two years of the study, all participants were switched to placebo. By the end of the study, candesartan hadsignificantly reduced the risk of hypertension, by more than 15%. Serious side effects were actually more common among participants receiving placebo than in those given candesartan.[2]

Candesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Candesartan/hydrochlorothiazide combination preparations are marketed under various trade names including Atacand HCT, Hytacand, Blopress Plus, Advantec and Ratacand Plus.

10 Tracleer

Tracleer (Actelion)
Patent expiry: November 2015   

2012 sales: $1.600 billion
2011 sales: $1.721 billion
Change: (7%)

Tracleer – FiercePharma http://www.fiercepharma.com/special-reports/tracleer#ixzz2UAF2iIJB 

Bosentan is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension (PAH). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of PAH under the trade name Tracleer.

Bosentan is a competitive antagonist of endothelin-1 at the endothelin-A (ET-A) and endothelin-B (ET-B) receptors. Under normal conditions, endothelin-1 binding of ET-A or ET-B receptors causes pulmonary vasoconstriction. By blocking this interaction, bosentan decreases pulmonary vascular resistance. Bosentan has a slightly higher affinity for ET-A than ET-B.

Clinical uses 

Bosentan is indicated mainly for the treatment of pulmonary hypertension. In 2007, bosentan was approved in the European Union also for reducing the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.

In the United States, bosentan is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO Class II-IV symptoms, to improve exercise capacity and decrease the rate of clinical worsening.[1]

http://www.fiercepharma.com/special-reports/top-10-cardio-drugs-2012

For years, cardio was king. The world’s all-time best-selling drug, Pfizer’s ($PFE) Lipitor, after all, is an antihyperlipidemic drug. Cardio drugs have traditionally made up one of the largest categories of therapeutic treatment in the drug universe.

According to EvaluatePharma‘s World Preview 2018 report, combined sales of antihypertensive drugs and antihyperlipidemics were more than $70 billion in 2011. That would put them at the top of the heap. Sales of antihypertensive drugs alone were more than $40 billion that year, making them the second-largest therapy area defined by the report, behind oncology drugs at $64.4 billion. The list, compiled by EvaluatePharma, includes the theraputic areas categorized as cardio, so it does not include some products sometimes used for heart disease but not in that therapeutic area, including blood thinners like Plavix.

But many of the top cardio drugs are long in the tooth, and generics are now eating their lunch. Did I mention Lipitor? Sales cratered last year, falling nearly 60%. Despite that, the drug placed third among the top 10 cardio drugs of 2012, a reminder of the stature it had achieved. Four of the top 10 have lost patent protection in the last two years, and most will be off patent by 2016, with only Merck’s ($MRK) Vytorin protected until 2017.

Last year, the top 10 cardio drugs racked up sales of $28.644 billion, down 23% from the $37.271 billion they sold in 2011. Still, the group has made a lot of money for its companies for years and, in some cases, completely changed the treatment of heart disease.

It is an interesting list. Only Merck has two drugs in the top 10. The other drugmakers make up a broad swath of the pharma industry. Read our report below, and if you have some insights you would like to share, please do.

Top 10 Cardio Drugs 2012 – FiercePharma http://www.fiercepharma.com/special-reports/top-10-cardio-drugs-2012#ixzz2UAByWR7s 

Part IV:

20 Highest-Paid Biopharma CEOs of 2012

Call it a rite of spring. Every year about this time, FiercePharma takes a look at executive compensation in the industry, and we rank the highest-paid CEOs. If you’re a regular reader, you’ll notice that this year’s list is longer than previous editions. And there’s a reason for that: curiosity.

As we were beginning to gather numbers from biopharma companies’ proxy statements and annual reports, news surfaced that Valeant Pharmaceuticals ($VRX) and Actavis ($ACT) had been in merger talks. The former CEO of Mylan ($MYL), one of Actavis’ rivals, regularly appeared on our highest-paid executives list, so we looked up the numbers on Actavis. No dice; CEO Paul Bisaro may have pulled off his biggest merger ever last year, but $8.66 million in compensation still didn’t qualify him for our ranking.

Then, we pulled out Valeant’s proxy statement. And while CEO Michael Pearson didn’t earn enough in 2012 to make the cutoff–his compensation just surpassed $6 million–he should have been at the top of the list last year. Pearson’s 2011 pay package broke $36 million. He collected more than $18 million in stock and option awards, plus a special $13.7 million dividend payment, stemming from agreements negotiated years before.

We hate to miss a scoop. Naturally. So, we vowed to avoid making the same mistake this time around. Rather than limit our executive-pay search to the biggest pharma companies and biotechs, plus the usual suspects who often make CEO-pay rankings, we used a bigger net. We collected compensation information from 50 companies, including numbers for CEOs, CFOs, R&D chiefs and other top executives.

Partly because of this search, but mostly because of big bonuses and awards at fast-growing Regeneron ($REGN), we have a brand-new No. 1 on our list. That’s Regeneron CEO Leonard Schleifer, whose 2012 compensation totaled $30.047 million. You’ll notice some other newbies, such as Leonard Bell from Alexion ($ALXN), whose pay bump put him in 12th place. And then there are familiar faces, such as Pfizer ($PFE) CEO Ian Read; Johnson & Johnson’s ($JNJ) former chairman and CEO, William Weldon; and Eli Lilly ($LLY) CEO John Lechleiter, who hung on in 10th place.

Many of the companies we researched pay their top people far less than the $10 million that served as our cutoff figure. Novo Nordisk ($NVO) CEO Lars Sorensen, who has presided over double-digit growth there for several years, collected a package of cash and stock awards worth about $5 million for 2012. GlaxoSmithKline ($GSK) CEO Andrew Witty made less than $6 million himself; he took a pay cut for the year because of Glaxo’s shortfall on certain performance targets.

And then there are others who would have made the list, had their titles been different. There’s Regeneron R&D chief George Yancopoulos, whose extraordinary $81 million in compensation shows how much the company appreciates its newly minted blockbuster, Eylea. There’s Mylan Chairman Robert Coury, who used to be a fixture on our list until Heather Bresch took over as CEO; he made more than $28 million last year. Novartis’ ($NVS) former chairman Daniel Vasella could have qualified for 12th place with his $13.98 million in compensation.

Vasella, then, gives us a quick segue to the ongoing debate over executive pay. In Switzerland, populist dismay at some high-profile compensation figures led to a public vote earlier this year. Citizens voted in new restrictions on common bonuses, such as golden parachutes, and gave shareholders a binding vote on executive pay. And local analysts figure that late-breaking news of Vasella’s behind-the-scenes noncompete agreement–worth some $78 million over 5 years–helped pay activists to get out the vote. (Vasella ended up refusing the deal, by the way.)

In the U.S., where executives are paid more than anywhere else in the world, shareholders at some companies have successfully lobbied for a greater emphasis on performance pay and against extraordinary bonuses, such as change-in-control payments that send top executives on their way with tens of millions after a merger. Other companies have instituted “say-on-pay” advisory votes for shareholders, but those often end up as rubber stamps for the status quo.

Now, we’re interested in what you have to say about executive compensation. Are the CEOs on this list worth their price? What’s a supersuccessful new drug worth? Should CEO pay be docked for R&D failures? What about failed launches? Should other, lower-paid executives earn more? Tweet your opinions to @FiercePharma using the hashtag #FPexecpay, leave your comments below or email us. We’ll collect your thoughts in a future article.

As always, feel free to send us your thoughts on our coverage. And if we missed a well-paid CEO, be sure to let us know.

— Tracy Staton (email | Twitter)

For more:
Top 10 Biotech CEO Pay Packages of 2012
Top 10 Pharma CEO salaries of 2010
Top 10 Pharma CEO salaries of 2009
2012’s 10 highest-paid Med Tech CEOs
Top 10 Medical Device Industry CEO Salaries for 2011


20 Highest-Paid Biopharma CEOs of 2012 – FiercePharma http://www.fiercepharma.com/special-reports/20-highest-paid-biopharma-ceos-2012#ixzz2UAGAlHay 

REFERENCES FOR Part I: Arterial Stiffness

1. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L,

Ducimetiere P, Benetos A. Aortic stiffness is an independent predictor

of all-cause and cardiovascular mortality in hypertensive patients.

Hypertension. 2001;37:1236–1241.

2. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular

events and all-cause mortality with arterial stiffness: a systematic

review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–1327.

3. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P,

Laurent S. Aortic stiffness is an independent predictor of primary coronary

events in hypertensive patients: a longitudinal study. Hypertension.

2002;39:10–15.

4. Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos

ML, Schalekamp MA, Asmar R, Reneman RS, Hoeks AP, Breteler MM,

Witteman JC. Arterial stiffness and risk of coronary heart disease and

stroke: the Rotterdam Study. Circulation. 2006;113:657–663.

5. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H,

Torp-Pedersen C, Olsen MH. Risk stratification with the risk chart from

the European Society of Hypertension compared with SCORE in the general

population. J Hypertens. 2009;27:2351–2357.

6. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ,

Hamburg NM, Vita JA, Levy D, Benjamin EJ. Arterial stiffness and

cardiovascular events: the Framingham Heart Study. Circulation. 2010;

121:505–511.

7. Gosse P, Cremer A, Papaioannou G, Yeim S. Arterial stiffness from monitoring

of timing of Korotkoff sounds predicts the occurrence of cardiovascular

events independently of left ventricular mass in hypertensive

patients. HYPERTENSIONAHA.113.01039 Published online before print May 20, 2013,doi: 10.1161/​HYPERTENSIONAHA.113.01039

Hypertension. 2013;62:XX–XX.

http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.01039.abstract.html?papetoc

8. Gosse P, Guillo P, Ascher G, Clementy J. Assessment of arterial distensibility

by monitoring the timing of Korotkoff sounds. Am J Hypertens.

1994;7:228–233.

9. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C,

Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier

H; European Network for Non-invasive Investigation of Large Arteries.

Expert consensus document on arterial stiffness: methodological issues

and clinical applications. Eur Heart J. 2006;27:2588–2605.

10. Dogui A, Redheuil A, Lefort M, DeCesare A, Kachenoura N, Herment A,

Mousseaux E. Measurement of aortic arch pulse wave velocity in cardiovascular

MR: comparison of transit time estimators and description of a

new approach. J Magn Reson Imaging. 2011;33:1321–1329.

downloaded from

http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.01372.citation

REFERENCES for Part II: Clinical Trials of Hypertension Management

1. Hanselin MR , Saseen JJ , Allen RR , Marrs JC , Nair KV . Description of

antihypertensive use in patients with resistant hypertension prescribed

four or more agents. Hypertension . 2011 ; 58 : 1008 – 1013 .

2. Bakris GL , Lindholm LH , Black HR , Krum H , Linas S , Linseman JV ,

Arterburn S , Sager P , Weber M . Divergent results using clinic and ambulatory

blood pressures: report of a darusentan-resistant hypertension trial.

Hypertension . 2010 ; 56 : 824 – 830 .

3. Smithwick RH , Thompson JE . Splanchnicectomy for essential hypertension;

results in 1,266 cases. J Am Med Assoc . 1953 ; 152 : 1501 – 1504 .

4. Esler M , Ferrier C , Lambert G , Eisenhofer G , Cox H , Jennings G .

Biochemical evidence of sympathetic hyperactivity in human hypertension.

Hypertension . 1991 ; 17 ( 4 Suppl ): III29 – III35 .

5. Esler MD , Krum H , Sobotka PA , Schlaich MP , Schmieder RE , Bohm

M . Symplicity HTN-2 investigators. Renal sympathetic denervation in

patients with treatment-resistant hypertension: a randomized controlled

trial. Lancet 2010 ; 376 : 1903 – 1909 .

6. Brinkmann J , Heusser K , Schmidt BM , Menne J , Klein G , Bauersachs J ,

Haller H , Sweep FC , Diedrich A , Jordan J , Tank J . Catheter-based renal

nerve ablation and centrally generated sympathetic activity in diffi cultto-

control hypertensive patients: prospective case series. Hypertension .

2012 ; 60 : 1485 – 1490 .

7. Mahfoud F , Cremers B , Janker J , et al . Renal hemodynamics and renal

function after catheter-based renal sympathetic denervation in patients

with resistant hypertension. Hypertension . 2012 ; 60 : 419 – 424 .

8. Lambert GW , Hering D , Esler MD , Marusic P , Lambert EA , Tanamas

SK , Shaw J , Krum H , Dixon JB , Barton DA , Schlaich MP . Health-related

quality of life after renal denervation in patients with treatment-resistant

hypertension. Hypertension . 2012 ; 60 : 1479 – 1484 .

9. Daugherty SL , Powers JD , Magid DJ , Masoudi FA , Margolis KL ,

O ’ Connor PJ , Schmittdiel JA , Ho PM . The association between medication

adherence and treatment intensifi cation with blood pressure control

in resistant hypertension. Hypertension . 2012 ; 60 : 303 – 309 .

10. Bobrie G , Frank M , Azizi M , Peyrard S , Boutouyrie P , Chatellier G ,

Laurent S , Menard J , Plouin PF . Sequential nephron blockade versus

sequential renin-angiotensin system blockade in resistant hypertension:

a prospective, randomized, open blinded endpoint study. J Hypertens .

2012 ; 30 : 1656 – 1664 .

11. Mancia G . Additional drug treatment in resistant hypertension: need for

randomized studies. J Hypertens . 2012 ; 30 : 1514 – 1515 .

12. Hermida RC , Ayala DE , Moj ó n A , Fontao MJ , Fern á ndez JR .

Chronotherapy with valsartan/hydrochlorothiazide combination in essential

hypertension: improved sleep-time blood pressure control with bedtime

dosing. Chronobiol Int . 2011 ; 28 : 601 – 610 .

13. Persu A , Renkin J , Thijs L , Staessen JA . Renal denervation: ultima

ratio or standard in treatment-resistant hypertension. Hypertension .

2012 ; 60 : 596 – 606 .

14. Lohmeier TE , Iliescu R . Chronic lowering of blood pressure by carotid

barorefl ex activation: mechanisms and potential for hypertension therapy.

Hypertension . 2011 ; 57 : 880 – 886 .

15. Bisognano JD , Bakris G , Nadim MK , Sanchez L , Kroon AA , Schafer J ,

de Leeuw PW , Sica DA . Barorefl ex activation therapy lowers blood pressure

in patients with resistant hypertension: results from the double-blind,

randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol .

2011 ; 58 : 765 – 773 .

16. Parving HH , Brenner BM , McMurray JJ , de Zeeuw D , Haffner SM ,

Solomon SD , Chaturvedi N , Persson F , Desai AS , Nicolaides M , Richard

A , Xiang Z , Brunel P , Pfeffer MA ; ALTITUDE Investigators . Cardiorenal

end points in a trial of aliskiren for type 2 diabetes. N Engl J Med .

2012 ; 367 : 2204 – 2213 .

17. The ONTARGET Investigators . Telmisartan, ramipril, or both in patients

at high risk for vascular events. N Engl J Med . 2008 ; 358 : 1547 – 1559 .

18. Mancia G , Parati G , Bilo G , et al . Ambulatory blood pressure values in

the Ongoing Telmisartan Alone and in Combination with Ramipril Global

Endpoint Trial (ONTARGET). Hypertension . 2012 ; 60 : 1400 – 1406 .

19. Roush GC , Holford TR , Guddati AK . Chlorthalidone compared with

hydrochlorothiazide in reducing cardiovascular events: systematic review

and network meta-analyses. Hypertension . 2012 ; 59 : 1110 – 1117 .

20. Cushman WC , Bakris GL , White WB , Weber MA , Sica D , Roberts A ,

Lloyd E , Kupfer S . Azilsartan medoxomil plus chlorthalidone reduces

blood pressure more effectively than olmesartan plus hydrochlorothiazide

in stage 2 systolic hypertension. Hypertension . 2012 ; 60 : 310 – 318 .

21. Alderman MH , Piller LB , Ford CE , Probstfi eld JL , Oparil S , Cushman WC ,

Einhorn PT , Franklin SS , Papademetriou V , Ong ST , Eckfeldt JH , Furberg

CD , Calhoun DA , Davis BR ; Antihypertensive and Lipid-Lowering

Treatment to Prevent Heart Attack Trial Collaborative Research Group .

Clinical signifi cance of incident hypokalemia and hyperkalemia in treated

hypertensive patients in the antihypertensive and lipid-lowering treatment

to prevent heart attack trial. Hypertension . 2012 ; 59 : 926 – 933 .

22. Kostis WJ , Thijs L , Richart T , Kostis JB , Staessen JA . Persistence of mortality

reduction after the end of randomized therapy in clinical trials of

blood pressure-lowering medications. Hypertension . 2010 ; 56 : 1060 – 1068 .

23. van Onzenoort HA , Menger FE , Neef C , Verberk WJ , Kroon AA , de

Leeuw PW , van der Kuy PH . Participation in a clinical trial enhances

adherence and persistence to treatment: a retrospective cohort study.

Hypertension . 2011 ; 58 : 573 – 578 .

24. Sever PS . The Anglo-Scandinavian Cardiac Outcomes Trial: implications

and further outcomes. Hypertension . 2012 ; 60 : 248 – 259 .

25. Larstorp AC , Ariansen I , Gjesdal K , Olsen MH , Ibsen H , Devereux RB ,

Okin PM , Dahl ö f B , Kjeldsen SE , Wachtell K . Association of pulse pressure

with new-onset atrial fi brillation in patients with hypertension and

left ventricular hypertrophy: the Losartan Intervention For Endpoint

(LIFE) reduction in hypertension study. Hypertension . 2012 ; 60 : 347 – 353 .

26. Rossignol P , Cridlig J , Lehert P , Kessler M , Zannad F . Visit-to-visit blood

pressure variability is a strong predictor of cardiovascular events in hemodialysis:

insights from FOSIDIAL. Hypertension . 2012 ; 60 : 339 – 346 .

27. Matsui Y , O ’ Rourke MF , Hoshide S , Ishikawa J , Shimada K , Kario

K . Combined Effect of Angiotensin II Receptor Blocker and Either a

Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home

Blood Pressure: The Japan Combined Treatment With Olmesartan and a

Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized

Effi cacy Study. Hypertension . 2012 ; 59 : 1132 – 1138 .

28. Jennings GL , Sudhir K . Initial therapy of primary hypertension. Med J

Aust . 1990 ; 152 : 198 – 203 .

29. Egan BM , Bandyopadhyay D , Shaftman SR , Wagner CS , Zhao Y ,

Yu-Isenberg KS . Initial monotherapy and combination therapy and hypertension

control the fi rst year. Hypertension . 2012 ; 59 : 1124 – 1131 .

30. Bavry AA , Pepine CJ . Treatment of hypertension: lower is better, or is it?

Hypertension . 2012 ; 60 : 281 – 282 .

31. Mizuno R , Fujimoto S , Saito Y , Okamoto Y . Optimal antihypertensive

level for improvement of coronary microvascular dysfunction: the lower,

the better? Hypertension . 2012 ; 60 : 326 – 332 .

32. Roman MJ , Howard BV , Howard WJ , Mete M , Fleg JL , Lee ET ,

Devereux RB . Differential impacts of blood pressure and lipid lowering

on regression of ventricular and arterial mass: the Stop Atherosclerosis in

Native Diabetics Trial. Hypertension . 2011 ; 58 : 367 – 371 .

33. Bertoia ML , Waring ME , Gupta PS , Roberts MB , Eaton CB . Implications

of new hypertension guidelines in the United States. Hypertension .

2012 ; 60 : 639 – 644 .

34. Stewart S , Carrington MJ , Swemmer CH , et al .; VIPER-BP Study

Investigators . Effect of intensive structured care on individual blood pressure

targets in primary care: multicentre randomised controlled trial. BMJ .

2012 ; 345 : e7156 .

35. Dickinson BD , Havas S ; Council on Science and Public Health, American

Medical Association . Reducing the population burden of cardiovascular

disease by reducing sodium intake: a report of the Council on Science and

Public Health. Arch Intern Med . 2007 ; 167 : 1460 – 1468 .

36. O ’ Donnell MJ , Yusuf S , Mente A , Gao P , Mann JF , Teo K , McQueen M ,

Sleight P , Sharma AM , Dans A , Probstfi eld J , Schmieder RE . Urinary

sodium and potassium excretion and risk of cardiovascular events. JAMA .

2011 ; 306 : 2229 – 2238 .

37. Hummel SL , Seymour EM , Brook RD , Kolias TJ , Sheth SS , Rosenblum

HR , Wells JM , Weder AB . Low-sodium dietary approaches to stop

hypertension diet reduces blood pressure, arterial stiffness, and oxidative

stress in hypertensive heart failure with preserved ejection fraction.

Hypertension . 2012 ; 60 : 1200 – 1206 .

38. Soedamah-Muthu SS , Verberne LD , Ding EL , Engberink MF , Geleijnse JM .

Dairy consumption and incidence of hypertension: a dose-response metaanalysis

of prospective cohort studies. Hypertension . 2012 ; 60 : 1131 – 1137 .

39. West SG , Gebauer SK , Kay CD , Bagshaw DM , Savastano DM ,

Diefenbach C , Kris-Etherton PM . Diets containing pistachios reduce systolic

blood pressure and peripheral vascular responses to stress in adults

with dyslipidemia. Hypertension . 2012 ; 60 : 58 – 63 .

40. Zhang X , Qi Q , Liang J , Hu FB , Sacks FM , Qi L . Neuropeptide Y promoter

polymorphism modifi es effects of a weight-loss diet on 2-year

changes of blood pressure: the preventing overweight using novel dietary

strategies trial. Hypertension . 2012 ; 60 : 1169 – 1175 .

41. Meredith IT , Friberg P , Jennings GL , Dewar EM , Fazio VA , Lambert GW ,

Esler MD . Exercise training lowers resting renal but not cardiac sympathetic

activity in humans. Hypertension . 1991 ; 18 : 575 – 582 .

42. Cornelissen VA , Fagard RH , Coeckelberghs E , Vanhees L . Impact of resistance

training on blood pressure and other cardiovascular risk factors: a metaanalysis

of randomized, controlled trials. Hypertension . 2011 ; 58 : 950 – 958 .

Downloaded from

http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.00863.citation

RELATED SOURCES:

Aortic pulse pressure is associated with the localization of coronary artery disease based on coronary flow lateralization. American journal of hypertension, 25(10), 1055-1063.

  1. Georges Khoueiry1,
  2. Basem Azab2,
  3. Estelle Torbey2,
  4. Nidal Abi Rafeh1,
  5. Jean-Paul Atallah2,
  6. Kathleen Ahern2,
  7. James Malpeso1,
  8. Donald McCord1 and
  9. Elie R. Chemaly3⇓

Author Affiliations


  1. 1Department of Cardiology, Staten Island University Hospital, Staten Island, New York, USA

  2. 2Department of Internal Medicine, Staten Island University Hospital, Staten Island, New York, USA

  3. 3Cardiovascular Institute, Mount Sinai School of Medicine, New York, New York, USA

Elie R. Chemaly (elie.chemaly@mssm.edu)

Abstract

Background Aortic pulse pressure (APP) is related to arterial stiffness and associated with the presence and extent of coronary artery disease (CAD). Besides, the left coronary artery (LCA) has a predominantly diastolic flow while the right coronary artery (RCA) receives systolic and diastolic flow. Thus, we hypothesized that increased systolic–diastolic pressure difference had a greater atherogenic effect on the RCA than on the LCA.

Methods A random sample of 433 CAD patients (145 females, 288 males, mean age 65.0 ± 11.1 years) undergoing coronary angiography at Staten Island University Hospital between January 2005 and May 2008 was studied. Coronary lesion was defined as a ≥50% luminal stenosis. Patients were divided into three groups, with isolated LCA lesions (n = 154), isolated RCA lesions (n = 36) or mixed LCA and RCA lesions (n = 243).

Results APP differed significantly between groups, being highest when the RCA alone was affected (67.6 ± 20.3 mm Hg for LCA vs. 78.8 ± 22.0 for RCA vs. 72.7 ± 22.6 for mixed, P = 0.008 for analysis of variance (ANOVA)). Age and gender were not associated with CAD location. Heart rate was associated with CAD location, lowest in RCA group, and negatively correlated with APP. However, left ventricular ejection fraction (LVEF) was lower in the mixed CAD group and positively correlated with APP. The association between APP and right-sided CAD persisted in multivariate logistic regression adjusting for confounders, including heart rate, LVEF and medication use. A similar but less significant pattern was seen with brachial arterial pressures.

Conclusions Aortic pulse pressure may affect CAD along with coronary flow phasic patterns.

American Journal of Hypertension, advance online publication 28 June 2012; doi:10.1038/ajh.2012.87

The Relationship Between Diastolic Pressure and Coronary Collateral Circulation in Patients With Stable Angina Pectoris and Chronic Total Occlusion. Am J Hypertens (2013)doi: 10.1093/ajh/hps096 

First published online: February 7, 2013

  1. Wang Shu1,
  2. Jing jing1,
  3. Liu Chang Fu1,
  4. Jiang Tie Min2,
  5. Yang Xiao Bo1,
  6. Zhou Ying1and
  7. Chen Yun Dai1,*
  1. 1 The Cardiovascular Medical Department of the General Hospital of the Chinese People’s Liberation Army, Beijing, China;

  2. 2 The Cardiovascular Medical Department of the Affiliated Hospital of the Chinese People’s Armed Police Logistics College, Tianjin, China.
  1. ↵Correspondence: Chen Yun Dai (chenyundai2002@163.com).

Abstract

BACKGROUND The most important biomechanical source of activation of the coronary collateral circulation (CCC) is increased tangential fluid shear stress at the arterial endothelial surface. The coronary circulation is unique in that most coronary blood flow occurs in diastole. Consequently, the diastolic blood pressure (DBP) may influence the tangential fluid shear stress on the arterial endothelial surface in diastole, therebyaffecting development of the CCC.

METHODS To investigate this, we conducted a study of 222 patients with stable angina pectoris and chronic total occlusion of coronary arteries. All of the patients had no history of coronary artery interventional therapy, coronary artery bypass surgery, cardiomyopathy, or congenital heart disease. The extent of the collateral vasculature of the area perfused by the artery affected by chronic total occlusion was graded as poor or well-developed according to Rentrop’s classification.

RESULTS Univariate analysis showed a significant difference between the study subgroup with poorly developed collaterals and that with well-developed collaterals in terms of high diastolic blood pressure (DBP) and mean DBP. Multivariate analysis revealed high DBP as the only independent positive predictor of a well-developed collateral circulation.

CONCLUSIONS High DBP is positively related to a well-developed CCC. Differences in development of the CCC may be one of the pathophysiologic mechanisms responsible for the J-curve phenomenon in the relationship between DBP and cardiovascular risk.

http://ajh.oxfordjournals.org/content/early/2013/02/06/ajh.hps096.abstract

Other related articles that were published on this Open Access Online Scientific Journal, include the following:

Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

Aviva Lev-Ari, PhD, RN May 17, 2013

http://pharmaceuticalintelligence.com/2013/05/17/synthetic-biology-on-advanced-genome-interpretation-for-gene-variants-and-pathways-what-is-the-genetic-base-of-atherosclerosis-and-loss-of-arterial-elasticity-with-aging/

Artherogenesis: Predictor of CVD – the Smaller and Denser LDL Particles

Aviva Lev-Ari, PhD, RN 11/15/2012

http://pharmaceuticalintelligence.com/2012/11/15/artherogenesis-predictor-of-cvd-the-smaller-and-denser-ldl-particles/

Cardiovascular Diseases: Causes, Risks and Management, Volume Two, Risks of Cardiovascular Diseases

Justin D. Pearlman MD ME PhD MA FACC, Editor

http://pharmaceuticalintelligence.com/biomed-e-books/cardiovascular-diseases-risks-and-management/cvd-2-risk-assessment-of-cardiovascular-diseases/

Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis

Aviva Lev-Ari, PhD, RN 4/28/2013

http://pharmaceuticalintelligence.com/2013/04/28/genetics-of-conduction-disease-atrioventricular-av-conduction-disease-block-gene-mutations-transcription-excitability-and-energy-homeostasis/

Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013

Aviva Lev-Ari, PhD, RN and Larry H. Bernstein, MD, FCAP 3/7/2013

http://pharmaceuticalintelligence.com/2013/03/07/genomics-genetics-of-cardiovascular-disease-diagnoses-a-literature-survey-of-ahas-circulation-cardiovascular-genetics-32010-32013/

Hypertriglyceridemia concurrent Hyperlipidemia: Vertical Density Gradient Ultracentrifugation a Better Test to Prevent Undertreatment of High-Risk Cardiac Patients

Aviva Lev-Ari, PhD, RN 4/4/2013

http://pharmaceuticalintelligence.com/2013/04/04/hypertriglyceridemia-concurrent-hyperlipidemia-vertical-density-gradient-ultracentrifugation-a-better-test-to-prevent-undertreatment-of-high-risk-cardiac-patients/

Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus

Justin D. Pearlman, MD, PhD and Aviva Lev-Ari, PhD, RN 5/11/2013

http://pharmaceuticalintelligence.com/2013/05/11/arterial-elasticity-in-quest-for-a-drug-stabilizer-isolated-systolic-hypertension-caused-by-arterial-stiffening-ineffectively-treated-by-vasodilatation-antihypertensives/

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN

 

 

  • Original Article

HYPERTENSIONAHA.113.00859 Published online before print May 20, 2013,doi: 10.1161/​HYPERTENSIONAHA.113.00859

Serum Uric Acid Level, Longitudinal Blood Pressure, Renal Function, and Long-Term Mortality in Treated Hypertensive Patients
  1. Jesse Dawson,
  2. Panniyammakal Jeemon,
  3. Lucy Hetherington,
  4. Caitlin Judd,
  5. Claire Hastie,
  6. Christin Schulz,
  7. William Sloan,
  8. Scott Muir,
  9. Alan Jardine,
  10. Gordon McInnes,
  11. David Morrison,
  12. Anna Dominiczak,
  13. Sandosh Padmanabhan,
  14. Matthew Walters

+Author Affiliations


  1. From the Institute of Cardiovascular and Medical Sciences (J.D., P.J., L.H., C.J., C.H., C.S., S.M., A.J., G.M., A.D., S.P., M.W.), West of Scotland Cancer Surveillance Unit (W.S., D.M.), College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, United Kingdom.
  1. Correspondence to Matthew Walters, Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary & Life Sciences, Western Infirmary, University of Glasgow, Glasgow G11 6NT, United Kingdom. E-mail matthew.walters@glasgow.ac.uk; or Sandosh Padmanabhan, BHF Glasgow Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, 126 University Pl, University of Glasgow, Glasgow G12 8TA, United Kingdom. E-mail Sandosh.padmanabhan@glasgow.ac.uk

Abstract

Uric acid may have a role in the development of hypertension and renal dysfunction. We explored the relationship among longitudinal blood pressure, renal function, and cardiovascular outcomes in a large cohort of patients with treated hypertension. We used data from the Glasgow Blood Pressure Clinic database. Patients with a baseline measure of serum uric acid and longitudinal measures of blood pressure and renal function were included. Mortality data were obtained from the General Register Office for Scotland. Generalized estimating equations were used to explore the relationship among quartiles of serum uric acid, blood pressure, and estimated glomerular filtration rate. Cox proportional hazard models were developed to assess mortality relationships. In total, 6984 patients were included. Serum uric acid level did not influence the longitudinal changes in systolic or diastolic blood pressure but was related to change in glomerular filtration rate. In comparison with patients in the first quartile of serum uric acid, the relative decrease in glomerular filtration rate in the fourth was 10.7 (95% confidence interval, 7.9–13.6 mL/min per 1.73 m2) in men and 12.2 (95% confidence interval, 9.2–15.2 mL/min per 1.73 m2) in women. All-cause and cardiovascular mortality differed across quartiles of serum uric acid in women only (P<0.001; hazard ratios for all-cause mortality 1.38 [95% confidence interval, 1.14–1.67] for the fourth quartile of serum uric acid compared with the first). Serum uric acid level was not associated with longitudinal blood pressure control in adults with treated hypertension but was related to decline in renal function and mortality in women.

Key Words:

  • Received February 19, 2013.
  • Revision received April 23, 2013.
  • Accepted April 23, 2013.

http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.00859.abstract.html?papetoc

 

Read Full Post »

Reporter: Aviva Lev-Ari, PhD, RN
  • Original Article

HYPERTENSIONAHA.113.01039 Published online before print May 20, 2013,doi: 10.1161/​HYPERTENSIONAHA.113.01039

Arterial Stiffness From Monitoring of Timing of Korotkoff Sounds Predicts the Occurrence of Cardiovascular Events Independently of Left Ventricular Mass in Hypertensive Patients

  1. Philippe Gosse,
  2. Antoine Cremer,
  3. Georgios Papaioannou,
  4. Sunthareth Yeim

+Author Affiliations


  1. From the Department of Cardiology and Hypertension, University Hospital of Bordeaux, Bordeaux, France.
  1. Correspondence to Philippe Gosse, Department of Cardiology and Hypertension, University Hospital of Bordeaux, Hopital Saint Andre, 1 Rue Jean Burguet, 33075 Bordeaux, France. E-mail philippe.gosse@chu-bordeaux.fr

Abstract

Several studies have established that the increase in arterial stiffness (AS) is a cardiovascular risk factor but to date no studies have evaluated in hypertensive patients its prognostic value in comparison with another powerful risk factor, left ventricular mass (LVM) as measured by echocardiography. We prospectively evaluated the prognostic value of AS and LVM in patients with essential hypertension. The population studied comprised 793 patients (56% men) aged 54±14 years. For 519 patients, baseline measurements were made before any antihypertensive treatment, for 274 patients, the measurement were obtained during the follow-up period under antihypertensive treatment. AS was assessed from ambulatory monitoring of blood pressure and timing of Korottkoff sounds. Left ventricular mass was measured in 523 patients. After a mean follow-up of 97 months, 122 cardiovascular events were recorded in the whole population and 74 in the group with LVM determination. AS as continuous or discontinuous variable was independently related to cardiovascular events. The existence or not of antihypertensive treatment at the time of its measurement did not affect its prognostic value. When LVM was forced in the model, AS remained significantly related to cardiovascular events. Thus, AS has an independent prognostic value in the hypertensive, whether measured before or after the administration of antihypertensive treatment. This prognostic value persists after taking LVM into account.

Key Words:

  • Received January 10, 2013.
  • Revision received March 25, 2013.
  • Accepted April 22, 2013.

http://hyper.ahajournals.org/content/early/2013/05/20/HYPERTENSIONAHA.113.01039.abstract.html?papetoc

Read Full Post »

iElastance: Calculates Ventricular Elastance, Arterial Elastance and Ventricular-Arterial Coupling using Echocardiographic derived values in a single beat determination

Reporter: Aviva Lev-Ari, PhD, RN

 

unnamed

unnamed-1unnamed-2

First iElastance release for Android!

iElastance is an application designed for calculate Ventricular Elastance, Arterial Elastance and Ventricular-Arterial Coupling using Echocardiographic derived values in a single beat determination.
This application is extremely useful to a variety of health care givers such as Cardiologists, Intensivists, Anesthesiologist and more who want to calculate ventricular arterial coupling even in the Critical Care setting and, above all, bedside.

The variables needed for the calculator to work are:

Systolic Blood Pressure (mmHg)
Diastolic Blood Pressure (mmHg)
Stroke Volume (ml)
Ejection Fraction (0-1)
Total Ejection Time (msec)
Pre Ejection Time (msec)

Formulas are validated and extracted from the article by Chen CH et Al J Am Coll Cardiol. 2001 Dec;38(7):2028-34.

DISCLAIMER: The calculator provided is not meant to be a substitute for professional advice and is not to be used for medical diagnosis. Extensive effort has been exerted to make this software as accurate as possible; however the accuracy of information provided by this software cannot be guaranteed. Health care professionals should use clinical judjement and individualize therapy to each patient care situation.

All rights reserved – 2013 Pietro Bertini – Department of Cardiothoracic Anesthesia and Intensive Care Medicine – University Hospital of Pisa – Dr. Fabio Guarracino, Head of Department

FULL NETWORK ACCESS
Allows the app to create network sockets and use custom network protocols. The browser and other applications provide means to send data to the internet, so this permission is not required to send data to the internet.

https://play.google.com/store/apps/details?id=air.iElastance

 

Read Full Post »

Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging

Curator: Aviva Lev-Ari, PhD, RN

Article ID #52: Synthetic Biology: On Advanced Genome Interpretation for Gene Variants and Pathways: What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging. Published on 5/17/2013

WordCloud Image Produced by Adam Tubman

UPDATED on 7/12/2021

  • Abstract. Synthetic biology is a field of scientific research that applies engineering principles to living organisms and living systems.
  • Introduction. This article is intended as a perspective on the field of synthetic biology. …
  • Genetic Manipulation—Plasmids. …
  • Genetic Manipulations—Genome. …
  • An Early Example of Synthetic Biology. …

UPDATED on 11/6/2018

Which biological systems should be engineered?

To solve real-world problems using emerging abilities in synthetic biology, research must focus on a few ambitious goals, argues Dan Fletcher, Professor of bioengineering and biophysics, and chair of the Department of Bioengineering at the University of California, Berkeley, USA. He is also a Chan Zuckerberg Biohub Investigator.
Start Quote

Artificial blood cells. Blood transfusions are crucial in treatments for everything from transplant surgery and cardiovascular procedures to car accidents, pregnancy-related complications and childhood malaria (see go.nature.com/2ozbfwt). In the United States alone, 36,000 units of red blood cells and 7,000 units of platelets are needed every day (see go.nature.com/2ycr2wo).

But maintaining an adequate supply of blood from voluntary donors can be challenging, especially in low- and middle-income countries. To complicate matters, blood from donors must be checked extensively to prevent the spread of infectious diseases, and can be kept for only a limited time — 42 days or 5 days for platelets alone. What if blood cells could be assembled from purified or synthesized components on demand?

In principle, cell-like compartments could be made that have the oxygen-carrying capacity of red blood cells or the clotting ability of platelets. The compartments would need to be built with molecules on their surfaces to protect the compartments from the immune system, resembling those on a normal blood cell. Other surface molecules would be needed to detect signals and trigger a response.

In the case of artificial platelets, that signal might be the protein collagen, to which circulating platelets are exposed when a blood vessel ruptures5. Such compartments would also need to be able to release certain molecules, such as factor V or the von Willebrand clotting factor. This could happen by building in a rudimentary form of exocytosis, for example, whereby a membrane-bound sac containing the molecule would be released by fusing with the compartment’s outer membrane.

It is already possible to encapsulate cytoplasmic components from living cells in membrane compartments6,7. Now a major challenge is developing ways to insert desired protein receptors into the lipid membrane8, along with reconstituting receptor signalling.

Red blood cells and platelets are good candidates for the first functionally useful synthetic cellular system because they lack nuclei. Complex functions such as nuclear transport, protein synthesis and protein trafficking wouldn’t have to be replicated. If successful, we might look back with horror on the current practice of bleeding one person to treat another.

Micrograph of red blood cells, 3 T-lymphocytes and activated platelets

Human blood as viewed under a scanning electron microscope.Credit: Dennis Kunkel Microscopy/SPL

Designer immune cells. Immunotherapy is currently offering new hope for people with cancer by shaping how the immune system responds to tumours. Cancer cells often turn off the immune response that would otherwise destroy them. The use of therapeutic antibodies to stop this process has drastically increased survival rates for people with multiple cancers, including those of the skin, blood and lung9. Similarly successful is the technique of adoptive T-cell transfer. In this, a patient’s T cells or those of a donor are engineered to express a receptor that targets a protein (antigen) on the surface of tumour cells, resulting in the T cells killing the cancerous cells (called CAR-T therapies)10. All of this has opened the door to cleverly rewiring the downstream signalling that results in the destruction of tumour cells by white blood cells11.

What if researchers went a step further and tried to create synthetic cells capable of moving towards, binding to and eliminating tumour cells?

In principle, untethered from evolutionary pressures, such cells could be designed to accomplish all sorts of tasks — from killing specific tumour cells and pathogens to removing brain amyloid plaques or cholesterol deposits. If mass production of artificial immune cells were possible, it might even lessen the need to tailor treatments to individuals — cutting costs and increasing accessibility.

To ensure that healthy cells are not targeted for destruction, engineers would also need to design complex signal-processing systems and safeguards. The designer immune cells would need to be capable of detecting and moving towards a chemical signal or tumour. (Reconstituting the complex process of cell motility is itself a major challenge, from the delivery of energy-generating ATP molecules to the assembly of actin and myosin motors that enable movement.)

Researchers have already made cell-like compartments that can change shape12, and have installed signalling circuits within them13. These could eventually be used to control movement and mediate responses to external signals.

Smart delivery vehicles. The relative ease of exposing cells in the lab to drugs, as well as introducing new proteins and engineering genomes, belies how hard it is to deliver molecules to specific locations inside living organisms. One of the biggest challenges in most therapies is getting molecules to the right place in the right cell at the right time.

Harnessing the natural proclivity of viruses to deliver DNA and RNA molecules into cells has been successful14. But virus size limits cargo size, and viruses don’t necessarily infect the cell types researchers and clinicians are aiming at. Antibody-targeted synthetic vesicles have improved the delivery of drugs to some tumours. But getting the drug close to the tumour generally depends on the vesicles leaking from the patient’s circulatory system, so results have been mixed.

Could ‘smart’ delivery vehicles containing therapeutic cargo be designed to sense where they are in the body and move the cargo to where it needs to go, such as across the blood–brain barrier?

This has long been a dream of those in drug delivery. The challenges are similar to those of constructing artificial blood and immune cells: encapsulating defined components in a membrane, incorporating receptors into that membrane, and designing signal-processing systems to control movement and trigger release of the vehicle’s contents.

The development of immune-cell ‘backpacks’ is an exciting step in the right direction. In this, particles containing therapeutic molecules are tethered to immune cells, exploiting the motility and targeting ability of the cells to carry the molecules to particular locations15.

A minimal chassis for expression. In each of the previous examples, the engineered cell-like system could conceivably be built to function over hours or days, without the need for additional protein production and regulation through gene expression. For many other tasks, however, such as the continuous production of insulin in the body, it will be crucial to have the ability to express proteins, upregulate or downregulate certain genes, and carry out functions for longer periods.

Engineering a ‘minimal chassis’ that is capable of sustained gene expression and functional homeostasis would be an invaluable starting point for building synthetic cells that produce proteins, form tissues and remain viable for months to years. This would require detailed understanding and incorporation of metabolic pathways, trafficking systems and nuclear import and export — an admittedly tall order.

It is already possible to synthesize DNA in the lab, whether through chemically reacting bases or using biological enzymes or large-scale assembly in a cell16. But we do not yet know how to ‘boot up’ DNA and turn a synthetic genome into a functional system in the absence of a live cell.

Since the early 2000s, biologists have achieved gene expression in synthetic compartments loaded with cytoplasmic extract17. And genetic circuits of increasing complexity (in which the expression of one protein results in the production or degradation of another) are now the subject of extensive research. Still to be accomplished are: long-lived gene expression, basic protein trafficking and energy production reminiscent of live cells.

End Quote

SOURCE

https://www.nature.com/articles/d41586-018-07291-3?utm_source=briefing-dy&utm_medium=email&utm_campaign=briefing&utm_content=20181106

UPDATED on 10/14/2013

Genetics of Atherosclerotic Plaque in Patients with Chronic Coronary Artery Disease

372/3:15 Genetic influence on LpPLA2 activity at baseline as evaluated in the exome chip-enriched GWAS study among ~13600 patients with chronic coronary artery disease in the STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) trial. L. Warren, L. Li, D. Fraser, J. Aponte, A. Yeo, R. Davies, C. Macphee, L. Hegg, L. Tarka, C. Held, R. Stewart, L. Wallentin, H. White, M. Nelson, D. Waterworth.

Genetic influence on LpPLA2 activity at baseline as evaluated in the exome chip-enrichedGWASstudy among ~13600 patients with chronic coronary artery disease in the STABILITY (STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY) trial.

L. Warren1, L. Li1, D. Fraser1, J. Aponte1, A. Yeo2, R. Davies3, C. Macphee3, L. Hegg3,

L. Tarka3, C. Held4, R. Stewart5, L. Wallentin4, H. White5, M. Nelson1, D.

Waterworth3.

1) GlaxoSmithKline, Res Triangle Park, NC;

2) GlaxoSmithKline, Stevenage, UK;

3) GlaxoSmithKline, Upper Merion, Pennsylvania, USA;

4) Uppsala Clinical Research Center, Department of Medical Sciences, Uppsala University, Uppsala, Sweden;

5) 5Green Lane Cardiovascular Service, Auckland Cty Hospital, Auckland, New Zealand.

STABILITY is an ongoing phase III cardiovascular outcomes study that compares the effects of darapladib enteric coated (EC) tablets, 160 mg versus placebo, when added to the standard of care, on the incidence of major adverse cardiovascular events (MACE) in subjects with chronic coronary heart disease (CHD). Blood samples for determination of the LpPLA2 activity level in plasma and for extraction of DNA was obtained at randomization. To identify genetic variants that may predict response to darapladib, we genotyped ~900K common and low frequency coding variations using Illumina OmniExpress GWAS plus exome chip in advance of study completion. Among the 15828 Intent-to-Treat recruited subjects, 13674 (86%) provided informed consent for genetic analysis. Our pharmacogenetic (PGx) analysis group is comprised of subjects from 39 countries on five continents, including 10139 Whites of European heritage, 1682 Asians of East Asian or Japanese heritage, 414 Asians of Central/South Asian heritage, 268 Blacks, 1027 Hispanics and 144 others. Here we report association analysis of baseline levels of LpPLA2 to support future PGx analysis of drug response post trial completion. Among the 911375 variants genotyped, 213540 (23%) were rare (MAF < 0.5%).

Our analyses were focused on the drug target, LpPLA2 enzyme activity measured at baseline. GWAS analysis of LpPLA2 activity adjusting for age, gender and top 20 principle component scores identified 58 variants surpassing GWAS-significant threshold (5e-08).

Genome-wide stepwise regression analyses identified multiple independent associations from PLA2G7, CELSR2, APOB, KIF6, and APOE, reflecting the dependency of LpPLA2 on LDL-cholesterol levels. Most notably, several low frequency and rare coding variants in PLA2G7 were identified to be strongly associated with LpPLA2 activity. They are V279F (MAF=1.0%, P= 1.7e-108), a previously known association, and four novel associations due to I1317N (MAF=0.05%, P=4.9e-8), Q287X (MAF=0.05%, P=1.6e-7), T278M (MAF=0.02%, P=7.6e-5) and L389S (MAF=0.04%, P=4.3e-4).

All these variants had enzyme activity lowering effects and each appeared to be specific to certain ethnicity. Our comprehensive PGx analyses of baseline data has already provided great insight into common and rare coding genetic variants associated with drug target and related traits and this knowledge will be invaluable in facilitating future PGx investigation of darapladib response.

SOURCE

http://www.ashg.org/2013meeting/pdf/46025_Platform_bookmark%20for%20Web%20Final%20from%20AGS.pdf

Synthetic Biology: On Advanced Genome Interpretation for

  • Gene Variants and
  • Pathways,
  • Inversion Polymorphism,
  • Passenger Deletions,
  • De Novo Mutations,
  • Whole Genome Sequencing w/Linkage Analysis

What is the Genetic Base of Atherosclerosis and Loss of Arterial Elasticity with Aging?

In a recent publication by my colleague, Stephen J. Williams, Ph.D. on  5/15/2013 titled

Finding the Genetic Links in Common Disease:  Caveats of Whole Genome Sequencing Studies

http://pharmaceuticalintelligence.com/2013/05/15/finding-the-genetic-links-in-common-disease-caveats-of-whole-genome-sequencing-studies/

we learned that:

  • Groups of variants in the same gene confirmed link between APOC3 and higher risk for early-onset heart attack
  • No other significant gene variants linked with heart disease

APOC3 – apolipoprotein C-III – Potential Relevance to the Human Aging Process

Main reason for selection
Entry selected based on indirect or inconclusive evidence linking the gene product to ageing in humans or in one or more model systems
Description
APOC3 is involved in fat metabolism and may delay the catabolism of triglyceride-rich particles. Changes in APOC3 expression levels have been reported in aged mice [1754]. Results from mice suggest that FOXO1 may regulate the expression of APOC3 [1743]. Polymorphisms in the human APOC3 gene and promoter have been associated with lipoprotein profile, cardiovascular health, insulin (INS) sensitivity, and longevity [1756]. Therefore, APOC3 may impact on some age-related diseases, though its exact role in human ageing remains to be determined.

Cytogenetic information

Cytogenetic band
11q23.1-q2
Location
116,205,833 bp to 116,208,997 bp
Orientation
Plus strand

Display region using the UCSC Genome Browser

Protein information

Gene Ontology
Process: GO:0006869; lipid transport
GO:0016042; lipid catabolic process
GO:0042157; lipoprotein metabolic process
Function: GO:0005319; lipid transporter activity
Cellular component: GO:0005576; extracellular region
GO:0042627; chylomicron

Protein interactions and network

No interactions in records.

Retrieve sequences for APOC3

Promoter
Promoter
ORF
ORF
CDS
CDS

Homologues in model organisms

Bos taurus
APOC3_BOVI
Mus musculus
Apoc3
Pan troglodytes
APOC3

In other databases

AnAge
This species has an entry in AnAge

Selected references

  • [2125] Pollin et al. (2008) A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection., PubMed
  • [1756] Atzmon et al. (2006) Lipoprotein genotype and conserved pathway for exceptional longevity in humans, PubMed
  • [1755] Araki and Goto (2004) Dietary restriction in aged mice can partially restore impaired metabolism of apolipoprotein A-IV and C-III, PubMed
  • [1743] Altomonte et al. (2004) Foxo1 mediates insulin action on apoC-III and triglyceride metabolism, PubMed
  • [1754] Araki et al. (2004) Impaired lipid metabolism in aged mice as revealed by fasting-induced expression of apolipoprotein mRNAs in the liver and changes in serum lipids, PubMed
  • [1753] Panza et al. (2004) Vascular genetic factors and human longevity, PubMed
  • [1752] Anisimov et al. (2001) Age-associated accumulation of the apolipoprotein C-III gene T-455C polymorphism C 

http://genomics.senescence.info/genes/entry.php?hgnc=APOC3

Apolipoprotein C-III is a protein component of very low density lipoprotein (VLDL). APOC3 inhibitslipoprotein lipase and hepatic lipase; it is thought to inhibit hepatic uptake[1] of triglyceride-rich particles. The APOA1, APOC3 and APOA4 genes are closely linked in both rat and human genomes. The A-I and A-IV genes are transcribed from the same strand, while the A-1 and C-III genes are convergently transcribed. An increase in apoC-III levels induces the development of hypertriglyceridemia.

Clinical significance

Two novel susceptibility haplotypes (specifically, P2-S2-X1 and P1-S2-X1) have been discovered in ApoAI-CIII-AIV gene cluster on chromosome 11q23; these confer approximately threefold higher risk ofcoronary heart disease in normal[2] as well as non-insulin diabetes mellitus.[3]Apo-CIII delays the catabolism of triglyceride rich particles. Elevations of Apo-CIII found in genetic variation studies may predispose patients to non-alcoholic fatty liver disease.

  1. ^ Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM (2009). “Metabolism of VLDL and LDL containing apolipoprotein C-III and not other small apolipoproteins – R2”.Arteriosclerosis, Thrombosis and Vascular Biology 30 (2): 239–45. doi:10.1161/ATVBAHA.109.197830. PMC 2818784. PMID 19910636.
  2. ^ Singh PP, Singh M, Kaur TP, Grewal SS (2007). “A novel haplotype in ApoAI-CIII-AIV gene region is detrimental to Northwest Indians with coronary heart disease”. Int J Cardiol 130 (3): e93–5. doi:10.1016/j.ijcard.2007.07.029. PMID 17825930.
  3. ^ Singh PP, Singh M, Gaur S, Grewal SS (2007). “The ApoAI-CIII-AIV gene cluster and its relation to lipid levels in type 2 diabetes mellitus and coronary heart disease: determination of a novel susceptible haplotype”. Diab Vasc Dis Res 4 (2): 124–29. doi:10.3132/dvdr.2007.030. PMID 17654446.

In 2013 we reported on the discovery that there is a

Genetic Associations with Valvular Calcification and Aortic Stenosis

N Engl J Med 2013; 368:503-512

February 7, 2013DOI: 10.1056/NEJMoa1109034

METHODS

We determined genomewide associations with the presence of aortic-valve calcification (among 6942 participants) and mitral annular calcification (among 3795 participants), as detected by computed tomographic (CT) scanning; the study population for this analysis included persons of white European ancestry from three cohorts participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology consortium (discovery population). Findings were replicated in independent cohorts of persons with either CT-detected valvular calcification or clinical aortic stenosis.

CONCLUSIONS

Genetic variation in the LPA locus, mediated by Lp(a) levels, is associated with aortic-valve calcification across multiple ethnic groups and with incident clinical aortic stenosis. (Funded by the National Heart, Lung, and Blood Institute and others.)

SOURCE:

N Engl J Med 2013; 368:503-512

Related Research by Author & Curator of this article:

Artherogenesis: Predictor of CVD – the Smaller and Denser LDL Particles

Cardiovascular Biomarkers

Genetics of Conduction Disease: Atrioventricular (AV) Conduction Disease (block): Gene Mutations – Transcription, Excitability, and Energy Homeostasis

Genomics & Genetics of Cardiovascular Disease Diagnoses: A Literature Survey of AHA’s Circulation Cardiovascular Genetics, 3/2010 – 3/2013

Hypertriglyceridemia concurrent Hyperlipidemia: Vertical Density Gradient Ultracentrifugation a Better Test to Prevent Undertreatment of High-Risk Cardiac Patients

Hypertension and Vascular Compliance: 2013 Thought Frontier – An Arterial Elasticity Focus

Personalized Cardiovascular Genetic Medicine at Partners HealthCare and Harvard Medical School

Genomics Orientations for Individualized Medicine Volume One

Market Readiness Pulse for Advanced Genome Interpretation and Individualized Medicine

We present below the MARKET LEADER in Interpretation of the Genomics Computations Results in the emerging new ERA of Medicine:  Genomic Medicine, Knome.com and its home grown software power house.

A second Case study in the  Advanced Genome Interpretation and Individualized Medicine presented following the Market Leader, is the Genome-Phenome Analyzer by SimulConsult, A Simultaneous Consult On Your Patient’s Diagnosis, Chestnut Hill, MA

 

2012: The Year When Genomic Medicine Started Paying Off

Luke Timmerman

An excerpt of an interesting article mentioning Knome [emphasis ours]…

Remember a couple of years ago when people commemorated the 10-year anniversary of the first draft human genome sequencing? The storyline then, in 200, was that we all went off to genome camp and only came home with a lousy T-shirt. Society, we were told, invested huge scientific resources in deciphering the code of life, and there wasn’t much of a payoff in the form of customized, personalized medicine.

That was an easy conclusion to reach then, when personalized medicine advocates could only point to a couple of effective targeted cancer drugs—Genentech’s Herceptin and Novartis’ Gleevec—and a couple of diagnostics. But that’s changing. My inbox the past week has been full of analyst reports from medical meetings, which mostly alerted readers to mere “incremental” advances with a number of genomic-based medicines and diagnostics. But that’s a matter of focusing on the trees, not the forest. This past year, we witnessed some really impressive progress from the early days of “clinical genomics” or “medical genomics.” The investment in deep understanding of genomics and biology is starting to look visionary.

The movement toward clinical genomics gathered steam back in June at the American Society of Clinical Oncology annual meeting. One of the hidden gem stories from ASCO was about little companies like Cambridge, MA-based Foundation Medicine and Cambridge, MA-based Knome that started seeing a surprising surge in demand from physicians for their services to help turn genomic data into medical information. The New York Times wrote a great story a month later about a young genomics researcher at Washington University in St. Louis who got cancer, had access to incredibly rich information about his tumors, and—after some wrestling with his insurance company—ended up getting a targeted drug nobody would have thought to prescribe without that information. And last month, I checked back on Stanford University researcher Mike Snyder, who made headlines this year using a smorgasbord of “omics” tools to correctly diagnose himself early with Type 2 diabetes, and then monitor his progress back into a healthy state–read the entire article

http://www.knome.com/knome-blog/2012-the-year-when-genomic-medicine-started-paying-off/

Knome and Real Time Genomics Ink Deal to Integrate and Sell the RTG Variant Platform on knoSYS™100 System

Partnership to bring accurate and fast genome analysis to translational researchers

CAMBRIDGE, MA –  May 6, 2013 – Knome Inc., the genome interpretation company, and Real Time Genomics, Inc., the genome analytics company, today announced that the Real Time Genomics (RTG) Variant platform will be integrated into every shipment of the knoSYS™100 interpretation system. The agreement enables customers to easily purchase the RTG analytics engine as an upgrade to the system. The product will combine two world-class commercial platforms to deliver end-to-end genome analytics and interpretation with superior accuracy and speed. Financial terms of the agreement were not disclosed.

“In the past year demand for genome interpretation has surged as translational researchers and clinicians adopt sequencing for human disease discovery and diagnosis,” said Wolfgang Daum, CEO of Knome. “Concomitant with that demand is the need for accurate and easy-to-use industrial grade analysis that meets expectations of clinical accuracy. The RTG platform is both incredibly fast and truly differentiating to customers doing family studies, and we are excited to add such a powerful platform to the knoSYS ecosystem.”

The partnership simplifies the purchasing process by allowing knoSYS customers to purchase the RTG platform directly from Knome sales representatives.

“The Knome system is a perfect complementary channel to further expand our commercial effort to bring the RTG platform to market,” said Steve Lombardi, CEO of Real Time Genomics. “Knome has built a recognizable brand around human clinical genome interpretation, and by delivering the RTG platform within their system, both companies are simplifying genomics to help customers understand human disease and guide clinical actions.”

About Knome

Knome Inc. (www.knome.com) is a leading provider of human genome interpretation systems and services. We help clients in two dozen countries identify the genetic basis of disease, tumor growth, and drug response. Designed to accelerate and industrialize the process of interpreting whole genomes, Knome’s big data technologies are helping to pave the healthcare industry’s transition to molecular-based, precision medicine.

About Real Time Genomics

Real Time Genomics (www.realtimegenomics.com) has a passion for genomics.  The company offers software tools and applications for the extraction of unique value from genomes.  Its competency lies in applying the combination of its patented core technology and deep computational expertise in algorithms to solve problems in next generation genomic analysis.  Real Time Genomics is a private San Francisco based company backed by investment from Catamount Ventures, Lightspeed Venture Partners, and GeneValue Ltd.

http://www.knome.com/knome-blog/knome-and-real-time-genomics-ink-deal-to-integrate-and-sell-the-rtg-variant-platform-on-knosys100-system/

Direct-to-Consumer Genomics Reinvents Itself

Malorye Allison

An excerpt of an interesting article mentioning Knome [emphasis ours]:

…Cambridge, Massachusetts–based Knome made one of the splashiest entries into the field, but has now turned entirely to contract research. The company began providing DTC whole-genome sequencing to independently wealthy individuals at a time when the price was still sky high. The company’s first client, Dan Stoicescu, was a former biotech entrepreneur who paid $350,000 to have his genome sequenced in 2008 so he could review it “like a stock portfolio” as new genetic discoveries unfolded4. About a year later, the company was auctioning off a genome, with such frills as a dinner with renowned Harvard genomics researcher George Church, at a starting price of $68,000; at the time, a full-genome sequence came at the price of $99,000, indicating that the cost of genome sequencing has been plummeting steadily.

Now, the company’s model is very different. “We stopped working with the ‘wealthy healthy’ in 2010,” says Jonas Lee, Knome’s chief marketing officer. “The model changed as sequencing changed.” The new emphasis, he says, is now on using Knome’s technology and technical expertise for genome interpretation. Knome’s customers are researchers, pharmaceutical companies and medical institutions, such as Johns Hopkins University School of Medicine in Baltimore, which in January signed the company up to interpret 1,000 genomes for a study of genetic variants underlying asthma in African American and African Caribbean populations.

Knome is trying to advance the clinical use of genomics, working with groups that “want to be prepared for what’s ahead,” Lee says. “We work with at least 50 academic institutions and 20 pharmaceutical companies looking at variants and drug response.” Cancer and idiopathic genetic diseases are the first sweet spots for genomic sequencing, he says. Although cancer genomics has been hot for a while, a recent string of discoveries of Mendelian diseases5 made by whole-genome sequencing has lit up that field, too. Lee is also confident, however, that “chronic diseases like heart disease are right behind those.” The company also provides software tools. The price for its KnomeDiscovery sequencing and analysis service starts at about $12,000 per sample–read the entire article here.

http://www.knome.com/knome-blog/direct-to-consumer-genomics-reinvents-itself/

Regenesis: How Synthetic Biology Will Reinvent Nature and Ourselves

VIEW VIDEO

http://www.colbertnation.com/the-colbert-report-videos/419824/october-04-2012/george-church

 

Knome Software Makes Sense of the Genome

The startup’s software takes raw genome data and creates a usable report for doctors.

DNA decoder: Knome’s software can tease out medically relevant changes in DNA that could disrupt individual gene function or even a whole molecular pathway, as is highlighted here—certain mutations in the BRCA2 gene, which affects the function of many other genes, can be associated with an increased risk of breast cancer.

A genome analysis company called Knome is introducing software that could help doctors and other medical professionals identify genetic variations within a patient’s genome that are linked to diseases or drug response. This new product, available for now only to select medical institutions, is a patient-focused spin on Knome’s existing products aimed at researchers and pharmaceutical companies. The Knome software turns a patient’s raw genome sequence into a medically relevant report on disease risks and drug metabolism. The software can be run within a clinic’s own network—rather than in the cloud, as is the case with some genome-interpretation services—which keeps the information private.

Advances in DNA sequencing technology have sharply reduced the amount of time and money required to identify all three billion base pairs of DNA in a person’s genome. But the use of genomic information for medical decisions is still limited because the process creates such large volumes of data. Less than five years ago, Knome, based in Cambridge, Massachusetts, made headlines by offering what seemed then like a low price—$350,000—for a genome sequencing and profiling package. The same service now costs just a few thousand dollars.

Today, genome profiling has two main uses in the clinic. It’s part of the search for the cause of rare genetic diseases, and it generates tumor-specific profiles to help doctors discover the weaknesses of a patient’s particular cancer. But within a few years, the technique could move beyond rare diseases and cancer. The information gleaned from a patient’s genome could explain the origin of specific disease, could help save costs by allowing doctors to pretreat future diseases, or could improve the effectiveness and safety of medications by allowing doctors to prescribe drugs that are tuned to a person’s ability to metabolize drugs.

But teasing out the relevant genetic information from a patient’s genome is not trivial. To find the particular genetic variant that causes a specific disease or drug response can require expertise from many disciplines—from genetics to statistics to software engineering—and a lot of time. In any given patient’s genome, millions of places in that genome will differ from the standard of reference. The vast majority of these differences, or variants, will be unrelated to a patient’s medical condition, but determining that can take between 20 minutes and two hours for each variant, says Heidi Rehm, a clinical geneticist who directs the Laboratory for Molecular Medicine at Partners Healthcare Center for Personalized Genetic Medicine in Boston, and who will soon serve on the clinical advisory board of Knome. “If you scale that to … millions of variants, it becomes impossible.”

A software package like Knome’s can help whittle down the list based on factors such as disease type, the pattern of inheritance in a family, and the effects of given mutations on genes. Other companies have introduced Web- or cloud-based services to perform such an analysis, but Knome’s software suite can operate within a hospital’s network, which is critically important for privacy-concerned hospitals.

The greatest benefit of the widespread adoption of genomics in the clinic will come from the “clinical intelligence” doctors gain from networks of patient data, says Martin Tolar, CEO of Knome. Information about the association between certain genetic variants and disease or drug response could be anonymized—that is, no specific patient could be tied to the data—and shared among large hospital networks. Knome’s software will make it easy to share that kind of information, says Tolar.

“In the future, you could be in the situation where your physician will be able to pull the most appropriate information for your specific case that actually leads to recommendations about drugs and so forth,” he says.

http://www.technologyreview.com/news/428179/knome-software-makes-sense-of-the-genome/

An End-to-end Human Genome Interpretation System

The knoSYS™100 seamlessly integrates an interpretation application (knoSOFT) and informatics engine (kGAP) with a high-performance grid computer. Designed for whole genome, exome, and targeted NGS data, the knoSYS™100 helps labs quickly go “from reads to reports.”


 


Advanced Interpretation and Reporting Software

The knoSYS™100 ships with knoSOFT, an advanced application for managing sequence data through the informatics pipeline, filtering variants, running gene panels, classifying/interpreting variants, and reporting results.

knoSOFT has powerful and scalable multi-sample comparison features–capable of performing family studies, tumor/normal studies, and large case-control comparisons of hundreds of whole genomes.

Multiple simultaneous users (10) are supported, including technicians running sequence data through informatics pipeline, developers creating next-generation gene panels, geneticists researching causal variants, and production staff processing gene panels.

http://www.knome.com/knosys-100-overview/

Publications

View our collection of journal articles and genome research papers written by Knome employees, Knome board members, and other industry experts.

Publications by Knome employees and board members

The Top Two Axes of Variation of the Combined Dataset (MS, BD, PD, and IBD)

21 Aug 2012

Discerning the Ancestry of European Americans in Genetic Association Studies

Co-authored by Dr. David Goldstein, Clinical and Scientific board member for Knome

Author summary: Genetic association studies analyze both phenotypes (such as disease status) and genotypes (at sites of DNA variation) of a given set of individuals. … more

Pedigree and genetic risk prediction workflow

20 Aug 2012

Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence

Co-authored by Dr. George Church and Dr. Heidi Rehm, Clinical and Scientific Board Members for Knome

Author summary: An individual’s genetic profile plays an important role in determining risk for disease and response to medical therapy. The development of technologies that facilitate rapid whole-genome sequencing will provide unprecedented power in the estimation of disease risk. Here we develop methods to characterize genetic determinants of disease risk and … more

20 Aug 2012

A Genome-Wide Investigation of SNPs and CNVs in Schizophrenia

Co-authored by Dr. David Goldstein, Clinical and Scientific board member for Knome

Author summary: Schizophrenia is a highly heritable disease. While the drugs commonly used to treat schizophrenia offer important relief from some symptoms, other symptoms are not well treated, and the drugs cause serious adverse effects in many individuals. This has fueled intense interest over the years in identifying genetic contributors to … more

fetchObject

20 Aug 2012

Whole-Genome Sequencing of a Single Proband Together with Linkage Analysis Identifies a Mendelian Disease Gene

Co-authored by Dr. David Goldstein, Clinical and Scientific board member for Knome

Author summary: Metachondromatosis (MC) is an autosomal dominant condition characterized by exostoses (osteochondromas), commonly of the hands and feet, and enchondromas of long bone metaphyses and iliac crests. MC exostoses may regress or even resolve over time, and short stature … more

19 Aug 2012

Exploring Concordance and Discordance for Return of Incidental Findings from Clinical Sequencing Co-authored by Dr. Heidi Rehm, Clinical and Scientific board member for Knome

Introduction: There is an increasing consensus that whole-exome sequencing (WES) and whole-genome sequencing (WGS) will continue to improve in accuracy and decline in price and that the use of these technologies will eventually become an integral part of clinical medicine.1–7 … more

Publications by industry experts and thought-leaders

22 Aug 2012

Rate of De Novo Mutations and the Importance of Father’s Age to Disease Risk

Augustine Kong, Michael L. Frigge, Gisli Masson, Soren Besenbacher, Patrick Sulem, Gisli Magnusson, Sigurjon A. Gudjonsson, Asgeir Sigurdsson, Aslaug Jonasdottir, Adalbjorg Jonasdottir, Wendy S. W. Wong, Gunnar Sigurdsson, G. Bragi Walters, Stacy Steinberg, Hannes Helgason, Gudmar Thorleifsson, Daniel F. Gudbjartsson, Agnar Helgason, Olafur Th. Magnusson, Unnur Thorsteinsdottir, & Kari Stefansson

Abstract: Mutations generate sequence diversity and provide a substrate for selection. The rate of de novo mutations is therefore of major importance to evolution. Here we conduct a study of genome-wide mutation rates by sequencing the entire genomes of 78 … more

15 Aug 2012

Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer

Florian L. Muller, Simona Colla, Elisa Aquilanti, Veronica E. Manzo, Giannicola Genovese, Jaclyn Lee, Daniel Eisenson, Rujuta Narurkar, Pingna Deng, Luigi Nezi, Michelle A. Lee, Baoli Hu, Jian Hu, Ergun Sahin, Derrick Ong, Eliot Fletcher-Sananikone, Dennis Ho, Lawrence Kwong, Cameron Brennan, Y. Alan Wang, Lynda Chin, & Ronald A. DePinho

Abstract: Inactivation of tumour-suppressor genes by homozygous deletion is a prototypic event in the cancer genome, yet such deletions often encompass neighbouring genes. We propose that homozygous deletions in such passenger genes can expose cancer-specific therapeutic vulnerabilities when the collaterally … more

1 Jul 2012

Structural Diversity and African Origin of the 17q21.31 Inversion Polymorphism

Karyn Meltz Steinberg, Francesca Antonacci, Peter H Sudmant, Jeffrey M Kidd, Catarina D Campbell, Laura Vives, Maika Malig, Laura Scheinfeldt, William Beggs, Muntaser Ibrahim, Godfrey Lema, Thomas B Nyambo, Sabah A Omar, Jean-Marie Bodo, Alain Froment, Michael P Donnelly, Kenneth K Kidd, Sarah A Tishkoff, & Evan E Eichler

Abstract: The 17q21.31 inversion polymorphism exists either as direct (H1) or inverted (H2) haplotypes with differential predispositions to disease and selection. We investigated its genetic diversity in 2,700 individuals, with an emphasis on African populations. We characterize eight structural haplotypes … more

http://www.knome.com/publications/

knome’s Systems & Software

Technical specifications

Connections and communications

Two networks: 40-Gigabit Infiniband QDR via a Mellanox Switch for storage traffic and HP ProCurve switch for network traffic

High performance computing cluster

Four nodes, each node with two 8-core/16 thread, 2.4Ghz, 64 bit Intel® Xeon® E5-2660 processor with 20MB cache, 128GB of DDR3 ECC 1600 memory; 2x2TB SATA drives (7,200RPM)

Metadata server

2x2TB 3.5″ drives with 6GB/sec SATA, RAID 1 and 2x300GB SSD (RAID 1)

Object storage server

Lustre array: Two 12x4TB arrays of 12 3.5″ drives with 6GB/sec serial SATA channels, each OSS powered by a 6-core Intel Xeon 64-bit processor running at 20GHz with 32GB RAM.

knoSYS_server

96TB total, 64TB useable storage (redundancy for failure tolerance). Expandable 384TB total.

Data sources

Reference genome GRCh37 (HG19)

dbSNP, v137

Condel (SIFT and PolyPhen-2)

HPO

OMIM

Exome Variant server, with allelisms and allele frequencies

1000 Genomes, with allelisms and allele frequencies

Human Gene Mutation db (HGMD)

Phastcons 46, mammalian conservation

PhyloP

Input/output formats

Input formats: kGAP accepts Illumina FASTQ and VCF 4.1 files as inputs

Output formats: annotated VCF files

Electrical and operating requirements

Line voltage: 110V to 120V AC, 200-240V (single phase)

Frequency: 50Hz to 60Hz

Current: 30A, RoSH compliant

Connection: NEMA L5-30

Operating temperature: 50° to 95° F

UPS included

Maximum operating altitude: 10,000 feet

Power consumption: 2,800 VA (peak)

Size and weight

Height 49.2 Inches (1250 mm)
Width 30.7 Inches (780 mm)
Depth 47.6 Inches (1210 mm)
Weight 394 lbs (179 kg)

Noise generation and heat dissipation

Enclosure provides 28dB of acoustic noise reduction; system suitable for placing in working lab environment

7200w of active heat dissipation

Included in the package

knoSYS™100 hardware

Knome software: knoSOFT, kGAP

Operating system: Linux (CentOS 6.3)

http://www.knome.com/knosys-100-specifications/

Our research services group uses a set of advanced software tools designed for whole genome and exome interpretation. These tools are also available to our clients through our knomeBASE informatics service. In addition to various scripts, libraries, and conversion utilities, these tools include knomeVARIANTS and knomePATHWAYS.

knomeVARIANTS

Genome_software_knomeVARIANTS

knome VARIANTS is a query kit that lets users search for candidate causal variants in studied genomes. It includes a query interface (see above), scripting libraries, and data conversion utilities.

Users select cases and controls, input a putative inheritance mode, and add sensible filter criteria (variant functional class, rarity/novelty, location in prior candidate regions, etc.) to automatically generate a sorted short-list of leading candidates. The application includes a SQL query interface to let users query the database as they wish, including by complex or novel sets of criteria.

In addition to querying, the application lets users export subsets of the database for viewing in MS Excel. Subsets can be output that target common research foci, including the following:

  • Sites implicated in phenotypes, regardless of subject genotypes
  • Sites where at least one studied genome mismatches the reference
  • Sites where a particular set of one or more genomes, but no other genomes, show a novel variant
  • Sites in phenotype-implicated genes
  • Sites with nonsense, frameshift, splice-site, or read-through variants, relative to reference
  • Sites where some but not all subject genome were called

knomePATHWAYS

Genome_software_knomePATHWAYS

knomePATHWAYS is a visualization tool that overlays variants found in each sample genome onto known gene interaction networks in order to help spot functional interactions between variants in distinct genes, and pathways enriched for variants in cases versus controls, differential drug responder groups, etc.

knomePATHWAYS integrates reference data from many sources, including GO, HPRD, and MsigDB (which includes KEGG and Reactome data). The application is particularly helpful in addressing higher-order questions, such as finding candidate genes and protein pathways, that are not readily addressed from tabular annotation data alone.

http://www.knome.com/interpretation-toolkit/

Genome-Phenome Analyzer by SimulConsult

A Simultaneous Consult On Your Patient’s Diagnosis

Clinicians can get a “simultaneous consult” about their patient’s diagnosis using SimulConsult’s diagnostic decision support software.

Using the free “phenome” version, medical professionals can enter patient findings into the software and get an initial differential diagnosis and suggestions about other useful findings, including tests.  The database used by the software has > 4,000 diagnoses, most complete for genetics and neurology.  It includes all genes in GeneTests and all diseases in GeneReviews.  The information about diseases is entered by clinicians, referenced to the literature and peer-reviewed by experts.  The software takes into account pertinent negatives, temporal information, and cost of tests, information ignored in other diagnostic approaches.  It transforms medical diagnosis by lowering costs, reducing errors and eliminating the medical diagnostic odysseys experienced by far too many patients and their families.

http://www.simulconsult.com/index.html

Using the “genome-phenome analyzer” version, a lab can combine a genome variant table with the phenotypic data entered by the referring clinician, thereby using the full power of genome + phenome to arrive at a diagnosis in seconds.  An innovative measure of pertinence of genes focuses attention on the genes accounting for the clinical picture, even if more than one gene is involved.  The referring clinician can use the results in the free phenome version of the software, for example adding information from confirmatory tests or adding new findings that develop over time.  For details, click here.

http://www.simulconsult.com/genome/index.html

Michael M. Segal MD, PhD, Founder,Chairman and Chief Scientist.  Dr. Segal did his undergraduate work at Harvard and his MD and PhD at Columbia, where his thesis project outlined rules for the types of chemical synapses that will form in a nervous system.  After his residency in pediatric neurology at Columbia, he moved to Harvard Medical School, where he joined the faculty and developed the microisland system for studying small numbers of brain neurons in culture.  Using this system, he developed a simplified model of epilepsy, work that won him national and international young investigator awards, and set the stage for later work on the molecular mechanism of attention deficit disorder.  Dr. Segal has a long history of interest in computers, and patterned the SimulConsult software after the way that experienced clinicians actually think about diagnosis.  He is on the Electronic Communication Committee of the Child Neurology Society and the Scientific Program Committee of the American Medical Informatics Association.

http://www.simulconsult.com/company/management.html

Read Full Post »

« Newer Posts - Older Posts »